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Abstract
Hierarchical

phosphorylation

of

four

Ser/Thr residues orchestrates

the

ubiquitination and proteasomal degradation of the transcriptional co-activator, p-catenin
[16]. To the best of our knowledge, P-catenin is the only known protein with this tetraphosphorylation motif (TPM). However, the sophistication of this scheme prompted our
hypothesis that there are other proteins regulated by this TPM.
Herein, we identified two novel TPM-containing proteins, TAZ and KLF7.
Characterization of the TAZ and KLF7 TPMs revealed significant similarities and
differences with respect to the biochemical role of the P-catenin TPM and demonstrated a
functional consequence of their TPMs within the TAZ- and KLF7-mediated inhibition of
adipogenesis.
We also provide the first direct evidence that TAZ is highly phosphorylated.
Using mass spectrometry, we identified ten TAZ phosphorylation sites, of which three
mapped to the TPM.

Additionally, we present preliminary functional analyses of

phosphorylation sites adjacent to the 14-3-3 binding site and WW domain of TAZ.
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Chapter 1
Introduction

/. 1 Post-Translational Modifications

The final stage in the biosynthetic pathway of numerous proteins involves their
exposure to various forms of further processing, collectively referred to as posttranslational modifications [1].

The functional significance of the numerous post-

translational modifications varies from one protein to the next. However, in general,
post-translational modifications have been shown to influence the regulation of various
biological properties of proteins, such as activity, stability, localization, or ligand binding
[1,2]. The key to understanding the consequence of protein modification lies within the
fact that the majority of post-translational modifications involve the covalent addition of
a functional group, such as a carboxyl group, an alkyl group, a glycosyl group, or a
phosphoryl group, to a specific amino acid residue; the covalent linkage of another
protein or peptide to the protein of interest, as is the case in the ubiquitination and
SUMOylation of proteins; or the alteration of the protein structure, which can occur in
response to disulfide bridge formation or proteolytic cleavage [1,2].

Thus, post-

translational modifications exert their influences through the introduction or removal of
chemically reactive groups.

Overall, post-translational modifications enhance the

diversity and versatility of the structure and functions of proteins, explaining their
prevalence in higher eukaryotic organisms [2,3].

1.2 Phosphorylation: A Reversible Regulatory Modification

One of the most prevalent forms of post-translational modification is the
reversible phosphorylation of proteins, which involves the addition of a phosphoryl group
to an amino acid side chain. The reversible nature of protein phosphorylation is afforded
by the opposing activities of two enzyme superfamilies, the protein kinases and protein
phosphatases.

Protein kinases catalyze the transfer of the y-phosphoryl group of

adenosine triphosphate (ATP) to an amino acid side chain of the recipient protein, while
protein phosphatases oversee the dephosphorylation reaction, catalyzing the hydrolysis of
the high energy phosphoester bond between the phosphoryl group and the implicated
amino acid side chain (Figure 1.1) [3]. Within eukaryotic cells, the most common form
of phosphorylation is O-phosphorylation, which involves the addition of a phosphoryl
group to the hydroxyl side chains of serine, threonine, and tyrosine residues (Figure 1.2)
[3].

Serine and threonine phosphorylation have been documented to be far more

abundant than the phosphorylation of tyrosine residues at a ratio of 1800:200:1 [4].
Studies of prokaryotic phosphorylation have also revealed the occurrence of Nphosphorylation (arginine, histidine, lysine), S-phosphorylation (cysteine), and acylphosphorylation (aspartate, glutamate), albeit still to a lesser degree than Ophosphorylation [5]. It has been reported that approximately 30 - 50% of proteins
present within a eukaryotic cell are phosphorylated at any given time and that genes
encoding protein kinases and protein phosphatases constitute approximately 2% of the
entire human genome, facts that attest to the prevalence and significance of protein
phosphorylation as a regulatory mechanism [6,7].

2

Protein Kinase
O
11

o-p-o"
I

Protein Phosphatase

Phosphorylated
Protein

Figure 1.1- Reversible Protein Phosphorylation. Protein phosphorylation involves the
addition of a phosphoryl group to an amino acid side chain. The reversible nature of
phosphorylation is afforded by the opposing activities of two enzyme superfamilies, the
protein kinases and protein phosphatases. Protein kinases catalyze the transfer of the yphosphoryl group of ATP to an amino acid side chain of the recipient protein. The addition
of a negatively charged phosphoryl group can shift a protein from one state (O) to another
( • ) by influencing many aspects of protein behavior, including structure, subcellular
localization, activity, stability, and substrate specificity. Protein phosphatases catalyze the
dephosphorylation reaction by facilitating the hydrolysis of the phosphoester bond between
the protein and the phosphoryl group, liberating inorganic phosphate (P;) that is used to form
ATP from ADP.
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Figure 1.2- O-Phosphorylation of Serine, Threonine, and Tyrosine [1]. Within
eukaryotic cells, the most common form of protein phosphorylation is O-phosphorylation,
which involves the addition of a phosphoryl group to the hydroxyl functional group of a
serine, threonine, or tyrosine residue.

4

1.2.1 Phosphorylation Regulates Numerous Cellular Processes

The regulatory capacity of protein phosphorylation is often likened to a light
switch, as phosphorylation or dephosphorylation can trigger the shift of the target protein
between a modified and an unmodified state [2].

Essential to understanding the

mechanism by which phosphorylation mediates protein behavior is the knowledge that
the addition of a phosphoryl group to a serine, threonine, or tyrosine residue replaces a
neutral functional group with that which is negatively charged. Protein phosphorylation
can lead to an alteration in protein structure, as a result of a change in the electrostatic
interactions, hydrogen bonding network, and/or hydrophobic interactions in the vicinity
of the newly incorporated phosphoryl group [2].

Induced changes in protein

conformation can have a number of consequences, including alterations in enzymatic
activity, substrate specificity, subcellular localization, stability, and complex formation
[8].

It is variations in protein behaviors such as these that assist in the relay of

information from an initial extracellular stimulus to the internal cellular machinery: the
central dogma of signal transduction.
Protein phosphorylation has long been identified as a critical regulator in a vast
number of cellular processes. Today, it is believed that phosphorylation plays some role
in practically every eukaryotic biological pathway [3].

Most notably, it has been

implicated in the inner-workings of signal transduction cascades regulating cell cycle
progression, transcription, translation, cell differentiation, cytoskeletal rearrangement,
apoptosis, and cellular metabolism [3]. Since phosphorylation is at the core of the
cellular signal transduction cascade, the activities of the protein kinases and protein
phosphatases that mediate this post-translational modification must be tightly maintained.
Aberrant control of the aforementioned enzymes can result in abnormal levels of
phosphorylation and dephosphorylation, which have both been associated with various

5

pathological conditions, such as cancer, diabetes, neurodegeneration, and cardiovascular
disease [3,9].

1.3 Multisite Phosphorylation

Research focused on the elucidation of the human phosphoproteome, the
complete collection of phosphorylated proteins within the cell, yielded the estimation that
the sum of potential phosphorylation sites likely exceeds 100,000 [7]. In 2002, it was
reported that fewer than 2,000 phosphorylation sites had been identified with the majority
of the unidentified phosphorylation sites predicted to map to proteins containing multiple
phosphorylation

sites

[10].

Multisite phosphorylation,

which refers

to the

phosphorylation of a protein on multiple amino acid residues, continues to emerge as a
widespread cellular mechanism.

Not only does the requisition for multiple

phosphorylation events heighten the potential for the regulation of all aspects of protein
behavior, but it also enables several regulatory strategies to operate within the same
protein, as the phosphorylation of each site can result in a unique set of consequences
[11]. The phosphorylation of several sites within a protein can transpire in a number of
ways. For instance, a single protein kinase may be responsible for phosphorylating a
multitude of sites in a protein, a feat shown to afford strict control over the strength and
duration of a specific cellular response, as the termination of the signal is dependent upon
multiple dephosphorylation events [11]. Multisite phosphorylation of a protein can also
be achieved through the activities of two or more distinct protein kinases, allowing the
potential for the integration of various signaling pathways [11].

6

1.3.1 Hierarchical Phosphorylation Generates Critical Thresholds for Cellular
Activities

The interactions between phosphorylation sites within a multiply phosphorylated
protein enhance the means by which phosphorylation can exert its regulatory capacity. It
has been shown that phosphorylation sites may be mutually exclusive, meaning that the
initial phosphorylation of an amino acid residue prevents subsequent phosphorylation
events on other residues [11]. Phosphorylation sites may also interact in a positive
manner, such that the phosphorylation of one site serves to favor the phosphorylation of
others [11].

Numerous proteins have been identified that undergo multisite

phosphorylation in a sequential manner, which is in accordance with this latter form of
phosphorylation site interdependency [12]. This pattern of phosphorylation, termed
ordered phosphorylation, sequential phosphorylation, or hierarchical phosphorylation, is
characterized by the phosphorylation of amino acid residues in a defined order; hence,
phosphorylation at a specific site is a requirement for successive phosphorylation events.
Traditionally, it was believed that hierarchical phosphorylation provided
redundant control of protein behavior.

However, it now appears that this intriguing

phosphorylation mechanism affords ultrasensitive regulation of cellular activities through
the generation of temporal and enzyme activation thresholds [13].

The ability of

hierarchical phosphorylation to impart a temporal threshold on its regulatory activities
stems from the presence of a lag period following the onset of phosphorylation, as a
critical level of protein kinase activity must be attained to ensure successful multisite
phosphorylation before the final regulatory goal can be achieved [13].

A single

phosphorylation event, even one where the catalysis of its phosphorylation has been
slowed to match the time required for multiple phosphorylation events, is unable to
produce a similar temporal threshold; thus, hierarchical phosphorylation provides a
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means by which the cell can assess the necessity for the execution of various cellular
processes, given that the proper conditions are met [13].
It has also been stated that the requirement for multiple phosphorylation events
sets a threshold for kinase activity, such that at low levels of kinase activation, the target
protein will exist in lowly phosphorylated forms, but as the activity of the implicated
kinase(s) increases, the amount of multiply phosphorylated protein will also increase
[13]. The presence of such a threshold allows the target protein to ignore low, or perhaps
basal, levels of kinase activity that exist during periods where its regulation is not
required, ensuring that a response is not elicited until the activity of the kinase has
exceeded the threshold level [13].

1.4 Ordered Multisite Phosphorylation Regulates P-catenin Degradation

The extensively studied, multifunctional

protein, P-catenin, provides an

interesting example of hierarchical phosphorylation coupled to ubiquitin-mediated
proteasomal degradation. Initial studies focused on elucidating the function of P-catenin
revealed its involvement in the cadherin-based cell adhesion system, where it serves to
tether transmembrane cadherin receptors to a-catenin, which in turn associates with actin
filaments of the cytoskeleton [14]. However, it was the discovery of its transcriptional
co-activation capabilities within a highly conserved Wnt signaling pathway that intrigued
researchers and spurred enormous research efforts towards understanding the regulation
of P-catenin [14]. The canonical Wnt/p-catenin pathway has been implicated in the
regulation of critical cellular processes, such as proliferation, cell fate determination, and
differentiation, in both the developing embryo and in adult tissues [14,15].
A critical output of the canonical Wnt/p-catenin signaling cascade is the
regulation of cytosolic P-catenin protein levels [16]. In accordance with the current
model of the pathway, the engagement of the Wnt co-receptors by specific Wnt ligands is
8

believed to initiate a series of events, which ultimately disrupt the function of a multiprotein P-catenin degradation complex that assembles along the scaffold protein, Axin,
and contains P-catenin, as well as the tumor suppressor protein, adenomatous polyposis
coli (APC), and two serine/threonine kinases (glycogen synthase kinase 3p (GSK3p) and
casein kinase la (CKIa)) [14,16]. Consequently, p-catenin escapes its degradation and
accumulates within the cytoplasm, with high levels of transcriptionally active P-catenin
undergoing

translocation

into the nucleus, where it associates with T cell

factor/lymphocyte enhancer factor (TCF/LEF) transcription factors to co-activate the
expression of Wnt-responsive genes [14].
The absence of extracellular Wnt stimulation is met by the constitutive
degradation of P-catenin, which preserves low levels of this transcriptional mediator for
the purpose of maintaining Wnt target genes in a transcriptionally inactive form. It is the
inclusion of P-catenin within the aforementioned multi-protein complex that promotes its
phosphorylation-dependent degradation [14].

Studies have shown that p-catenin

degradation is tightly regulated by the ordered multisite phosphorylation of four Ser/Thr
residues located within its highly conserved amino (N)-terminal region by the kinases
present within the destruction complex (Figure 1.3). The initial phosphorylation of pcatenin, which occurs on Ser45, is catalyzed by CKIa [16,17]. In the context of Pcatenin phosphorylation, CKIa is said to function as a "priming" kinase, since its
phosphorylation of Ser45 is both necessary and sufficient for the ensuing phosphorylation
of p-catenin by GSK3p [16,17].

The introduction of a phosphate group at Ser45

generates a GSK3p consensus site, which consists of a phosphorylated residue separated
from a second putative phosphorylation site by three arbitrary residues (S/TXXXpS/pT),
enabling GSK3P to catalyze the phosphorylation of Thr41, followed by that of Serf 7, and
finally Ser33, as each of these sites also constitutes a GSK3P consensus site [16,17]. The
hierarchical phosphorylation of P-catenin at these four sites generates an intriguing
phosphorylation motif that we have termed the tetra-phosphorylation motif (TPM).
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Figure 1.3- Phosphorylation-Dependent Degradation of p-catenin [15,19]. In the
absence of Wnt signaling, Axin binds simultaneously to APC, P-catenin, GSK3P, and
CKIa, forming the p-catenin destruction complex.
Consequently, P-catenin is
phosphorylated on Ser45 by CKIa, which allows the phosphorylation of Thr41, Ser37, and
Ser33 by GSK3P in an ordered fashion (shown in box). Phosphorylation at Ser33 and Ser37
creates a docking site for P-TrCP, present within an SCF (Skpl/Cull/F-box) complex,
facilitating the poly-ubiquitination of P-catenin. (El, ubiquitin (Ub)-activating enzyme; E2,
ubiquitin (Ub)-conjugating enzyme). Subsequent to its ubiquitination, p-catenin is targeted
to the proteasome for degradation.
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Studies focused on deducing the degradation mechanism of P-catenin revealed
that it proceeded via the ubiquitin-proteasome pathway, which involves its ubiquitination
and subsequent degradation by the proteasome [18].

The presence of the

hyperphosphorylated TPM within the N-terminal region of P-catenin generates a docking
site for p-TrCP, the specificity component of the ubiquitination apparatus, whose
phosphorylation-dependent recognition of P-catenin invokes its ubiquitination [18,19].
The ligation of a multimeric ubiquitin chain to P-catenin, primarily at Lysl9, marks Pcatenin for recognition and, ultimately, destruction by the 26S proteasome [20,21].

1.4.1 Ubiquitin-Mediated Proteolysis

Protein degradation via the ubiquitin-proteasome pathway involves two distinct
systems: the ubiquitin conjugation cascade and the 26S proteasome complex [22]. The
initial stage of this bipartite pathway involves the enzymatic ligation of ubiquitin, a
highly conserved 76 amino acid protein, to the target protein, in a process referred to as
ubiquitination.

Ubiquitination is afforded by the concerted actions of three unique

enzymes, denoted El, E2, and E3 (Figure 1.4) [22]. Firstly, the El, or ubiquitinactivating enzyme, catalyzes the adenylation of ubiquitin at the expense of ATP, serving
to activate ubiquitin, which then engages in a thioester bond with an active site cysteine
residue of El. El then transfers the bound ubiquitin to a cysteine residue located within
the active site of an E2, also known as the ubiquitin-carrier protein or ubiquitinconjugating enzyme [22]. Lastly, the E2 seeks out and binds to a member of the
ubiquitin-protein ligase family, or E3, which is responsible for the recognition and
binding of specific substrates. The binding of E2 to an E3 brings the E3-bound substrate
into the vicinity of the ubiquitin-bound E2, enabling the ligation of the ubiquitin
monomer to an internal lysine residue of the protein substrate.

Following mono-

ubiquitination, a poly-ubiquitin chain may be synthesized through the actions of the same
11

Poly-ubiquitinated
protein
Peptides

Figure 1.4- Ubiquitin-Proteasome Pathway [22,23], El (ubiquitin-activating enzyme)
catalyzes the adenylation of ubiquitin (Ub) at the expense of ATP, which serves to activate
ubiquitin. Activated ubiquitin then forms a thioester bond with a Cys residue within the El
active site. The activated ubiquitin is then transferred to an active site Cys residue of an E2
(ubiquitin-conjugating enzyme). E2 complexes with an E3 (ubiquitin ligase), which
associates with the target protein substrate. The activated ubiquitin moiety is then
transferred to the side chain of a Lys residue within the protein substrate, yielding a monoubiquitinated protein. After multiple rounds of ubiquitin transfer, a poly-ubiquitin chain is
formed. Poly-ubiquitinated proteins are recognized and hydrolyzed into small peptides by
the 26S proteasome. In a manner that remains to be determined, the ubiquitin polymer is
cleaved from the substrate and the ubiquitin monomers are recycled.
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enzymatic cascade; however, the activated ubiquitin moiety is not ligated to the substrate,
but is conjugated to a specific lysine residue within the previously bound ubiquitin
molecule [22,23].
Since a diverse array of critical regulatory proteins undergoes ubiquitin-mediated
proteolysis, it is important that the degradation machinery explicitly recognizes target
proteins, so as to ensure specific control of their degradation [22]. The specificity of the
ubiquitin-proteasome pathway is conferred mainly through the identity of the
participatory E3 ligase. There exist a number of different ubiquitin ligase families, with
each family exhibiting unique substrate binding preferences afforded through their
recognition of a specific motif within the substrate(s) [24]. In the case of the ubiquitinmediated degradation of p-catenin, hierarchical phosphorylation of its TPM results in the
generation of a degradation signal, or phosphodegron, constituting phosphorylated Ser37
and phosphorylated Ser33, as well as neighboring residues, namely Asp32 and Gly34
[19].

A phosphodegron akin to this form, DpSG<|>XpS, where <>
j and X represent

hydrophobic and arbitrary amino acids, respectively, has been identified in all known
substrates of the E3 ligase complex, SCFp"TlCP [20]. This E3 ligase, which has been
shown to facilitate the ubiquitination of P-catenin, consists of four subunits: the scaffold
protein, Cullinl (Cull); the RING-domain protein, Rbxl, which is anchored by Cull,
allowing it to bridge the E2-E3 interaction; and the adaptor protein, Skpl, which tethers
the fourth subunit, the F-box protein, p-TrCP, to Cull [19,20]. The F-box protein is the
component of the SCF (Skpl/Cull/F-box) ligase that directly interacts with the specific
protein substrate; thus, the presence of protein-protein interaction domains within the Fbox proteins dictates their substrate specificities [20]. For example, P-Transducin repeat
containing protein (P-TrCP), the F-box protein of the SCF ligase responsible for the
ubiquitination of P-catenin, directly associates with the p-catenin phosphodegron via its
WD40-repeat domains [20].
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Consequent of their poly-ubiquitination, proteins fated for degradation are subject
to the second branch of the ubiquitin-proteasome pathway. The presence of a covalently
linked ubiquitin polymer along the length of a protein acts as a recognition signal for the
eukaryotic 26S proteasome, which is composed of three major subunits: the core 20S
protein and two 19S regulatory complexes [25]. The 19S complexes are positioned at
either end of the 20S proteasome forming a pseudo lid and base, which function in the
binding and unfolding of the poly-ubiquitinated protein substrate, as well as in the
threading of the unfolded substrate protein into the 20S proteolytic chamber [25]. Studies
of the 20S proteasome have revealed that it is of a multi-enzymatic nature, in that it is
capable of at least three different protease activities, akin to chymotrypsin, trypsin,
among others [24,25]. This array of protease activity ensures that virtually all of the
peptide bonds within a protein substrate are susceptible to cleavage, enabling the
generation and release of relatively small peptides from the ubiquitinated protein. It is
interesting to note that, in a manner which remains to be established, the poly-ubiquitin
chain is stripped from the target protein and the individual ubiquitin monomers are
recycled [25].

The involvement of the 26S proteasome provides direction to this

degradation scheme, for it is not until this final step that the fate of the targeted protein is
ultimately decided, as its proteolytic degradation poses the first non-reversible step [24].

1.4.2 Aberrant Control of P-catenin Protein Levels Leads to Malignant Tumor
Formation

The significance of the P-catenin TPM in the regulation of its phosphorylationdependent degradation is underscored by the identification of P-catenin variants that
harbor mutations at the TPM phosphorylation sites and at surrounding residues in various
human malignant tumors [26]. Mutations at Ser33 and Ser37, as well as other residues
imperative to the formation of the P-catenin phosphodegron, such as Asp32, Gly34, and
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Ile35, have been shown to abolish p-TrCP binding. Mutations at Thr41 and Ser45
eradicate the potential for subsequent phosphorylation events at Ser37 and Ser33;
thereby, also impeding the phosphorylation-dependent recognition of P-catenin by PTrCP. Studies have shown that, due to all such mutations, P-catenin is able to escape
ubiquitination and as a result is stabilized [16,19].

The failure to promote the

proteasomal degradation of P-catenin enables irregular cytoplasmic accumulation and its
subsequent localization into the nucleus, resulting in prolonged transcriptional coactivation of TCF/LEF target genes, which include a number of known oncogenes,
namely c-myc, cyclin Dl, and matrilysin [26]. Therefore, excessive transcription driven
by the co-activation of P-catenin can lead to abnormal cell proliferation and ultimately,
tumor formation.
To our knowledge, P-catenin remains the only protein reported, thus far, as
having this specific tetra-phosphorylation motif (TPM). However, the level of inborn
sophistication within the regulation of p-catenin degradation leads one to speculate that
there likely exist other TPM-containing proteins regulated in a manner similar to Pcatenin.

1.5 Valuable Tools in the Analysis of Phosphoproteins

A systems biology approach to studying signal transduction cascades involves a
comprehensive identification of all of the factors that function in the relay of information
from an extracellular stimulus to the intracellular machinery.

As the reversible

phosphorylation of proteins is known to be the foremost event in the transmission of
cellular signals, a thorough understanding of the inner-workings of the various signaling
cascades is heavily reliant on the detection and characterization of all of the proteins
regulated by this post-translational modification [27]. The analysis of phosphorylated
proteins can be a formidable challenge, owing to the highly dynamic nature of
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phosphorylation. It can be difficult to capture proteins in their phosphorylated form,
especially already lowly abundant signaling proteins, as only a small fraction of the
available pool of a protein is likely phosphorylated at any given time [28]. Hence, largescale phosphoproteomic studies have been hampered, due to the inability to effectively
utilize traditional proteomic techniques, for, when used alone, the sensitivity and
specificity of these conventional tools often permit the detection of only the most
abundant phosphoproteins and phosphopeptides [10].

The last decade has seen a

dramatic advancement in the field of phosphoproteomics; a feat attributed to the
development of efficient phosphopeptide and phosphoprotein enrichment methods. The
employment of such methods to isolate phosphorylated proteins and peptides from the
gamut of unphosphorylated moieties, prior to further analytical processing, namely
through biological mass spectrometry, has become the mainstay of phosphoproteomic
investigations [28].

1.5.1 Application of PhosphorylationSpecific Antibodies

Antibodies with specificities directed against phosphorylated residues have been
commercially available for years, although, only recently have they enjoyed application
to the study of the phosphoproteome. Phosphoantibodies provide a simple, specific, and
sensitive method of phosphoprotein isolation and detection, as, in theory, they can be
utilized in both immunoprecipitation and immunoblotting experiments [10].

The

employment of phosphotyrosine-specific antibodies has proven the most fruitful, as their
successful application in the aforementioned methodologies, in conjunction with mass
spectrometry, has made possible the identification of a vast number of novel
phosphotyrosine-containing proteins, enhancing the knowledge of this phosphorylation
event during both physiological and pathophysiological circumstances [29,30].
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Historically, phosphoserine and phosphothreonine antibodies have not been met
with the same enthusiasm as their phosphotyrosine counterparts, as their reputations have
been plagued by poor conduct in immunoprecipitation procedures [31].

However,

optimizations in the field of phosphoserine and phosphothreonine antibody development
have yielded promising results. For example, using a variety of phosphoserine and/or
phosphothreonine antibodies, Granborg et al. were able to enrich for proteins
phosphorylated on these residues via immunoprecipitation, enabling the mass
spectrometric identification of Frigg, a novel substrate of protein kinase A (PKA) [27].
Perhaps the most significant development with respect to phosphoserine- and
phosphothreonine-specific antibodies has come in the production of antibodies against
specific phosphorylated sequences (phosphomotifs), most notably, consensus kinase
phosphorylation sites [7]. The utilization of a phosphoantibody reactive to a sequence
optimally phosphorylated by a given kinase subfamily has the potential for more focused
and biologically informative phosphoproteomic investigations, as it enables the capture
of only subsets of the phosphoproteome.
In the first study of its kind with phosphoserine/phosphothreonine motif
antibodies, Kane et al. successfully enriched putative substrates of protein kinase Akt,
also termed protein kinase B (PKB), through immunoprecipitation with a phosphomotif
antibody raised against the Akt consensus sequence, RXRXXpS/pT (X, arbitrary amino
acid; pS/pT, phosphoserine/phosphothreonine) from insulin-stimulated, mouse 3T3-L1
preadipocyte cells.

Their efforts, which also relied on immunoblotting with the

phosphomotif antibody and mass spectrometry, led to the identification of a novel Akt
substrate, shown to be doubly phosphorylated by Akt, which they designated Akt
substrate of 160 kDa, or AS 160 [32]. At least four other promising Akt substrate
candidates were pending further characterization at the time of this investigation. In
recent years, it appears that at least two of these putative substrates, AS47 and AS250,
were revealed as novel Akt substrates [33,34]. The simplicity and productivity of this
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phosphomotif antibody-based method proved its value in experiments of this type,
spawning numerous studies focused on elucidating the signaling networks of specific
protein kinases.
Following many years dedicated to improving the quality of phosphomotif
antibodies, their utility in immunoprecipitation experiments was expanded to include
phosphopeptide enrichment.

As has been the case with all phosphorylation-state

antibodies, antibodies specific to phosphotyrosine-containing motifs were the first to be
successfully employed in the isolation of phosphopeptides from a complex mixture of
enzymatically-digested peptides [30].

However, in a recent phosphoproteomic

undertaking, Matsuoka et al. successfully immunoprecipitated phosphopeptides with
phosphoserine/phosphothreonine-specific motif antibodies in an attempt to identify
putative substrates of the protein kinases, ATM (ataxia telangiectasia-mutated) and ATR
(ATM-Rad3-related), key components of the cellular DNA damage response [35]. An
array of phosphomotif antibodies, specific for the consensus sequences of a variety of
well known ATM and ATR substrates, were used to enrich for phosphopeptides
belonging to potential ATM and ATR substrates. Studies have shown that these highly
related kinases, which share substrate specificity, optimally phosphorylate serine (S) or
threonine (T) residues immediately followed by a glutamine (Q) residue, generating fairly
limited consensus sequences of SQ and TQ [35].
This study also illustrates the application of phosphomotif antibodies to a specific
biological process. In order to delineate the signaling pathways involved in the cellular
response to DNA damage, Matsuoka et al. compared the phosphorylation state of
peptides isolated from untreated cells to that of peptides isolated from irradiated cells
using a mass spectrometric-based technique, referred to as SILAC (stable isotope labeling
with amino acids in cell culture), which involves differential in vivo labeling of proteins
[35]. Distinctive labeling was afforded by the incorporation of heavy or light isotopeladen arginine and lysine residues into the proteins of the two cell populations during
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normal protein synthesis. Subsequent to the irradiation, the heavy and light cell lysates
were mixed in a 1:1 ratio, digested with trypsin, and the resultant tryptic peptides were
subjected to immunoprecipitation with phospho-SQ- and phospho-TQ-specific antibodies
[35]. Separation and analysis of the bound phosphopeptides by liquid chromatography
(LC) coupled to tandem mass spectrometry (MS/MS) revealed some 900 phosphorylation
sites, all of which contained an ATM/ATR consensus site, exhibiting phosphorylationinduction upon DNA damage as indicated by a comparison of the intensities of the
differentially labeled SILAC pairs, which represent the phosphorylated peptide in the
presence or absence of irradiation. Interestingly, functional characterization of a limited
number of the candidate ATM/ATR substrates revealed a high concentration of proteins
involved in the regulation of the DNA damage response and DNA repair [35]. The
identification of such a vast number of proteins containing phosphorylated S/T motifs
analogous to those found within known ATM and ATR substrates, clearly demonstrates
the advantage of phosphopeptide enrichment prior to further analysis.

1.5.2 Unambiguous Identification of Phosphopeptides and Phosphorylation Sites
Using MALDI-TOFMass Spectrometry

A thorough characterization of protein phosphorylation and the regulatory
mechanisms it imparts on the modified protein must involve an identification of the
site(s) targeted for phosphorylation. Nowadays, the detection of phosphoproteins and
phosphopeptides, as well as the localization of specific phosphorylation sites, are usually
accomplished with mass spectrometry. This powerful analytical tool has become the
mainstay for the analyses of amino acid sequencing and post-translational modifications,
namely phosphorylation, as its sensitivity, mass accuracy, analytical speed, and
information output are unparalleled [36]. Although a variety of mass spectrometric
instrumentation is available, all mass spectrometers are comprised of four major
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components: a sample inlet, an ionization source, a mass analyzer, and a detection system
[36]. It is the nature of these former three components that is often used to define the
class of instrument, with different combinations of the various forms of these elements
providing a diverse array of mass spectrometric technologies [36]. For the purpose of
this study, only MALDI-TOF and MALDI-TOF/TOF mass spectrometry will be
described.
Mass spectrometry can be described as the study of gas-phase ions; hence,
analytes must be converted to gaseous ions prior to their analysis. Historically, the
production of gas-phase ions of high molecular weight biomolecules, such as proteins
and peptides, was viewed as an abominable challenge; however, the advent of 'soft'
ionization techniques, such as matrix-assisted laser desorption/ionization (MALDI), have
made this feat a fairly routine process [36]. MALDI involves dissolving the analyte
material, usually enzymatically-digested peptides, in a solution containing a UVabsorbing matrix [36]. Upon evaporation of the solvent, the matrix crystallizes, with the
peptide molecules being incorporated into the crystals. The processes of dissolution and
crystallization are conducted on the surface of a MALDI probe, which ultimately enters
the spectrometer at the sample inlet. Pulses of UV laser light are concentrated on the
probe, facilitating the vaporization of the matrix, which serves to promote the covaporization of the integrated peptides. Peptide ionization is afforded by the inherent
acidity of the matrix, as well as by the addition of dilute acids to the peptides during
sample preparation [36].
The nature of MALDI to generate ions in a pulsed fashion was ideal for its being
coupled to the method of mass analysis referred to as time-of-flight (TOF) [36]. TOF
mass analysis bases the measurement of the mass-to-charge (m/z) ratio of a peptide upon
the time it takes to travel through a field-free region to the detector.

Following

ionization, peptide ions are given a fixed amount of kinetic energy through their
acceleration within an electric field, generated through the application of a high voltage
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(Figure 1.5A). The peptides then enter the field-free flight tube, where they travel at a
velocity inversely related to their m/z ratio; thus, peptides with relatively low m/z ratios
travel more rapidly, reaching the detector first, while those with larger m/z ratios lag
behind and are detected later [36]. This provides a peptide mass fingerprint of the analyte
material, which not only depicts the m/z ratios of the peptide ions present, but also the
intensity at which they were detected. In order to facilitate the putative identification of
an unknown protein, the experimental m/z ratios can be assessed by mass mapping
software, such as MS-Fit, which attempts to identify the protein in question by comparing
these query ratios to theoretical and/or experimental ratios stored within sequence
databases [36].
MALDI-TOF mass spectrometry (MALDI-TOF-MS) is one of the most
commonly used mass spectrometric strategies, owing to its sensitivity and relative
simplicity;

however,

conventional

MALDI-TOF

analysis

cannot

provide

the

protein/peptide sequence information obtained through tandem mass spectrometry
(MS/MS) [36,37]. An extension of TOF mass analyzers are configured such that they are
capable of studying post-source decay (PSD) reactions, which can provide primary
sequence information of a selected peptide ion. PSD describes the process whereby a
peptide ion, often referred to as the precursor ion in the context of PSD, fragments in the
flight tube as a result of its instability, which is due to excess internal energy gained
directly from the laser or through high-energy collisions with other peptide ions [37].
Within the flight tube, the precursor ion and its fragment ions travel at the same velocity
and are therefore, not differentiated by the detector when operating in linear mode [36].
MALDI-TOF-PSD, which is performed in reflector mode, takes advantage of the fact that
the kinetic energy of the fragment ions is much lower than that of the original precursor
ion, due to their mass difference (Figure 1.5B). The precursor and fragment ions are
deflected toward a second detector using an electrically charged reflectron mirror located
at the end of the flight tube. Once again, the ions are discriminated by flight time
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Figure 1.5- Schematic Diagrams of MALDI-TOF and MALDI-TOF/TOF Mass
Spectrometers [3638]. Laser pulses vaporize the matrix crystals, carrying the peptide ions
into the gas phase. Gaseous ions are accelerated through the ion source into the flight tube
to the detector. (A) MALDI-TOF mass spectrometer. (B) MALDI-TOF mass spectrometer
operating in reflector mode. The reflector redirects the flight path of a precursor ion and its
fragments to a second detector. (C) MALDI-TOF/TOF mass spectrometer operating in
reflector mode. TOF1 ranges from the ion source to Source 2, whereas TOF2 comprises the
area spanning Source 2 to the reflector.
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dispersion with the fragment ions reaching the final detector at different times depending
on their m/z ratios [36]. The presence of an electrostatic ion gate, often referred to as a
timed ion-selector (TIS), allows PSD analysis of a precursor ion with a specific m/z ratio,
by deflecting non-selected m/z ions away from the entrance of the flight tube [36]. The
resulting spectrum displays the precursor ion, as well as its fragment ions, whose
detection provides amino acid sequencing information whether through de novo
sequencing or through the use of information maintained within protein sequencing
databases.
The classical method of PSD analysis can be time-consuming, as the acquisition
of PSD data involves the detection of fragment ions in multiple mass ranges using
different mirror voltages with a final stitching of these segments to produce the complete
fragment ion spectra [36,38]. In an effort to overcome the shortcomings of PSD analysis,
MALDI is often coupled to a TOF/TOF mass analyzer, which is capable of true tandem
mass spectrometric (MS/MS) experimentation [38]. As the name suggests, TOF/TOF
mass analyzers differ from their TOF counterparts in that they house two TOF mass
analyzers in a linear arrangement (Figure 1.5C). The first TOF region, functions in a
manner similar to a singular TOF mass analyzer, as it is responsible for the acceleration
and focusing of the analyte ions [38]. Following precursor ion selection, a precursor ion
and its fragment ions move into a second ion source contained within the second TOF
region, where they are reaccelerated and forced to travel at velocities inversely related to
their own m/z ratios, allowing the acquisition of a complete fragmentation spectra in one
step at a fixed mirror voltage [38]. MALDI-TOF/TOF mass spectrometers are also most
often equipped with a collision cell, which enables the collision-induced dissociation
(CID) of a selected precursor ion through high-energy collisions with inert gas molecules.
This allows TOF/TOF mass analyzers to provide MS/MS data from the analysis of both
PSD and CID products, which enhances the quality of the fragment ion spectra, as PSD is

23

often limited to the formation of large fragment ions, whereas CID can promote the
generation of smaller fragments [38].
The interpretation of an MS/MS spectrum, whether generated through PSD and/or
CID, relies on a common nomenclature to characterize the various types of fragment ions
that may occur. A majority of the fragmentation events of a precursor ion involves the
breakage of the peptide bond, resulting in the formation of two fragments, one containing
the N-terminus and the other the C-terminus [39]. The classification of these ions
depends upon the location of the proton on the precursor ion. If the proton is retained on
the N-terminal fragment, a b-ion will be observed, whereas, if the proton is present on the
fragment containing the C-terminal, a y-ion is detected (Figure 1.6A).

Although

relatively less abundant in CID, other forms of fragmentation do exist, namely those
resulting in immonium ions, which are characteristic of individual amino acids, or
internal fragment ions, produced by a double cleavage of the peptide backbone [39].
The post-translational modification of a protein commonly involves the addition
of a functional group to a particular amino acid side chain. Thus, the identification of
modified peptides by mass spectrometry is made possible through the detection of
characteristic mass differences between the modified and unmodified versions of a given
peptide. In the case of phosphorylation, mass spectrometric analysis reveals a net mass
increase of 80 daltons (Da) from the unphosphorylated peptide to its phosphorylated
form, owing to the addition of a phosphate group and the concerted loss of a water
molecule [37]. Provided that the amino acid sequence of the protein in question is
known, phosphopeptides can be putatively identified using peptide mass calculator
programs, such as MS-Digest, which enable the comparison of experimental m/z data to
theoretical data determined by in silico digestion.
Unambiguous identification of a phosphopeptide and precise determination of its
phosphorylation site(s) can be achieved through PSD or MS/MS analysis.

Putative

phosphopeptides, detected through initial mass spectrometric analysis, can be selectively
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Figure 1.6- Peptide Ion Fragmentation [39]. (A) The predominant fragmentation of a
precursor ion involves the breakage of the peptide bond. If the charge is retained on the Nterminal fragment, a b-ion is detected; whereas, if the charge is retained on the C-terminal
fragment, a y-ion is observed. (B) Fragmentation of phosphoserine- and phosphothreoninecontaining peptides is often accompanied by a neutral loss of phosphoric acid (H 3 P0 4 ),
which results in their conversion to dehydroalanine and 2-aminobutyric acid, respectively.
The loss of-98 m/z from the precursor ion is diagnostic of the loss of H 3 P0 4 .
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fragmented and the fragment ions analyzed for the presence of a phosphate group.
Phosphopeptide ions can be identified by their tendency to lose meta-phosphoric acid
(HPO3) and phosphoric acid (H3PO4) during fragmentation, which are diagnostically
represented as losses of 80 Da and 98 Da, respectively. While serine- or threoninephosphorylated peptide ions predominantly exhibit the loss of 98 Da (Figure 1.6B),
peptide ions containing phosphotyrosine residues generally show only a loss of 80 Da,
enabling the differentiation between tyrosine and serine/threonine phosphorylation [28].
Examination of the set of fragment ions generated through PSD and/or CID can provide
the information required to map the phosphate group to a specific residue along the
precursor ion. As mentioned previously, the highly reversible nature of phosphorylation
poses a challenge to the study of phosphoproteins.

Phosphopeptide detection and

phosphorylation site identification is further confounded by the suppression of signals
elicited by phosphoproteins, which can be attributed to the sheer abundance of
unphosphorylated peptides within complex peptide mixtures [28]. The prevalence of
phosphopeptide signal suppression makes the enrichment of phosphorylated peptides
prior to mass spectrometric analysis a very critical task.
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1.6 Project Objectives

The overall purpose of this study is to identify proteins containing a novel
phosphorylation motif, first discovered within the N-terminal region of P-catenin [16].
This phosphomotif is comprised of four phosphorylated serine or threonine residues with
each phosphorylation site separated from the last by three amino acid residues:
pS/pTXXXpS/pTXXXpS/pTXXXpS/pT, where pS, pT represent phosphoserine and
phosphothreonine residues, respectively, and X represents arbitrary amino acid residues.
We have termed this specific phosphorylated sequence the tetra-phosphorylation motif
(TPM). The remarkable level of regulation imparted by the P-catenin TPM in the control
of its degradation leads us to hypothesize that the TPM exists within other proteins.

Specifically, our objectives are as follows:

1.) Characterize a purified, polyclonal phosphospecific antibody raised against a TPM
phosphopeptide library.

2.) Identify novel TPM-containing proteins using bioinformatic, immunological, and
mass spectrometric methods.

3.) Characterize the functional consequence of the TPM in novel proteins containing this
phosphomotif, in terms of its role in protein stability and cellular regulation.
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Chapter 2
Materials and Methods

2.1 Antibodies

The chicken TPM phosphoantibody was developed by Aves Labs Inc. (Tigard,
OR) against a synthetic phosphopeptide antigen library (CZ[pS] XXX [pS]XX X[pS]X
XX[pS]), which consists of phosphopeptides with phosphoserine (pS) residues at every
fourth position and all possible combinations of amino acids at the X positions.
Polyclonal, TPM phosphoantibodies were purified by double subtractive affinity
chromatography. Mouse ANTI-FLAG® M2 Monoclonal, rabbit anti-actin, and rabbit Pcatenin antibodies were purchased from Sigma-Aldrich, Inc. (Saint Louis, MO). The
monoclonal, mouse haemagglutinin (HA) antibody was obtained from Berkeley Antibody
Company (BAbCO; Richmond, CA), whereas the mouse KLF7 polyclonal antibody was
from Abnova Corp. (Taipei, Taiwan).

Mouse c-Myc (clone 9E10) antibody was

purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Rabbit anti-TAZ and
mouse anti-ubiquitin (clone P4D1) antibodies were purchased from Cell Signaling
Technology, Inc. (Beverly, MA). The rabbit 14-3-3 antibody was from Abeam Inc.
(Cambridge, MA). Horseradish peroxidase-conjugated, donkey anti-chicken IgY (H+L)
antibody was purchased from Gallus Immunotech, Inc. (Fergus, ON).

Horseradish

peroxidase-conjugated, goat anti-rabbit IgG (H+L) antibody was from Bio-Rad
Laboratories, Inc. (Hercules, CA) and the horseradish peroxidase-conjugated, goat antimouse IgG (H+L) antibody was from Promega Corp. (Madison, WI).

2.2 Plasmids

Wild-type TAZ cDNA (MGC-19891; ATCC) was subcloned into the pFLAGCMV-2 eukaryotic expression vector (Sigma-Aldrich, Inc.) to generate FLAG-TAZ.
Briefly, full-length, human, placental TAZ cDNA, cloned within the prokaryotic
expression vector, pOTB7, was obtained as an E. coli stab. The bacteria were cultured in
Luria's Broth (LB) with 25 p.g/mL chloramphenicol.

The plasmid DNA was then

isolated using the GenElute Plasmid Miniprep Kit (Sigma-Aldrich, Inc.), according to
the manufacturer's instructions.

The TAZ cDNA was amplified via PCR with the

Platinum® Pfic DNA Polymerase (Invitrogen Corp.; Burlington, ON), using the following
primers: Sense, 5'-CGGAATTCGATGAATCCGGCCTCG-3' and Antisense,
5'-CGTTAAGGATCCTTACAGCCAGGTTAG-3', which contain the EcoR I and BamH
I restriction enzyme recognition sites, respectively.

The resulting PCR product was

verified on a 1% agarose gel with 0.02% ethidium bromide and subsequently purified
using the QIAquick® PCR Purification Kit (Qiagen, Inc.; Mississauga, ON), according to
the manufacturer's instructions. The verified product was then subcloned into the EcoR I
and BamH I sites of the pFLAG-CMV2 expression vector, which incorporates a FLAG
tag at the N-terminus of all constructs, via in-gel ligation. Briefly, pFLAG-CMV-2 and
the purified TAZ PCR product were digested with EcoR I (Promega Corp.) and BamH I
(Promega Corp.) at 37°C for 2 h, and run on a 1% low-melt agarose gel with 0.02%
ethidium bromide. The corresponding bands were excised from the gel and melted at
65°C for 10 - 15 min.. Ligation was then performed overnight at 4°C with T4 DNA
Ligase (Promega Corp.). DH5a E. coli competent cells were transformed with the
ligated pFLAG-CMV-2-TAZ expression vector and grown on LB/Agar medium with 100
|j.g/mL ampicillin.

Wild-type KLF7, encoded within the pCS2+MT eukaryotic

expression vector, which incorporates 6 Myc tags at the N-terminal of the encoded
protein, was kindly provided by Dr. L. Lei (Arizona State University).
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Mutant constructs were generated via site-directed mutagenesis with cloned Pfu
DNA Polymerase from Stratagene (Cedar Creek, TX). The PCR products, verified by
1% agarose gel with 0.02% ethidium bromide and digested with Dpn I (New England
Biolabs, Ltd.; Pickering, ON) to degrade the methylated template DNA, were then
transformed in DH5a E. coli competent cells and grown on LB/Agar medium with 100
ug/mL ampicillin. The plasmid DNA was isolated as previously mentioned. The FLAGtagged TAZ S58A/S62A double mutant construct (FLAG-TAZ SDM) was generated by
subsequent site-directed mutagenesis events. Initially, FLAG-TAZ S58A was created
with the following primers: Sense, 5'-GAGCCTGATGCGGGCTCGCACTCG-3' and
Antisense, 5'-CGAGTGCGAGCCCGCATCAGGCTC-3', using FLAG-TAZ as the
template DNA. The FLAG-TAZ SDM construct was then generated by mutating Ser62
to an alanine using FLAG-TAZ S58A as the template DNA, along with the following
primers: Sense, 5'-GCTCGCACGCGCGCCAGTCCAG-3' and Antisense,
5'-CTGGACTGGCGCGCGTGCGAGC-3\

The Myc-tagged, double mutant of KLF7

(Myc-KLF7 STDM), which harbours alanine substitutions at Thrl9 and Ser23, was
created in the same manner as mentioned above for FLAG-TAZ SDM. The initial
mutation

was

made

at

Thrl9

with

the

following

CAACTTGTCCACGACGCCGGCTACTTCTC-3'

and

primers:

Sense,

Antisense,

5'5'-

GAGAAGTAGCCGGCGTCGTGGACAAGTTG-3' using Myc-KLF7 as the template
DNA. The S23A mutation was then made on the Myc-KLF7 T19A template DNA, with
the following primers: Sense, 5'-GGCTACTTCGCAGCTTTACCATCCCTGGAG-3'
and Antisense, 5'-CTCCAGGGATGGTAAAGCTGCGAAGTAGCC-3\

The FLAG-

tagged TAZ tetra-mutant construct (FLAG-TAZ ATPM), which contains alanine
mutations at Ser58, Ser62, Ser66, and Ser70, was also generated by subsequent sitedirected mutagenesis experiments. Firstly, Ser66 was mutated to an alanine, using the
following primers and FLAG-TAZ SDM as the template DNA: Sense, 5'GCGCC AGTCCGCC ACCGACTCGTCG-3'
30

and

Antisense,

5'-

CGACGAGTCGGTGGCGGACTGGCGC-3', followed by the mutation of Ser70 to an
alanine, using the following primers and FLAG-TAZ S58A/S62A/S66A as the template
DNA:

Sense,

5'-CACCGACTCGGCGGGCGGCC-3'

and

Antisense,

5'-

GGCCGCCCGCCGAGTCGGTG-3'.
FLAG-TAZ SI 17A was created by introducing an alanine mutation at Serl 17 on
the

FLAG-TAZ

template

DNA

with

the

CCGCCAGCAGGCCTACGACGTGAC-3'
GTCACGTCGTAGGCCTGCTGGCG-3'.

following

primers:

Sense,

and

Antisense,

5'5'-

The FLAG-TAZ S117D mutant was also

produced from the FLAG-TAZ template DNA by substituting Serl 17 with an aspartic
acid

residue

using

the

following

CCTCCGCCAGC AGGACTACGACGTGACC-3'

primers:
and

Sense,
Antisense,

5'
5'-

GGTCACGTCGTAGICCTGCTGGCGGAGG-3'. FLAG-TAZ S93A was generated by
substituting Ser93 of FLAG-TAZ with an alanine residue using the primers listed here:
Sense,

5'-GTCGCCCGCGGCCCTGCAGCTG-3'

CAGCTGCAGGGCCGCGGGCGAC-3'.

and

Antisense,

5'-

The FLAG-TAZ S93D mutant was also

produced on FLAG-TAZ by replacing Ser93 with an aspartic acid residue using the
following primers: Sense, 5'-GTCGCCCGCGGACCTGCAGCTGGG-3' and Antisense,
5'-CCCAGCTGCAGGJCCGCGGGCGAC-3'.

The 14-3-3 binding mutant of TAZ,

FLAG-TAZ S89A, was produced by mutating Ser89 to an alanine on FLAG-TAZ using
the following primers: Sense, 5'-CTCGCACGCGTCGCCCGCGTC-3' and Antisense,
5'-GACGCGGGCGACGCGTGCGAG-3\
The FLAG-TAZ AClDSG and FLAG-TAZ ATPM/AClDSG mutants were
generated by substituting Ser314, which corresponds to Ser309 of mouse TAZ, of FLAGTAZ or FLAG-TAZ ATPM, respectively, with an alanine residue, using the ensuing
primers: Sense, 5'-GCAGAGCACTGACGCTGGCCTGGGGTTAG-3' and Antisense,
5'-CTAACCCCAGGCCAGCGTCAGTGCTCTGC-3'.

Myc-TAZ, Myc-TAZ ATPM,

Myc-TAZ AC'DSG, and Myc-TAZ ATPM/AC'DSG were then constructed by liberating
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the gene encoding KLF7 from the pCS2+MT vector and inserting the genes encoding the
aforementioned TAZ variants in its place. Briefly, FLAG-TAZ, FLAG-TAZ ATPM,
FLAG-TAZ AClDSG, and FLAG-TAZ ATPM/AClDSG were amplified via PCR with the
Platinum® PJx DNA Polymerase (Invitrogen Corp.), using the following primers: Sense,
5'-CGGj\ATTCGATGAATCCGGCCTCG-3\ which adds an EcoR I site upstream of
the taz gene, and Antisense, 5'-GGATTCTCTAGATTACAGCCAGGTTAG-3', which
inserts an Xba I restriction site at the 3' end of the taz gene. The resulting PCR products
were verified on a 1% agarose gel with 0.02% ethidium bromide and then purified using
the QIAquick

PCR Purification Kit (Qiagen, Inc.), according to the manufacturer's

instructions. The klf7 gene was then excised from the pCS2+MT vector by digesting the
vector with EcoR I (Promega Corp.) and Xba I (Promega Corp) for 2 h at 37°C. The
varying forms of the taz gene were digested in the same manner as pCS2+MT and
subsequently inserted into the EcoR I and Xba I restriction sites of the pCS2+MT
expression vector via in-gel ligation, using the method described previously for the
generation of pFLAG-CMV-2-TAZ.
All PCR primers were synthesized by Invitrogen Corp. and the sequences of all of
the DNA constructs were verified by automated DNA sequencing (ACGT Corp.;
Toronto, ON).

All plasmid DNA was amplified by transforming DH5a E. coli

competent cells and subsequently isolated using the HiSpeed® Plasmid Maxi Kit
(Qiagen, Inc.), according to the manufacturer's specifications.
The HA-tagged ubiquitin construct was generously provided by Dr. L. Porter
(University of Windsor).

FLAG-P-TrCP, encoded within the pcDNA3 mammalian

expression vector, was obtained as a bacterial stab from Addgene Inc. (Cambridge, MA).
The HA-tagged GSK-3P (S9A) mutant construct was generously provided by Dr. K. L.
Guan (University of Michigan). The Myc-tagged P-catenin ATPM mutant was a gracious
gift from Dr. A. Ali (University of Windsor).
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2.3 Cell Culture

Human embryonic kidney (HEK) 293 and mouse 3T3-L1 embryonic fibroblast
cells were obtained from American Type Tissue Culture Collection (ATCC; Manassas,
VA).

HEK 293 cells were grown as a monolayer in Dulbecco's Modified Eagle's

Medium/Nutrient F-12 Ham (D-MEM/F-12), supplemented with 10% fetal bovine serum
(FBS), 2mM L-glutamine, and antibiotics (100 units/mL penicillin, 100 ug/mL
streptomycin), at 5% CO2 and 37°C.

3T3-L1 cells were grown as a monolayer in

Dulbecco's Modified Eagle Medium (D-MEM/F-12), supplemented with 10% bovine
calf serum (BCS), 2mM L-glutamine, and antibiotics (100 units/mL penicillin, 100
|^g/mL streptomycin), at 5% CO2 and 37°C.

The cells were maintained at 70 - 80%

confluency on 6-well plates or 100 mm tissue culture dishes (Sarstedt, Inc.; Montreal,
QC). L-glutamine, antibiotics, and 10X Trypsin-EDTA were purchased from Gibco™
Life Technologies (Invitrogen Corp.). D-MEM/F-12 and FBS were from Sigma-Aldrich,
Inc., while the BCS was purchased from Hyclone (Thermo Fisher Scientific, Inc.;
Ottawa, ON).

2.4 Transient Transfection, Cell Treatments, and Cell Lysis

HEK 293 and 3T3-L1 cells were transfected with expression vectors encoding
HA-GSK3P (S9A) (7 ug/100 mm dish), Myc-p-catenin ATPM (7 ug/100 mm dish),
various FLAG-TAZ and Myc-TAZ constructs (1-3 fig/30 mm dish; 5 ug/100 mm dish),
wild-type Myc-KLF7 and Myc-KLF7 STDM (1-3 ng/30 mm dish; 5 ug/100 mm dish),
FLAG-p-TrCP (10 ug/100 mm dish), and HA-ubiquitin (10 ug/100 mm dish). These
amounts of DNA were maintained within co-transfection experiments. Empty vector
DNA (pFLAG-CMV-2) was transfected alongside single transfections to normalize the
DNA content during co-transfections.
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Briefly, approximately 5xl0 5 cells per 30 mm dish and approximately 2xl0 6 cells
per 100 mm dish were seeded in D-MEM/F-12 media 24 h prior to transfection. Cells
were transiently transfected at a confluency of approximately 70 - 80% with FuGENEHD Transfection Reagent (Roche Diagnostics; Laval, QC), according to manufacturer's
specifications, unless a different transfection method was specified. Four hours posttransfection, cell culture media was replaced with fresh media.
Cells were treated with MG-132 (Calbiochem; San Diego, CA), a proteasome
inhibitor, and Calyculin A (LC Laboratories; Woburn, MA), a Ser/Thr phosphatase
inhibitor, approximately 24 h after transfection. Cells were incubated with 10 uM MG132 and/or 100 nM Calyculin A for 1 h at 37°C and 5% C0 2 , prior to cell lysis. Cells
were then lysed in lysis buffer (50 mM Tris-HCl (pH 7.4), 1% Triton X-100, 150 mM
NaCl, 0.1% SDS) in the presence of protease (aprotinin, PMSF, EDTA) and phosphatase
(NaF) inhibitors.

Briefly, untreated cells or cells solely treated with MG-132 were

washed with cold Dulbecco's Phosphate-Buffered Saline (D-PBS; Sigma-Aldrich, Inc.)
and then suspended in ice cold lysis buffer. Calyculin A-treated cells lift from the tissue
culture dish and become suspended in the media, consequently, they were pelleted at
2500 rpm for 5 min. at room temperature. The cells were then washed with cold PBS and
resuspended in ice-cold lysis buffer. Whole cell lysates were cleared at 14,000 rpm at
4°C for 20 min., so as to pellet the cellular debris. Where indicated, protein concentration
was measured using the Bradford reagent (BioRad Laboratories, Inc.), according to
manufacturer's instructions.

Cleared cell lysates were immediately subjected to

immunoprecipitation or were maintained at -20°C until further experimentation.

2.5 Immunoprecipitation and Immunoblotting Analysis

The immunoprecipitation of FLAG-tagged and Myc-tagged proteins was enabled
through the incubation of cleared cell lysates with Anti-FLAG® M2-Affinity Gel (Sigma34

Aldrich, Inc.) or Anti-c-Myc Agarose Conjugate (Sigma-Aldrich, Inc.), respectively, for
3 h at 4°C on a horizontal rotator. Following incubation, immune complexes were gently
centrifuged at <6000 rpm for 1 min. and washed 2 - 4 times with cold IP wash buffer (50
mM Tris-HCl (pH 7.4), 0.1% Triton X-100, 150 mM NaCl, 0.1% SDS). The bound
proteins were eluted through the addition of 2X SDS protein loading dye (0.120 M TrisHCl (pH 6.8), 4% SDS, 0.3% p-mercaptoethanol, 10% glycerol, 0.004% bromophenol
blue, 3% dithiothreitol (DTT)), boiling for 5 min. at 95 - 100°C, followed by harsh
vortexing and centrifugation at > 14,000 rpm. The samples were maintained at -20°C
until subsequent analysis.
Cleared cell lysates, denatured in 6X SDS protein loading dye (0.350 M Tris-HCl
(pH 6.8), 10% SDS, 0.3% p-mercaptoethanol, 30% glycerol, 0.012% bromophenol blue,
3% DTT) and proteins eluted from immune complexes were resolved via SDS-PAGE on
10 - 12% polyacrylamide gels. All gels were run at 150 V in IX SDS-PAGE running
buffer (0.192 M, 0.025 M Tris-base, 0.01% SDS, pH 8.3).
proteins were transferred

to methanol-activated,

Following SDS-PAGE,

Immobilon™-P

polyvinylidene

difluoride (PVDF) membrane (Millipore Corp.; Bedford, MA), unless otherwise
specified. Protein transfer was performed for 1 h at 100 V in ice-cold IX transfer buffer
(20% methanol, 0.192 M glycine, 0.025 M Tris-base, pH 8.3). Following transfer, all
membranes were blocked in 5% non-fat, dry milk in IX Tris-Buffered Saline (IX TBS;
0.068 M NaCl, 8.3mM Tris-base, pH 7.6) containing 0.1% Tween®-20 (IX TBSt; Fisher
Scientific, Inc.), with the exception of membranes to be probed with the TPM
phosphoantibody, which were blocked in 5% bovine serum albumin (BSA; SigmaAldrich, Inc.) in IX TBSt. Membranes probed with primary antibodies requiring 1 h
incubation were blocked overnight at 4°C with gentle agitation, whereas those incubated
with primary antibodies overnight were blocked for only 1 h at room temperature.
Immediately following blocking, the membranes were probed with the indicated primary
antibody as outlined below. Anti-TPM was used at a dilution of 1:1000 in IX TBSt. The
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(3-catenin primary antibody was also used at 1:1000 in 5% BSA in IX TBSt. Anti-TAZ
was used at a dilution of 1:2500 in IX TBSt, whereas anti-actin was utilized at 1:1000 in
IX TBSt. The pan-14-3-3 antibody was used at 1:1000 in IX TBSt. Membranes probed
with the antibodies described above were incubated overnight at 4°C with gentle
agitation. Anti-FLAG was used at 1:3000 in 2.5% milk dissolved in IX TBSt, while antic-Myc was used at 1:1000 in 2.5% milk in IX TBSt. The KLF7 antibody was diluted
1:3000 in 2.5% milk in IX TBSt. The ubiquitin antibody was used at 1:5000 in 2.5%
milk in IX TBSt. Anti-HA was utilized at a dilution of 1:1000 in 2.5% milk in IX TBSt.
The antibodies listed above were incubated for 1 h at room temperature with gentle
agitation.

Following primary antibody incubation, all membranes underwent three

washes of 5 min. each with IX TBSt, with the exception of those membranes probed with
anti-TPM, which were subjected to three 15 min. washes.

Membranes were then

incubated with their species-specific, horseradish peroxidase-conjugated secondary
antibody, followed by washing as indicated above.

All secondary antibodies were

incubated for 45 min. at room temperature at a dilution of 1:5000 in IX TBSt.
Immunoreactive bands were visualized via chemiluminescence using the SuperSignal®
West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, Inc.), according
to the manufacturer's instructions.

2.6 In Vitro Dephosphorylation Assays

2.6.1 Synthetic Peptide Library Assays

The synthetic phosphopeptide (CZ[pS] XXX [pS]XX X[pS]X XX[pS]; Aves
Labs, Inc.) and non-phosphopeptide libraries (CZS XXX SXX XSX XXS; Aves Labs,
Inc.) were reconstituted with HPLC-grade water (Honeywell, Inc.; Muskegon, MI) to 4
mg/mL. Calf intestinal alkaline phosphatase (CIAP; Promega, Corp.), was diluted from 1
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unit/uL to 0.5 units/uL with 50 mM ammonium bicarbonate, pH 8.0, to reduce the
glycerol content of the CIAP storage buffer, as glycerol is incompatible with mass
spectrometry. Twenty micrograms of the phosphopeptide library were incubated with 2
units of CIAP in 20 uL of 50 mM ammonium bicarbonate, pH 8, at 37°C for increasing
time points to achieve dephosphorylation of approximately 1 phosphate group (5 min.),
approximately 2 phosphate groups (90 min.), and approximately 3 phosphate groups (120
min.). At the indicated time points, 4 uL aliquots were taken from the reaction mixture
and the dephosphorylation reaction was quenched by the addition of 5% formic acid
(Sigma-Aldrich, Inc.).

The reconstituted phosphopeptide and peptide libraries were

subjected to the same reaction conditions described above; however the reactions were
quenched immediately with 5% formic acid to generate tetra-phosphorylated and
unphosphorylated peptides, respectively.
The phosphopeptide and peptide libraries were then analysed by mass
spectrometry using a matrix-assisted laser desorption ionization (MALDI)-time of flight
(TOF) mass spectrometer (Applied BioSystems Voyager-DE™ PRO BioSpectrometry™
Workstation; Applied BioSystems, Framingham, MA) in linear mode. The samples were
crystallized on a MALDI target plate (Applied BioSystems) with a matrix of a-cyano-4hydroxycinnamic acid (Sigma-Aldrich, Inc.) in 60% acetonitrile, 1% formic acid. The
mass profiles of the phosphopeptide libraries were analysed for a loss of phosphate
group(s) (-m/z 80, -m/z 160, -m/z 240, -m/z 320), so as to determine the approximate
number of phosphates remaining on the phosphopeptide libraries.
The peptide libraries corresponding to 0 phosphates, approximately 1 phosphate,
approximately 2 phosphates, approximately 3 phosphates, and 4 phosphate groups were
diluted to a final concentration of 0.1 ng/uL in HPLC-grade water for dot blot analysis.
One microlitre of each sample was directly spotted on nitrocellulose membrane
(Millipore Corp.) and allowed to completely dry. Immunoblot analysis with the TPM
phosphoantibody was then conducted as outlined above (2.5).
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2.6.2 Immunoprecipitant and Lysate Assays

Following the final wash step of the immunoprecipitation procedure outlined
earlier (2.5), the immune complexes were resuspended in 200 uL of lysis buffer.
Approximately 100 uL of the resuspended immunoprecipitants were incubated with 3
units of CIAP (1 unit/uL; Promega Corp.), as was a 25 uL aliquot of cleared cell lysate,
for 30 min. at 37°C, while the remaining immunoprecipitants and a second aliquot of
lysate were left untreated. CIAP activity was quenched by the addition of 20 uL of 2X
SDS protein loading dye to the immunoprecipitants and 10 uL of 6X SDS protein loading
dye to the lysates. Proteins were then resolved by SDS-PAGE and detected through antiFLAG immunoblotting (2.5).

2.7 Phosphorylation Site Analysis ofFLAG-TAZ

2.7.1 LargeScale Immunoprecipitation

Six 10 cm tissue culture plates were each seeded with approximately 2xl0 6 HEK
293 cells in DMEM/F12 media 24 h prior to transient transfection. The cells were given
fresh DMEM/F12 media 1 h prior to transfection. Each plate was transfected with 15 ug
of FLAG-TAZ DNA using the calcium phosphate (CaP04) method [40]. Briefly, 15 (ig
of FLAG-TAZ DNA were diluted in 50 uL of 2.5 M CaCb, which was then brought to a
final volume of 500 uL with 1/10 TE buffer (1 mM Tris-HCl, 0.1 mM EDTA, pH 7.6).
The mixture was then added in a drop-wise fashion to an equal volume (500 uL) of 2X
HEPES buffer (140 mM NaCl, 1.5 mM Na 2 HP0 4 , 50 mM HEPES, pH 7.05) while
mixing. In order to facilitate DNA-CaPC>4 co-precipitate formation, the mixture was
allowed to incubate for 20 min. at room temperature. The DNA-CaP04 complexes were
then added drop-wise to the cells and incubated for 4 h at 37°C, 5% CO2, after which the
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culture media was replaced with fresh DMEM/F12.

Approximately 24 h post-

transfection, the cells were treated with 10 uM MG-132 and 100 nM Calyculin A for 1 h
at 37°C, 5% CO2. Each plate of cells was then harvested in 300 uL of lysis buffer and
lysed in the manner indicated above (2.4). The cleared cell lysates were then pooled and
immunoprecipitation of FLAG-TAZ was performed using 75 uL of Anti-FLAG® M2Affinity Gel (Sigma-Aldrich, Inc.), as outlined previously (2.5). Immune complexes
were eluted from the beads by boiling at 95°C for 5 min. in 65 uL of 2X SDS protein
loading dye and subsequently resolved by 10% SDS-PAGE. Proteins were visualized by
Coomassie staining (40% ethanol, 10% acetic acid, 0.1% Coomassie Brilliant Blue) and
subsequently destained with Destain Solution (40% ethanol, 10% acetic acid) to reduce
the background stain.

They were also transferred to PVDF membrane and

immunoblotted with the FLAG antibody, as specified above (2.5).

2.7.2 Mass Spectrometric Analysis

The protein band corresponding to FLAG-TAZ, visualized through Coomassie
staining, was carefully excised from the polyacrylamide gel using a sterile blade in a
laminar flow hood. The band was then destained in destain solution (50% acetonitrile, 50
mM ammonium bicarbonate) for 35 min. at 37°C with gentle agitation. Dependent on the
extent of staining, the destaining procedure may have been repeated once with fresh
destain solution. Dehydration of the gel piece was then achieved with two changes of
HPLC-grade acetonitrile (Honeywell, Inc.), until it appeared opaque. The gel piece was
then thoroughly dried by speed vacuuming (Speedvac Plus SC110A; Sorvall) for 20
minutes. The protein was then subjected to in-gel trypsin digestion with approximately
500 - 750 ng of modified, sequencing grade trypsin (Promega Corp.) resuspended in 50
mM ammonium bicarbonate, pH 8.0, to a final concentration of 13 ng/uL. A 5 u.L
aliquot was taken from the in-gel digestion sample, following approximately 1 - 3 h of
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digestion.

Trypsin digestion was then allowed to proceed overnight at 37°C with

agitation.

Following digestion, the sample was harshly vortexed and centrifuged at

> 14,000 rpm. The supernatant (pre-extraction solution), containing digested peptides
freed from the gel piece, was then collected and acidified with 5% formic acid (SigmaAldrich, Inc.). Remaining peptides were extracted from the gel through incubation in 200
^L of extraction solution (60% acetonitrile, 1% formic acid) for 45 min. at 37°C with
shaking.

The sample was then vortexed and centrifuged, and the supernatant was

removed and added to 5 uL of 5% formic acid. Peptide extraction was repeated one time
with 100 (iL of extraction solution for 10 minutes. The collected peptide solutions were
then concentrated to approximately 10 uL by speed vacuuming (Speedvac Plus SCI 10A;
Sorvall).
If required, peptide samples were desalted using ZipTip® CI8 Microtips
(Millipore, Inc.), following speed vacuuming. Briefly, microtips with a volume capacity
of 10 uL (1 volume) were activated with 5 volumes of 60% acetonitrile, followed by
equilibration with 10 volumes of 1% formic acid. The peptides were then bound to the
resin by repeated pipetting in the concentrated peptide solution and washed with 5
volumes of 1% formic acid. The bound peptides were eluted by repeated pipetting in 1
volume of 60% acetonitrile, 1% formic acid.
Tryptic peptides were spotted on a MALDI target plate (Applied BioSystems), as
indicated previously (2.6.1), and were analyzed on a MALDI-TOF mass spectrometer
(Applied BioSystems Voyager-DE™ PRO BioSpectrometry™ Workstation; Applied
BioSystems). The mass spectra were acquired in linear mode and were internally masscalibrated. The tryptic peptide ion masses were compared to those generated by an in
silico tryptic digestion of the human TAZ protein (NCBI Accession #: NP056287) using
the MS-Digest program of Protein Prospector (UCSF; University of California, San
Francisco, CA), which enabled the recognition of all potential phosphopeptide ions.
Multiple precursor ions of interest were subjected to automated, collision-induced
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dissociation (CID) to verify the identity of the phosphopeptides and to map the
phosphorylation sites to specific residues, unless indicated otherwise. MS/MS analysis
was conducted at the University of Michigan Mass Spectrometry Facility (Ann Arbor,
MI) via MALDI-TOF/TOF (4800 MALDI-TOF/TOF™ Analyzer; Applied BioSystems).
The precursor ion fragment masses were analysed with the MS-Product program of
Protein Prospector (UCSF).

2.8 Protein Stability Assay

Approximately 2.5xl0 4 HEK 293 cells were seeded in 30 mm tissue culture
dishes 24 h prior to transient transfection.

Cells were then transfected with 1 fig of

FLAG-TAZ, FLAG-TAZ ATPM, Myc-KLF7, or Myc-KLF7 STDM using FuGENE-HD
Transfection Reagent (Roche Diagnostics), according to manufacturer's instructions.
Forty-eight hours post-transfection, cells were treated with 200 (xg/mL of cycloheximide
(Sigma-Aldrich, Inc.) resuspended in DMSO to induce the inhibition of protein
translation. At the indicated time points following cycloheximide treatment, the cells
were lysed in 200 uL of lysis buffer, as described previously (2.4). The concentration of
extracted protein in each of the samples was measured using the Bradford reagent
(BioRad Laboratories, Inc.), according to product specifications.

Equal amounts of

protein were then resolved by SDS/PAGE and subsequently analysed by anti-FLAG or
anti-c-Myc immunoblot analysis, as outlined above (2.5). The same membranes were
also probed with actin antibody to ensure equal protein loading.

2.9 Preadipocyte Differentiation and Oil Red O Staining

Mouse 3T3-L1 preadipocyte cells were seeded 24 h prior to transfection at
approximately 5xl0 5 cells per 30 mm tissue culture dish in DMEM/F12 containing 10%
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BCS. Cells were transiently transfected with 3 u.g of the specified DNA using FuGENEHD Transfection Reagent (Roche Diagnostics), according to manufacturer's instructions.
Preadipocyte differentiation was conducted according to the specifications outlined in the
Adipogenesis Assay Kit from Caymen Chemical (Ann Arbor, MI). All reagents required
for the differentiation were provided within the aforementioned kit. Briefly, cells were
allowed to reach confluency (approximately 24 - 30 h post-transfection), at which time
differentiation was induced by the addition of induction media, which contains IX
solutions of 3-isobutyl-l -methyl xanthine (IBMX), dexamethasone, and insulin in
DMEM/F12 containing 10% FBS. After 72 h of induction, the cells were weaned from
the induction media by its replacement with insulin media, which contains a IX solution
of insulin in DMEM/F12 with 10% FBS. Forty-eight hours later, fresh insulin media was
added to the cells to support further differentiation. The cells were then monitored until
the desired degree of lipid accumulation was reached (approximately 48 h after the
second change of insulin media), at which time Oil Red O (ORO) staining was
commenced.
All of the reagents required for ORO staining were also provided within the
Adipogenesis Assay Kit (Caymen Chemical). The staining was conducted in accordance
with the kit instructions. All steps were performed at room temperature with a 2 mL
solution volume. Briefly, the differentiated cells were fixed for 15 min. in IX Fixative
Solution, followed by two 5 min. wash steps in an alcohol-based solution. The fixed cells
were allowed to completely dry and then stained in a working solution of ORO (60%
ORO in water; filtered with a 0.45 uM syringe filter). Following the 20 min. staining
period, residual dye was removed through multiple washes with distilled water and two 5
min. washes with the Wash Solution. Phase contrast images of the ORO stained cells
were then taken at magnifications of 5 Ox or lOOx using a Leica Inverted Research
Microscope (Leica Microsystems; Richmond Hill, ON).

42

Chapter 3
Results

PART I) Identification and Characterization of TPM-Containing Proteins

3.1 Characterization of the TPM Phosphoantibody

In order to identify novel tetra phosphorylation motif (TPM)-containing proteins,
a polyclonal antibody was raised against a phosphopeptide library consisting of peptides
with the TPM sequence (pSXXXpSXXXpSXXXpS). The antibody was purified through
double

subtractive

affinity

chromatography,

using

phosphorylated

and

non-

phosphorylated (SXXXSXXXSXXXS) peptide-library-conjugated columns to obtain
phosphospecific antibodies.

3.1.1 The TPM Phosphoantibody Reacts with Tetra-Phosphorylated Peptides

The specificity of the TPM phosphoantibody was tested through its reactivity with
differentially phosphorylated peptide libraries by dot blot analysis. In order to achieve
phosphopeptide libraries with approximately three, two, and one phosphate group(s), the
synthetic TPM phosphopeptide library was subjected to dephosphorylation by alkaline
phosphatase for increasing time periods. The original non-phosphopeptide library and
the TPM phosphopeptide library were used to represent peptide libraries with zero and
four phosphate groups, respectively.

Following alkaline phosphatase incubation, MALDI-TOF mass spectrometry was
employed to determine the phosphorylation state of each of the peptide libraries. Each of
the peptide libraries yielded a broad peak, representative of the fact that the libraries
contain a large number of different peptides (Figure 3.1 A). Comparison of the masses
associated with the central most portion of the peaks with that of the tetra-phosphorylated
peptide library revealed mass shifts of approximately 80 m/z (5 min.), 160 m/z (90 min.),
and 240 m/z (120 min.), signifying a loss of approximately one, two, and three phosphate
groups, respectively.
To evaluate the reactivity of the TPM phosphoantibody with the various peptide
libraries, dot blot analysis was conducted (Figure 3.IB). It was observed that increased
incubation of the TPM phosphopeptide library with alkaline phosphatase lead to a loss of
recognition by the TPM phosphoantibody. Importantly, the phosphoantibody exhibited
the strongest reactivity with the tetra-phosphorylated peptide library, while not reacting
with the non-phosphorylated peptide library, demonstrating the phosphospecificity of the
TPM phosphoantibody.

3.1.2 The TPM Phosphoantibody Does Not Recognize the TPM Mutant of
P-catenin

As P-catenin is the only protein reported, thus far, to contain a TPM [16,17], the
specificity of the TPM phosphoantibody was further evaluated through its ability to
distinguish between wild-type P-catenin and a P-catenin TPM mutant (P-catenin ATPM),
in which all four of the TPM phosphorylation sites have been mutated to alanine residues.
HEK 293 cells were untransfected, transfected with HA-GSK-3p (S9A), a constitutively
active GSK-3P mutant, or co-transfected with HA-GSK-3p (S9A) and Myc-P-catenin
ATPM.

Anti-P-catenin immunoblot analysis of the whole cell lysates, resolved by

SDS/PAGE, revealed two bands at approximately 110 kDa and 115 kDa, which coincide
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1630.93
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Figure 3.1- Analysis of Anti-TPM Specificity. (A) The reconstituted synthetic TPM
phosphopeptide library was incubated with 2 units of CIAP for 5 min., 90 min., and 120
min. to generate phosphopeptide libraries with ~3, ~2, and ~1 phosphate group(s),
respectively. The non-phosphopeptide library and the TPM phosphopeptide library were
used to represent peptides that have 0 and 4 phosphate groups, respectively. The
reactions were quenched with 5% formic acid. The libraries were all analysed by
MALDI-TOF mass spectrometry for the loss of phosphate groups (~80 m/z). (B) Dot
blot (DB) analysis of the peptide libraries was conducted with the TPM phosphoantibody.
This figure is representative of three different experiments.
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with endogenous, wild-type p-catenin and Myc-P-catenin ATPM, respectively (Figure
3.2A). The mutant form of P-catenin migrates slightly slower than does wild-type Pcatenin, due to the addition of the Myc epitope tag. The anti-TPM immunoblot revealed
reactivity with only wild-type P-catenin (Figure 3.2B) and not with the TPM mutant,
indicating that the antibody specifically recognizes proteins phosphorylated at a TPM.
This also conveyed that the TPM phosphoantibody reacted with P-catenin at the TPM
and not at any other position along the protein. The TPM phosphoantibody was also
reactive with an array of proteins across a wide molecular weight range, with each band
representing a potential TPM-containing protein. The anti-HA immunoblot (Figure 3.2C)
was performed to ensure equivalent exogenous expression of HA-GSK-3P (S9A). The
results obtained also indicate the ability of the TPM phosphoantibody to function within
immunoblot experiments.

3.2 Identification of Putative TPM-Containing Proteins

3.2.1

Phosphatase and Proteasome Inhibition Enables TPM Phosphoantibody
Recognition of Potential TPM Proteins

In order to observe the cellular profile of TPM-containing proteins, we performed
an anti-TPM immunoblot analysis of whole cell lysates isolated from HEK 293 cells.
Putative TPM proteins were identified based on their reactivity with the TPM
phosphoantibody and by their responsiveness to phosphatase and proteasome inhibition.
Cells were pre-treated with Calyculin A, a potent Ser/Thr phosphatase inhibitor, to
increase the stoichiometry of phosphorylated proteins.

MG-132 (Carbobenzoxy-L-

leucyl-L-leucyl-L-leucinal), a potent proteasome inhibitor, was also applied to cells to
prevent the proteasome-mediated degradation of ubiquitin-conjugated, phosphorylated
TPM-containing proteins. The anti-TPM immunoblot of untreated whole cell lysates
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A

B

IB: <x-TPM

Figure 3.2- Mutation of the (3-catenin TPM Abolishes Its Recognition by the TPM
Phosphoantibody. HEK 293 cells were left untransfected or were transfected with HAGSK-3p(S9A) alone or co-transfected with HA-GSK-3p (S9A) and Myc-p-catenin
ATPM. Cell lysates were resolved by SDS/PAGE and immunoblotted (IB) with (A)
anti-p-catenin, (B) anti-TPM, and (C) anti-HA. The positions of the molecular weight
markers (in kDa) along the anti-TPM imrnunoblot are as indicated. These results are
representative of two separate experiments.
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revealed numerous immunoreactive protein bands (Figure 3.3A; upper panel).
Importantly, a number of these anti-TPM reactive proteins (110 kDa, 100 kDa, 90 kDa,
75 kDa, 65 kDa, 60 kDa, 45 kDa, 40 kDa, and 35 kDa) exhibited increased intensity with
proteasome and phosphatase inhibitor treatment. An assay of the actin levels, conducted
via anti-actin immunoblot, proved that the intensity differences between the untreated and
treated lysates on the anti-TPM immunoblot were not the result of unequal protein
loading (Figure 3.3A; lower panel).

3.2.2 Immunoblot and Bioinformatic Analyses Reveal TAZ and KLF7 as Putative
TPM Proteins

Bioinformatic sequence analysis of the human SwissProt database with an
ambiguous form of the TPM sequence (DS/TGXXS/TXXXSATXXXS/T) identified
approximately 30 genes encoding putative TPM-containing proteins (Appendix 1).
Interestingly, examination of these potential TPM proteins revealed two proteins,
Transcriptional co-activator with PDZ-binding motif (TAZ) and Kruppel-like factor 7
(KLF7), with intriguing similarities to P-catenin. Since, both TAZ and KLF7, like Pcatenin, function as transcriptional mediators in the regulation of processes, such as cell
differentiation and development, and the TPMs of all three proteins are located in their
extreme N-termini, we questioned whether endogenous TAZ and/or KLF7 could be
aligned with a TPM-reactive band within Figure 3.3 A. Immunoblot analyses of the same
untreated and treated HEK 293 cell lysates with anti-TAZ and anti-KLF7 enabled the
alignment of endogenous TAZ and KLF7 with two predominant, anti-TPM-reactive
bands at 65 kDa (p65) and 40 kDa (p40), respectively (Figure 3.3B).
Alignment of the amino acid sequences of human TAZ (Accession No.:
NP_056287), KLF7 (Accession No.: CAG46909), and p-catenin (Accession No.:
CAA61107), presented in Figure 3.4, highlights the presence of the TPM in the N48
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Figure 3.3- Identification of Putative TPM-Containing Proteins. HEK 293 cells were
untreated (-) or treated (+) ~48 h after being seeded. Treatment (T) involved a 1 h
incubation with 10 uM MG-132 and 100 nM Calyculin A. Equal amounts of protein, as
measured by the Bradford method, were resolved through SDS/PAGE and immunoblotted
(IB) with (A) anti-TPM (upper panel). Potential TPM proteins are indicated with arrows.
(3-catenin (pi 10) and the putative TPM proteins, TAZ (p65) and KLF7 (p40) are
represented by Protein (p) followed by their approximate molecular weights. An anti-actin
immunoblot (lower panel) was conducted to ensure equal protein loading. (B) Immunoblot
analyses of the same lysates with anti-TAZ (upper panel) and anti-KLF7 (lower panel)
were aligned with the anti-TPM immunoblot. Molecular weight markers (in kDa) are
indicated. These results are representative of three experiments.
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Figure 3.4- TAZ and KLF7 are Putative TPM-Containing Proteins. TAZ and KLF7,
the putative TPM-containing proteins with approximate molecular weights of 65 kDa and
40 kDa, respectively, were aligned with (3-catenin, the only TPM protein reported to date.
The presence of the TPM is highlighted in all three proteins. The common p-TrCP
recognition site (DS/TGXXS) between P-catenin, TAZ, and KLF7 is also shown. The
amino acid position at which the alignment was initiated is indicated at left.
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terminal region of each of these proteins. The spacing of the phosphorylation sites,
constituting the P-catenin TPM, is also maintained within the putative TPM sequences of
TAZ and KLF7. Moreover, both TAZ and KLF7 contain consensus P-TrCP recognition
sequences (DS/TGXXS) within the context of their TPMs, similar to that observed in Pcatenin, which is responsible for its ubiquitin-mediated proteasomal degradation [18,19].

3.2.3 TAZ and KLF7 React with the TPM Phosphoantibody

To facilitate further investigation of TAZ and KLF7 as putative TPM proteins,
full-length human taz cDNA was subcloned into the pFLAG-CMV-2 vector, generating
an N-terminally, FLAG-tagged taz construct.

pCS2+MT/KLF7, which encodes N-

terminally, Myc(x6) epitope-tagged KLF7, was kindly provided by Dr. L. Lei (Arizona
State University). As a means of confirming our identifications of TAZ and KLF7 as
TPM-containing proteins, we examined their reactivity with the TPM phosphoantibody.
Firstly, FLAG-TAZ was over-expressed in HEK 293 cells, treated with Calyculin
A and/or MG-132 to enrich for TPM-modified FLAG-TAZ, and subsequently subjected
to anti-FLAG immunoprecipitation. Interestingly, anti-FLAG immunoblot analysis of
the cleared cell lysates revealed that, upon treatment, FLAG-TAZ undergoes a significant
upward mobility shift, which indicates that TAZ is likely subject to post-translational
modification (Figure 3.5; lower panel). This slower migrating species of FLAG-TAZ
was observed with Calyculin A treatment, in the absence of MG-132, suggesting that
TAZ is a heavily phosphorylated protein. Both of the differentially modified forms of
FLAG-TAZ were immunoprecipitated, with the faster migrating, unmodified TAZ comigrating with the IgG heavy chain (Figure 3.5; middle panel). Immunoblot analysis of
the anti-FLAG immune complexes revealed that the slower migrating, posttranslationally modified form of FLAG-TAZ was detected by the TPM phosphoantibody,
indicating the presence of a putative TPM within TAZ (Figure 3.5; upper panel).
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Figure 3.5- FLAG-TAZ is Recognized by the TPM Phosphoantibody. HEK 293 cells
were untransfected or transiently transfected with FLAG-TAZ. Approximately 24 h posttransfection, cells were treated with (+) or without (-) MG-132 (10 uM) and/or Calyculin A
(100 nM) for 1 h. Following lysis, cleared cell lysates were subjected to anti-FLAG
immunoprecipitation (IP). The immune complexes were resolved by SDS/PAGE and
immunoblotted (IB) with anti-TPM (upper panel) and anti-FLAG (middle panel). Cleared
cell lysates were also separated by SDS/PAGE and immunoblotted with anti-FLAG (lower
panel). In the anti-FLAG immunoblots, the two arrows from the FLAG-TAZ label indicate
its differentially modified forms. Where required, the IgG heavy chain is indicated (HC).
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Notably, the unmodified, faster migrating form of FLAG-TAZ did not react with the
TPM phosphoantibody; thus, it is probable that the TPM is not phosphorylated in this
formofTAZ.
The reactivity of KLF7 with the TPM phosphoantibody was assayed in the same
manner as was that of TAZ. Myc-KLF7 was transiently transfected in HEK 293 cells,
treated

with

Calyculin

immunoprecipitation.

A

and/or

MG-132,

and

isolated

via

anti-c-Myc

Immunoblotting of the cell lysates and anti-c-Myc immune

complexes with the c-Myc antibody shows that Myc-KLF7 also exhibits a mobility shift
with Calyculin A treatment, indicating its potential phosphorylation (Figure 3.6; middle
and lower panels). Unlike TAZ, treated KLF7 produces an upward smearing pattern,
which is suggestive of the presence of higher molecular weight, ubiquitinated forms of
KLF7. Immunoblot analysis of the immune complexes depicted the reactivity of MycKLF7 with the TPM phosphoantibody, indicating KLF7 as a putative TPM protein
(Figure 3.6; upper panel).

It was again observed that anti-TPM recognition was

dependent upon phosphatase inhibition, as only Myc-KLF7, previously treated with
Calyculin A, was detected. This indicates that TPM phosphorylation of both TAZ and
KLF7 is likely to be regulated by phosphatases, whose identities remain to be
determined.

3.2.4 Mass Spectrometric Analysis of TAZ Validates the Presence of its TPM

In order to unambiguously confirm that the TPM of TAZ is phosphorylated, we
analysed over-expressed FLAG-TAZ via MALDI-TOF mass spectrometry. HEK 293
lysates, over-expressing FLAG-TAZ, were either untreated or treated with Calyculin A
and MG-132 and then immunoprecipitated with anti-FLAG-conjugated

agarose.

Following extensive washing, the proteins were resolved by SDS/PAGE and
subsequently visualized via Coomassie stain. A prominent Coomassie-stained band was
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Figure 3.6- The TPM Phosphoantibody Reacts with Myc-KLF7. HEK 293 cells were
either untransfected or were transiently transfected with Myc-KLF7. Approximately 24 h
post-transfection, cells were untreated (-) or treated (+) with MG-132 (10 uM) and/or
Calyculin A (100 nM) for 1 h. The cells were then lysed and the lysates were subjected to
anti-c-Myc immunoprecipitation (IP). The resulting immune complexes were resolved by
SDS/PAGE and immunoblotted (IB) with anti-TPM (upper panel) and anti-c-Myc (middle
panel). Cleared cell lysates were also separated by SDS/PAGE and immunoblotted with
anti-c-Myc (lower panel). The double arrows indicate the differentially modified forms of
Myc-KLF7. These results were representative of three separate experiments.
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observed at approximately 65 kDa in the treated cell lysate (Figure 3.7A). Alignment of
the stained gel with an anti-FLAG immunoblot of the immunoprecipitant material
confirmed the identity of this band as the highly modified form of FLAG-TAZ (Figure
3.7B). Unmodified FLAG-TAZ, isolated from the untreated cell lysate, co-migrated with
the heavy chain of the mouse IgG.
The protein band corresponding to modified FLAG-TAZ was excised and
subjected to in-gel trypsin digestion. The tryptic peptides were extracted from the gel
piece, concentrated by speed vacuuming, and desalted with microtips containing C18
resin.

The resultant tryptic peptides were then analysed by MALDI-TOF mass

spectrometry. Analysis of the tryptic peptide mass fingerprint revealed a number of
peptides with masses matching those predicted by the in silico digestion of TAZ
conducted by the MS-Digest command of the Protein Prospector software (UCSF),
confirming the identity of the excised protein as TAZ (Figure 3.8A). The TAZ tryptic
peptides detected by MALDI-MS analysis are highlighted on the mass fingerprint by
their experimentally determined m/z ratios. Importantly, we identified a tryptic peptide
with a mass corresponding to that predicted for a tetra-phosphorylated peptide containing
the TAZ TPM (2643.18 m/z), (K)55EPDSGSHSRQSSTDSSGGHPGPR77(L).

This

peptide contains one missed cleavage site, indicated by the underlined arginine (R)
residue, which may be due to interference from the multiple phosphate groups on this
peptide.
We further analysed the 2643.18 m/z peptide by tandem mass spectrometry
(MS/MS) to obtain information regarding its amino acid sequence and phosphorylation
status, as well as to attempt to locate the exact sites of phosphorylation. Post-source
decay (PSD) MS/MS analysis of this peptide revealed phosphorylation on four serine or
threonine residues, as demonstrated by four consecutive losses of approximately 98 m/z
from the precursor ion, 2642.5 m/z (Figure 3.8B). A neutral loss of 98 m/z indicates the
loss of phosphoric acid (H3PO4) from a phosphorylated serine or threonine residue. The
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Figure 3.7- Large-Scale Anti-FLAG Immunoprecipitation. HEK 293 cells (~12xl06)
were transiently transfected with FLAG-TAZ. The cells were either untreated (-) or treated
(+) with 10 |JM MG-132 and 100 nM Calyculin A, collectively represented as T, for 1 h.
Following cell lysis, the lysates underwent anti-FLAG immunoprecipitation (IP). The
immune complexes were resolved by SDS/PAGE and proteins were visualized by (A)
Coomassie staining or were (B) transferred and immunoblotted with anti-FLAG. The
Coomassie stained gel was aligned with the anti-FLAG immunoblot to verify the identity of
the treated FLAG-TAZ band, which is indicated with an asterisk (*). This band was excised
from the polyacrylamide gel and subsequently prepared for in-gel trypsin digestion.
Molecular weight markers (in kDa) are shown to the left of the Coomassie-stained gel. The
IgG heavy chain is indicated (HC).
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Figure 3.8- Mass Spectrometric Analysis of FLAG-TAZ Reveals a TetraPhosphorylated Tryptic Peptide Ion Presumed to Contain the TAZ TPM. The
Coomassie stained band corresponding to modified FLAG-TAZ was excised and subjected
to in-gel trypsin digestion. The resulting tryptic peptides were concentrated, desalted, and
then analyzed by MALDI-TOF mass spectrometry. (A) MALDI-TOF peptide mass
fingerprint of FLAG-TAZ. Ions matching those predicted for TAZ by MS-Digest are
indicated by their experimental m/z ratios. The peptide ion (2643.18 m/z), predicted to
contain the TAZ TPM, is highlighted. MALDI-MS/MS was performed on the 2643.18 m/z
peptide ion. (B) Portion of the MALDI-MS/MS spectrum of 2643.18 m/z. The presence of 4
phosphate groups on this peptide was confirmed by four H 3 P0 4 eliminations (loss of 98 m/z)
from the precursor ion (2642.5 m/z).
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MS/MS data also revealed a number of fragment ions matching the TPM tryptic peptide
(Figure 3.9A,B). To verify the occurrence of phosphorylation at each of the predicted
TAZ TPM sites, we closely examined the fragment ions detected through CID. The
detection of a fragment ion at 508.78 m/z confirmed Ser58 as a phosphorylation site on
this peptide, for this mass corresponds to a phosphorylated D4 ion. Based upon the
identification of the b6 (653.38 m/z) and bg - 98 m/z (1015.07 m/z) fragment ions, we
were able to rule out Ser60 as a phosphorylation site, while proving that Ser62 does
indeed undergo phosphorylation. The presence of a fragment ion at 844.80 m/z, which
matches a theoretically determined yg ion containing a single phosphate group, verified
the phosphorylation of Ser70.
Analysis of the detected fragment ions enabled the unambiguous identification of
three of the four phosphorylation sites as Ser58, Ser62, and Ser70. Since these three
residues are those that were originally hypothesized to be phosphorylated as part of the
TPM, their identification bolsters our claim that TAZ is a novel TPM-containing protein.
Although, we were unable to unambiguously determine the location of the fourth
phosphorylation site, the presence of fragment ions corresponding to b9 - 98 m/z and yn 98 m/z directed our assignment of this phosphorylation site to either Ser65 or Ser66.
Interestingly, Ser66 is located at the hypothesized third phosphorylation site of the
putative TAZ TPM; thus, the possibility of a phosphorylation event at this site serves to
strengthen our confidence in the existence of a veritable TAZ TPM. Our inability to
delineate the exact location of this final phosphorylation site is likely due to signal
suppression, resulting from the co-elution of at least two other peptides ions with the
2643.18 m/z peptide.
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Figure 3.9- Localization of TAZ TPM Phosphorylation Sites by Tandem Mass
Spectrometry. (A, B) Different portions of the MALDI-MS/MS spectrum of 2643.18 m/z.
The fragment ions with m/z ratios matching those predicted by MS-Product for b and y ions,
including b and y ions with a loss of H 3 P0 4 (98 m/z), are labelled. The detected fragment
ions verified the peptide to be that containing the TAZ TPM (shown in (A)). Three
phosphorylation sites were identified at Ser58, Ser62, and Ser70 and are indicated by a small
p before the Ser residue. The location of the fourth phosphorylation site remains uncertain,
the possible sites are underlined (Ser66 or Ser67) and highlighted with a question mark (?).
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3.3 Interaction of TPM-Containing Proteins with the F-box Protein, 0-TrCP

3.3.1 Mutation of the KLF7 TPM Inhibits p-TrCP Binding

Phosphorylation of p-catenin at its TPM has been shown to facilitate its
interaction with the F-box/WD40-repeat protein, P-TrCP [19]. Since, like P-catenin,
KLF7 also contains a P-TrCP recognition sequence within its putative TPM (Figure 3.4),
we wanted to investigate whether KLF7 could also associate with (3-TrCP. To examine
this potential interaction, HEK 293 cells were transiently co-transfected with Myc-KLF7
and FLAG-P-TrCP and either untreated or treated with proteasome and phosphatase
inhibitors to increase the stoichiometry of phosphorylated KLF7. Following cell lysis,
the cleared cell lysates were subjected to immunoprecipitation with anti-c-Mycconjugated agarose to isolate exogenous Myc-KLF7, along with any interacting proteins.
Anti-FLAG immunoblot analysis of these immune complexes, resolved by SDS/PAGE,
revealed that FLAG-P-TrCP co-immunoprecipitated with Myc-KLF7 (Figure 3.10;
uppermost panel). Importantly, FLAG-p-TrCP was only found to associate with MycKLF7 under treatment conditions, indicating the phosphorylation-dependent nature of the
P-TrCP-KLF7 interaction, akin to that observed between P-TrCP and p-catenin [19].
In order to determine whether P-TrCP was interacting with KLF7 through
recognition of the consensus P-TrCP binding site located within the KLF7 TPM, we
generated a KLF7 TPM mutant, which harbours alanine substitutions at both Thrl9 and
Ser23 (KLF7 STDM; KLF7 Serine Threonine Double Mutant). As in the case of pcatenin, we believe that ordered phosphorylation of KLF7 at its TPM, culminating in the
phosphorylation of Ser23 and Thrl9, which exist within the P-TrCP consensus sequence,
mediates P-TrCP binding.

Co-immunoprecipitation analysis revealed that the TPM

mutant of Myc-KLF7 could not associate with FLAG-P-TrCP, both in the presence or
absence of phosphatase and proteasome inhibition (Figure 3.10; uppermost panel). Its
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Figure 3.10- FLAG-P-TrCP Binds the KLF7 TPM. HEK 293 cells were transiently cotransfected with FLAG-(3-TrCP alongside pFLAG-CMV-2 (empty vector), Myc-KLF7, or
Myc-KLF7 STDM, as indicated by +/-. Twenty-four hours post-transfection, cells were
either untreated (-) or treated (+) with MG-132 (10 uM) and Calyculin A (100 nM).
Following 1 h treatment (T), the cells were lysed and subjected to anti-c-Myc
immunoprecipitation. The immune complexes were washed, resolved by SDS/PAGE, and
immunoblotted with anti-FLAG (uppermostpanel) to determine whether FLAG-P-TrCP was
co-immunoprecipitated and anti-c-Myc (second upper panel). The cell lysates were also
resolved by SDS/PAGE and immunoblotted with anti-FLAG (second lower panel) and antic-Myc (lowermost panel). These results are representative of three separate experiments.
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inability to bind the KLF7 TPM mutant indicates that P-TrCP interacts with KLF7 via
phosphorylation-dependent recognition of the p-TrCP consensus sequence.

It is

worthwhile to note that anti-c-Myc immunoblot analysis of the cell lysates reveals two
anti-c-Myc reactive bands in cells over-expressing Myc-KLF7 (Figure 3.10; lowermost
panel). Interestingly, the slower migrating band is absent in the extracts from cells overexpressing the KLF7 TPM mutant, KLF7 STDM. This band likely represents a higher
phosphorylated form of KLF7, which is abolished with the alanine mutations of Thrl9
and Ser23, providing evidence that the aforementioned amino acid residues are indeed
TPM phosphorylation sites.

3.3.2 The Function of the fi-TrCP Consensus Site within the TAZ TPM Remains
Unknown

Recent studies conducted by Tian et al., unveiled TAZ as a binding partner of PTrCP. The association of TAZ with P-TrCP, within the context of an SCFp"TrCP E3 ligase
complex, was shown to facilitate the degradation of polycystin 2 (PC2), a calciumpermeable cation channel protein, responsible for regulating the entry and release of
calcium from the endoplasmic reticulum (ER) [41]. Within this study, Tian et al. tested
the function of two putative p-TrCP consensus sequences within mouse TAZ:
DS58GSHS62 and S302REQS306TDS309GLG.

The first p-TrCP recognition sequence is

contained within the TPM, whereas the second is in the remote C-terminal region.
Mutational analyses, followed by co-immunoprecipitation, revealed the C-terminal PTrCP recognition sequence as necessary for the TAZ/p-TrCP interaction, whereas, serine
to alanine substitutions at the TPM consensus sequence appeared to have no effect on the
binding of P-TrCP to TAZ [41].
The above study did not employ phosphatase or proteasome inhibitors in their
analysis; therefore, we assessed the effect these treatments would have on the binding of
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p-TrCP to TAZ. We generated the two TAZ mutants employed by Tian et al, TAZ
AC'DSG and TAZ ATPM/AC'DSG, which contain an alanine substitution at Ser314 of
wild-type human TAZ (Ser309 of mouse TAZ) and of the human TAZ TPM mutant,
respectively.

The TAZ TPM mutant (TAZ ATPM) features alanine substitutions at

Ser58, Ser62, Ser66, and Ser70. We then subcloned TAZ, TAZ ATPM, TAZ AClDSG,
and TAZ ATPM/AC'DSG into the pCS2+MT vector, producing N-terminally, Myctagged versions of these constructs.
Cells expressing these TAZ variants with FLAG-p-TrCP were treated with MG132 and Calyculin A and anti-c-Myc immunoprecipitation was conducted to isolate the
Myc-tagged TAZ constructs. Anti-FLAG immunoblot analysis demonstrated that the
association between P-TrCP and TAZ is dependent upon an intact C-terminal P-TrCP
binding site (Figure 3.11; uppermost panel), since both Myc-TAZ AC'DSG and MycTAZ ATPM/AC'DSG could not interact with FLAG-p-TrCP. Our results agree with
those published by Tian et al, as the potential enrichment of TPM-regulated TAZ did not
appear to have any bearing on its interaction with p-TrCP, as indicated by the inability of
FLAG-P-TrCP to co-immunoprecipitate with Myc-TAZ AClDSG, as well as by the
binding of FLAG-P-TrCP to Myc-TAZ ATPM. It is interesting to note that the antiFLAG immunoblot of the immunoprecipitant (Figure 3.11; second upper panel) shows
the slower migration of TAZ in comparison to that of the TAZ TPM mutant, TAZ ATPM.
This migratory difference is indicative of the higher phosphorylation status of TAZ,
lending further credence to our previous assignments of Ser58, Ser62, Ser70, and
potentially Ser66, as the phosphorylation sites of the TAZ TPM.

3.4 Ubiquitination of TAZ and KLF7 is Mediated by their Respective TPMs

Since the phosphorylation-dependent degradation of P-catenin has been shown to
involve the ubiquitin-proteasome pathway [18,19], we next set out to determine whether
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Figure 3.11- Interaction Between P-TrCP and TAZ Does Not Appear to Involve the
TAZ TPM. HEK 293 cells were transiently co-transfected with FLAG-{3-TrCP and MycTAZ, Myc-TAZ ATPM, Myc-TAZ O A D S G , or Myc-TAZ ATPM/ O A D S G , as shown by
the +/-. Twenty-fours post-transfection, cells were treated (+) with 10 uM MG-132 and 100
nM Calyculin A. Following the 1 h treatment, cells were lysed and lysates were incubated
with anti-c-Myc agarose. The immune complexes were resolved by SDS/PAGE and
immunoblotted with anti-FLAG {uppermost panel) and anti-c-Myc {second upper panel).
The lysates were also separated by SDS/PAGE and immunoblotted with anti-FLAG {second
lower panel) and anti-c-Myc {lowermost panel). These results are representative of three
separate experiments.
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tetra-phosphorylation at the TPM induces the ubiquitination of both TAZ and KLF7. In
order to assess the ubiquitination state of KLF7, HEK 293 cells, over-expressing MycKLF7, were either untreated or treated with phosphatase (Calyculin A) and proteasome
(MG-132) inhibitors to increase the stoichiometry of proteins that are phosphorylated
and/or ubiquitinated, in effect increasing the level of proteins ubiquitinated in response to
phosphorylation. Following treatment and cell lysis, the lysates were incubated with antic-Myc-conjugated agarose, enabling the isolation of Myc-KLF7.

Anti-ubiquitin

immunoblot analysis displayed prominent banding solely for anti-KLF7 immune
complexes treated with phosphatase and proteasome inhibitors, indicating that KLF7 may
be regulated by ubiquitination (Figure 3.12; upper panel).
To further characterize the putative ubiquitination of KLF7, we investigated
whether the TPM affects its ubiquitination status. HEK 293 cells, co-expressing HAtagged ubiquitin alongside Myc-KLF7 or Myc-KLF7 STDM, were treated with
phosphatase and proteasome inhibitors, since the potential ubiquitination of KLF7 was
detected solely under treatment conditions (Figure 3.12; upper panel).

Exogenously

expressed KLF7 was isolated via anti-c-Myc immunoprecipitation. Anti-HA immunoblot
analysis of the immune complexes revealed a detectable difference in the amount of HAubiquitin present within the extracts containing over-expressed wild-type KLF7
compared to those over-expressing KLF7 STDM, the TPM mutant (Figure 3.13; upper
panel). These results verify the occurrence of ubiquitin-conjugated proteins within the
immunoprecipitants over-expressing Myc-KLF7, while, depicting a lesser degree of HAubiquitin adducts in the samples generated from cells over-expressing Myc-KLF7
STDM. Immunoblot analysis of the immunoprecipitants with anti-c-Myc (Figure 3.13;
middle panel) and of the cell lysates with the HA antibody (Figure 3.13; lower panel)
demonstrate equal expression levels of the Myc-KLF7 constructs and of the HA-ubiquitin
construct between samples. Thus, we suggest that phosphorylation of KLF7 at its TPM

65

s?

J?

HC
IP: a-c-Myc
IB: a-Ubiquitin

Myc-KLF7

Myc-KLF7

IP: a-c-Myc
IB: a-c-Myc

'

^HPP^HHf ^fjj^^^m''

Lysate
IB: a-c-Myc

Figure 3.12- KLF7 Undergoes Ubiquitination. HEK 293 cells were transiently transfected
with Myc-KLF7. The cells were either untreated (-) or treated (+) approximately 24 h posttransfection with 10 uM MG-132 and 100 nM Calyculin A for 1 h. Following treatment (T),
the cells were lysed and the cleared cell lysates were incubated with anti-c-Myc-conjugated
agarose. The immune complexes were extensively washed and resolved by SDS/PAGE, as
were the cleared cell lysates. Immunoblot analysis was then conducted with anti-ubiqutin
(upper panel) and anti-c-Myc {middle, lower panels). The double arrows indicate the
differentially modified forms of Myc- KLF7. Potential higher molecular weight complexes
of Myc-KLF7 and ubiquitin are highlighted with a bracket and an asterisk (*). The IgG
heavy chain is indicated (HC). These results are representative of three separate
experiments.
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Figure 3.13- The KLF7 TPM is Necessary for Its Ubiquitination. HEK 293 cells were
transiently co-transfected with HA-Ubiquitin (Ub) and Myc-KLF7 or Myc-KLF7 STDM, as
indicated by the +/-. The cells were treated (T) with 10 uM MG-132 and 100 nM Calyculin
A for 1 h approximately 24 h post-transfection. Following cell lysis, cleared lysates were
subjected to anti-c-Myc immunoprecipitation. The resulting immune complexes were
extensively washed, resolved by SDS/PAGE, and immunoblotted with anti-HA {upper
panel) and anti-c-Myc {middle panel). The lysates were also separated by SDS/PAGE and
immunoblotted with anti-HA {lower panel) to ensure comparable HA-ubiquitin overexpression between samples. Putative higher molecular weight complexes of Myc-KLF7
and HA-ubiquitin are indicated with an asterisk (*). The double arrows indicate the
differentially modified forms of Myc-KLF7. The IgG heavy chain is indicated (HC). These
results are representative of two separate experiments.
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may be responsible for driving its putative ubiquitination, as the KLF7 TPM mutant
appears unable to be ubiquitinated.
We next wanted to assay whether TAZ undergoes ubiquitination in response to
phosphorylation at its TPM. HEK 293 cells co-expressing HA-ubiquitin and FLAG-TAZ
or FLAG-TAZ SDM, which encodes FLAG-tagged TAZ harbouring serine to alanine
mutations at Ser58 and Ser62, were subjected to co-immunoprecipitation analysis. AntiHA immunoblot analysis of the immune complexes revealed a considerable degree of
high-molecular weight, HA-ubiquitin-conjugated species within the extracts containing
exogenous TAZ (Figure 3.14; upper panel). It is important to note that this extensive
ubiquitination is only detected in the presence of proteasome and phosphatase inhibitors,
hinting at the probable regulation of TAZ ubiquitination by phosphatases and the
proteasome.

The detection of HA-ubiquitin-adducts in these immune complexes

indicates the presence of ubiquitinated TAZ and/or ubiquitinated binding partners of
TAZ. As the extracts containing over-expressed TAZ SDM do not exhibit a significant
amount of HA-ubiquitin-conjugated proteins, it is likely that the HA-ubiquitin adducts
detected in the FLAG-TAZ immunoprecipitants are those of TAZ conjugated to HAtagged ubiquitin chains of varying length. The absence of HA-ubiquitin-conjugated
FLAG-TAZ SDM illustrates that phosphorylation at the TAZ TPM likely governs the
putative ubiquitination of TAZ. An anti-FLAG immunoblot of the immune complexes
(Figure 3.14; middle panel) and an anti-HA immunoblot of the original cell lysates
(Figure 3.14; lower panel) demonstrate equal expression levels of FLAG-TAZ and
FLAG-TAZ SDM, as well as that of HA-ubiquitin between samples, confirming that the
differential ubiquitination can likely be attributed to the difference between the TAZ
constructs investigated: an intact TAZ TPM.
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Figure 3.14- Ubiquitination of TAZ Requires an Intact TAZ TPM. HEK 293 cells were
co-transfected with HA-ubiquitin (Ub) and FLAG-TAZ or FLAG-TAZ SDM, indicated by
+/-. Approximately 24 h post-transfection, cells were untreated (-) or treated (+) with 10 uM
MG-132 and 100 nM Calyculin A. Following 1 h treatment (T), cells were lysed and lysates
were incubated with anti-FLAG-conjugated agarose. The immune complexes were
extensively washed, resolved by SDS/PAGE, and immunoblotted with anti-HA (upper
panel) and anti-FLAG (middle panel). Cell lysates were also separated by SDS/PAGE and
immunoblotted with anti-HA (lower panel). Potential complexes of FLAG-TAZ and HAubiquitin are indicated by an asterisk (*). The double arrows highlight the differentially
modified forms of FLAG-TAZ. The IgG heavy chain is indicated (HC). These results are
representative of two separate experiments.
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3.5 Investigation of the Effect of the TPM on TAZ and KLF7 Protein Stability

Proteins are commonly targeted to the proteasome for destruction by the
conjugation of poly-ubiquitin chains to their lysine residue(s) [22]. Since we have shown
that TAZ undergoes ubiquitination, we were interested in determining whether the TPMmediated ubiquitination ultimately leads to its demise. In order to determine whether the
ubiquitination plays a role in the regulation of TAZ turnover, we ectopically expressed
FLAG-TAZ or FLAG-TAZ ATPM in HEK 293 cells. Approximately 48 hours posttransfection, cycloheximide (CHX; 200 [ig/mL) was added to the cell culture medium to
inhibit protein synthesis. At the indicated time intervals, the cells were lysed and equal
amounts of extracted cellular protein were resolved by SDS/PAGE and immunoblotted
with anti-FLAG and anti-actin (Figure 3.15). It was initially hypothesized that wild-type
FLAG-TAZ would degrade at a considerably faster rate than would the TPM mutant
based upon the inability of the mutant to be ubiquitinated; however, comparison of the
turnover rate of FLAG-TAZ and FLAG-TAZ ATPM showed no significant difference in
their half-lives (Figure 3.15A,B; upper panels).

It is apparent from the anti-FLAG

immunoblots that both FLAG-TAZ and FLAG-TAZ ATPM are quite stable over the time
interval examined, which suggests that the ubiquitination of TAZ may have no bearing on
the regulation of TAZ stability. Anti-actin immunoblot analyses revealed consistent actin
levels between all of the samples, indicating equal protein loading (Figure 3.15A,B;
lower panels).
We have shown that the proposed tetra-phosphorylation of KLF7 at its TPM
enables its recognition by P-TrCP, an interaction that is likely responsible for the
subsequent ubiquitination of KLF7. As this course of events has been shown to promote
the proteasome-dependent degradation of p-catenin, we questioned whether KLF7 was
destined for the same fate [16,18,19]. In order to determine if the aforementioned
activities culminate in the degradation of KLF7, we assessed the stability of transiently
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Figure 3.15- Effect of the TPM on TAZ Protein Stability. HEK 293 cells were
transiently transfected with FLAG-TAZ or FLAG-TAZ ATPM. Cells were treated with
200 |j.g/mL cycloheximide (CHX) approximately 48 h post-transfection. At the indicated
time points, the cells were lysed and prior to resolution by SDS/PAGE, the extracted
cellular proteins were normalized via the Bradford method. (A) Anti-FLAG immunoblot
analysis (upper panel) of the lysate samples over-expressing FLAG-TAZ. (B) Anti-FLAG
immunoblot analysis (upper panel) of the cells over-expressing FLAG-TAZ ATPM. The
anti-FLAG immunoblots were subsequently immunoblotted with anti-actin (lower panels)
to ensure equal protein loading. These results are representative of four separate
experiments.
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transfected Myc-KLF7 and Myc-KLF7 STDM in HEK 293 cells treated with
cycloheximide for increasing time intervals. The examination of KLF7 stability was
conducted in the same manner as indicated previously for the assessment of TAZ
stability. Equal amounts of protein, extracted from the cells over-expressing Myc-KLF7
or Myc-KLF7 STDM, were resolved by SDS/PAGE and subsequently immunoblotted
with c-Myc and actin antibodies (Figure 3.16).

Anti-c-Myc immunoblot analysis

revealed a comparable turnover rate for both Myc-KLF7 and Myc-KLF7 STDM in the
time interval spanning from 0 to 10 hours (Figure 3.16A,B; upper panels). Interestingly,
within the last time interval investigated (10 - 12 hours), the level of wild-type MycKLF7 was considerably reduced, whereas, no significant decrease was detected for the
TPM mutant of KLF7 during this time. Examination of the anti-actin immunoblots
demonstrated similar levels of actin within all of the samples investigated, verifying
equal protein loading (Figure 3.16A,B; lower panels).
We had expected that wild-type Myc-KLF7 would degrade at a much faster rate
than its TPM mutant counterpart, as the mutant does not associate with P-TrCP, nor does
it undergo ubiquitination; however, no conclusions can be drawn regarding the role of the
KLF7 TPM in the governance of the half-life of KLF7 based upon our stability data.
Since it appears that we may only have detected the onset of KLF7 degradation during
the final time interval studied, further time intervals will have to be analysed to confirm
that the wild-type protein continues to degrade, while the TPM mutant remains stable.

3.6 The Binding of TAZ by 14-3-3 is TPM-Dependent

In an attempt to understand the purpose of the TAZ TPM, we looked to the
critical regulatory interaction between the 14-3-3 proteins and TAZ. Previous studies
conducted by Kanai et al. revealed that 14-3-3 binding acts to sequester TAZ in the
cytoplasm, thereby halting its transcriptional co-activation activities [42].
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Figure 3.16- KLF7 Protein Stability is Regulated by Its TPM. HEK 293 cells were
transiently transfected with Myc-KLF7 or Myc-KLF7 STDM. Forty-eight hours posttransfection, cells were treated with 200 fj,g/mL cycloheximide (CHX). The cells were lysed
at the indicated time points and the amount of extracted cellular protein was normalized by
the Bradford method. Cell lysates were resolved by SDS/PAGE and protein stability was
assessed through anti-FLAG immunoblotting of the samples over-expressing (A) Myc-KLF7
(upper panel) or (B) Myc-KLF7 STDM (upper panel). The anti-FLAG immunoblots were
also probed with anti-actin (lower panels) to ensure equal protein loading. These results are
representative of two separate experiments.
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phosphorylation-dependent nature of the association between 14-3-3 proteins and their
target ligands holds true for the interaction between TAZ and 14-3-3, in that
phosphorylation at Ser89 of TAZ, catalyzed by the Lats kinase, is necessary for 14-3-3
binding [42,43]. In order to determine whether activities dictated at or by the TAZ TPM
influence its interaction with 14-3-3, co-immunoprecipitation experiments were
conducted. We generated a TAZ mutant containing an alanine substitution at Ser89
(TAZ S89A), which was previously shown to diminish the interaction between TAZ and
14-3-3 [42]. We over-expressed FLAG-TAZ, FLAG-TAZ ATPM, and FLAG TAZ S89A
in 3T3-L1 mouse pre-adipocytes. Cleared cell lysates were then subjected to anti-FLAGconjugated agarose to enable isolation of FLAG-tagged TAZ. Anti-14-3-3 immunoblot
analysis demonstrated that 14-3-3 could indeed co-immunoprecipitate with FLAG-TAZ,
while, as expected, TAZ S89A could not associate with 14-3-3 (Figure 3.17; upper
panel).

Interestingly, no 14-3-3 was detected in the TAZ ATPM immunoprecipitants,

indicating that the TPM is necessary for the interaction of TAZ with 14-3-3 proteins.
The analogous experiment in HEK 293 cells depicted the existence of an
interaction between 14-3-3 and FLAG-TAZ ATPM, albeit at a lower affinity than that
observed for wild-type TAZ (Figure 3.18; upper panel). The fact that the TPM mutant of
TAZ can still interact with 14-3-3 in HEK 293 cells, while there appears to be no
detectable interaction in 3T3-L1 cells, indicates that the influence of the TAZ TPM on
14-3-3 binding may be cell-type specific.

3.7 TPM Mutants of TAZ and KLF7 Strongly Inhibit Adipocyte Differentiation in
3T3-L1 Preadipocyte Cells

Perhaps the most intriguing facet of the identification of TAZ and KLF7 as TPMcontaining proteins is their functional similarity to P-catenin, which remains the only
bona fide TPM protein reported to date [16]. A commonality between these three TPM74
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Figure 3.17- TAZ ATPM Does Not Associate with 14-3-3 in 3T3-L1 Preadipocytes.
Mouse 3T3-L1 preadipocyte cells were untransfected or transiently transfected with FLAGTAZ, FLAG-TAZ ATPM, or FLAG-TAZ S89A. Twenty-four hours post-transfection, the
cells were lysed and the cleared cell lysates were subjected to anti-FLAG
immunoprecipitation (IP). The resulting immune complexes were resolved by SDS/PAGE
and subsequently immunoblotted (B) with a pan-14-3-3 antibody {upper panel) and a FLAG
antibody {middle panel).
Cell lysates were also separated by SDS/PAGE and
immunoblotted with a pan-14-3-3 antibody {lower panel) to detect the amount of
endogenous 14-3-3. These results are representative of two experiments.
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Figure 3.18- Mutation of the TAZ TPM Diminishes the Interaction Between TAZ and
14-3-3 in HEK 293 Cells. HEK 293 cells were transiently transfected with FLAG-TAZ
S89A, FLAG-TAZ, or FLAG-TAZ ATPM. Cells were lysed approximately 24 h posttransfection and the cleared cell lysates were incubated with anti-FLAG-conjugated agarose.
The resulting immune complexes were resolved by SDS/PAGE and immunoblotted (IB)
with a pan-14-3-3 antibody (upper panel) and a FLAG antibody (middle panel). The cleared
cell lysates were also resolved by SDS/PAGE and subsequently immunoblotted with a pan14-3-3 antibody (lower panel). These results are representative of two separate experiments.
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containing, transcriptional mediators is their regulation of adipocyte differentiation. (3catenin signalling has been implicated in the inhibition of adipogenesis by halting the
transcription of a subset of genes necessary for proper adipocyte formation [44]. The fate
of mesenchymal stem cells (MSCs) to differentiate into osteoblasts or adipocytes has
been shown to be governed by TAZ protein levels, with TAZ acting to stimulate
osteogenesis, while simultaneously inhibiting adipocyte differentiation [45]. KLF7 has
also been linked to the inhibition of adipogenic differentiation potential in model
preadipocyte and adipocyte cell lines through the transcriptional repression of a number
of adipocyte-specific genes [46,47].
In light of the similar impact that TAZ and KLF7 have on adipocyte
differentiation, we questioned whether these outcomes were a functional consequence of
activities centred at their TPMs. In order to assess the effect of the TPM on adipogenesis,
we analysed the adipogenic progression in mouse 3T3-L1 preadipocyte cells overexpressing the wild-type and TPM mutant forms of both TAZ and KLF7. We also
transiently transfected cells with the empty pFLAG-CMV-2 vector DNA to control for
any effect the transfection reagents may have on adipogenesis. Approximately 3 0 - 3 6
hours post-transfection, when the cells were perceived to be 100% confluent,
differentiation was induced via the addition of cell culture medium supplemented with
10% FBS, IX isobutylmethylxanthine (IBMX), IX dexamethasone, and a IX insulin
solution. At this time, control samples were lysed and the lysates were resolved by
SDS/PAGE and subjected to anti-FLAG (Figure 3.19A) or anti-c-Myc (Figure 3.20A)
immunoblot analyses to confirm successful expression and comparable expression levels
between the constructs under investigation.

Following a 72 hour period of

differentiation, the cell culture media was replaced with insulin media, consisting of 10%
FBS and a IX insulin solution. Fresh insulin media was provided 48 hours after the
initial weaning of the cells from induction media, at which time significant lipid
accumulation was visible. Forty-eight hours following the second insulin change, the
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Figure 3.19- TPM-Mediated Activities Regulate the TAZ-Induced Inhibition of
Adipogenesis. Mouse 3T3-L1 preadipocyte cells were transiently transfected with pFLAGCMV-2 (empty vector), FLAG-TAZ, or FLAG-TAZ SDM. Transfection control cells were
lysed 24 h post-transfection. Cell lysates were resolved by SDS/PAGE and (A) anti-FLAG
immunoblot analysis was performed. 3T3-L1 cells were exposed to IBMX, dexamethasone,
insulin, and FBS -24-30 h post-transfection to induce adipocyte differentiation. After 72 h,
the culture medium was replaced with insulin media and 48 h later fresh insulin media was
supplied. The cells were monitored until the desired degree of differentiation was reached
(-48 h after the second insulin media change). The cells were then fixed and stained for
neutral lipids with Oil Red O. (B) Phase contrast images of the cells were taken at 50x
magnification. These results are representative of seven separate experiments.
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Figure 3.20- KLF7 STDM Strongly Inhibits Adipocyte Differentiation. Mouse 3T3-L1
preadipocyte cells were transiently transfected with pFLAG-CMV-2 (empty vector), MycKLF7, and Myc-KLF7 STDM. Approximately 24 h post-transfection, transfection control
cells were lysed. The lysates were separated by SDS/PAGE and (A) immunoblotted with
anti-c-Myc.
To induce adipogenesis, confluent cells were exposed to IBMX,
dexamethasone, insulin, and FBS -24-30 h post-transfection. After 72 h, the cells were
incubated in insulin media for 48 h, following which fresh insulin media was supplied. Once
the desired degree of differentiation was reached, -48 h after the second change of insulin
media, the cells were fixed and subsequently stained for neutral lipids with Oil Red O. (B)
Phase contrast images of the Oil Red O stained cells were taken at a magnification of lOOx.
These results are representative of two separate experiments.
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3T3-L1 cells were fixed and stained with Oil Red O (ORO), a fat-soluble dye capable of
binding neutral lipids, whose presence is suggestive of adipocyte maturation.
Phase contrast images of the differentiated 3T3-L1 cells were taken following
ORO staining. Cells housing ORO-stained lipids appear darker in contrast than do cells
lacking significant lipid accumulation. It can be seen from Figure 3.19B that the overexpression of FLAG-TAZ indeed limits the adipogenic differentiation progression of
preadipocyte cells when compared to those which were mock transfected, a finding that
was previously published by Hong et al. [45]. Intriguingly, we reproducibly observed
levels of adipocyte differentiation drastically lower for the TPM mutant of TAZ than
those documented for the wild-type protein. We were also able to reproduce the results
reported by Kanazawa et al, which revealed that the over-expression of KLF7 in
preadipocyte cells inhibited adipogenesis [46]. This is evident within Figure 3.20B, as
3T3-L1 cells over-expressing Myc-KLF7 exhibited a lesser degree of ORO staining than
did the mock-transfected cells. Most importantly, however, we again observed that the
TPM mutant of KLF7 further inhibited adipocyte differentiation compared to wild-type
KLF7. The ability of the TPM mutants of both TAZ and KLF7 to inhibit adipogenesis to
a greater extent than their respective wild-type proteins suggests that events orchestrated
by their TPMs likely influence their regulation of adipocyte differentiation.

PART II) A Comprehensive Analysis of TAZ Phosphorylation Sites

3.8 TAZ is a Heavily Phosphorylated Protein

3.8.1 Phosphorylation Accounts/or the Mobility Shift of Treated FLAG-TAZ

Throughout our characterization of TAZ as a novel TPM-containing protein, antiFLAG immunoblot analyses reproducibly revealed a pronounced, upward mobility shift
80

of FLAG-TAZ upon phosphatase and proteasome inhibition (Figures 3.5, 3.7, 3.14). We
hypothesized that this slower migration of FLAG-TAZ was likely attributable to
phosphorylation, as treatment solely with Calyculin A, a potent Ser/Thr phosphatase
inhibitor, could induce the upward shift (Figure 3.5). To substantiate our claim that the
mobility shift of treated FLAG-TAZ is due to the addition of numerous phosphate
groups, we performed a dephosphorylation assay.

HEK 293 cells, over-expressing

FLAG-TAZ, were either untreated or treated with proteasome and phosphatase inhibitors
to increase the stoichiometry of phosphorylated FLAG-TAZ.

Following anti-FLAG

immunoprecipitation, which was performed in order to isolate FLAG-TAZ, the resultant
immune complexes were washed and divided evenly between two samples. The first
sample was incubated with 3 units of calf intestinal alkaline phosphatase (1 unit/uL) for
30 minutes at 37 °C. The second sample was incubated as outlined above; however, no
alkaline phosphatase was added.

Lysate samples, with and without the addition of

alkaline phosphatase, were also put through the dephosphorylation assay and all of the
dephosphorylation reactions were terminated by boiling the samples in SDS protein
loading dye. Immunoprecipitant and lysate samples were then resolved by SDS/PAGE,
immobilized on PVDF membrane, and analysed by immunoblotting with anti-FLAG.
Immunoblot analysis of the samples not subjected to alkaline phosphatase once
again displayed the difference in mobility between untreated and treated FLAG-TAZ,
with treated FLAG-TAZ migrating much slower than its untreated counterpart (Figure
3.21).

Examination of the anti-FLAG immunoprecipitants incubated with alkaline

phosphatase revealed that treated FLAG-TAZ underwent a considerable shift downward
to a molecular weight comparable to that of untreated FLAG-TAZ. Since the mobility
shift could be counteracted by alkaline phosphatase-induced dephosphorylation, it is
believed that phosphorylation is indeed the source of the mobility shift and that TAZ is
likely a heavily phosphorylated protein.
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Figure 3.21- TAZ Mobility Shift is Abolished by Its Dephosphorylation with Alkaline
Phosphatase. HEK 293 cells were either untransfected or transiently transfected with
FLAG-TAZ. Approximately 24 h post-transfection, cells were left untreated (-) or were
treated (+) with 10 uM MG-132 and 100 nM Calyculin A for 1 h. Following treatment (T),
the cells were lysed and cleared cell ly sates were subjected to anti-FLAG
immunoprecipitation (IP). The resulting immune complexes, as well as lysate samples, were
incubated with (+) or without (-) 3 units of calf-intestinal alkaline phosphatase (CIAP) for 30
min. at 37°C. Dephosphorylation reactions were quenched by boiling the immune
complexes and lysate samples at 95°C in 2X or 6X SDS/PAGE protein loading dye,
respectively. Both the immune complexes (upper panel) and lysates (lower panel) were
resolved by SDS/PAGE and subsequently analyzed by immunoblotting (IB) with antiFLAG. The double arrows indicate the differentially phosphorylated forms of TAZ. The
IgG heavy chain is indicated (HC). These results are representative of three separate trials.
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3.8.2 Identification of TAZPhosphorylation Sites by Mass Spectrometry

Since reversible protein phosphorylation is a common form of post-translational
modification implicated in the regulation of numerous aspects of protein function, it is
probable that a major advancement in the understanding of the cellular role of TAZ may
be achieved with the delineation and characterization of its multiple phosphorylation
sites. Therefore, we performed a global analysis of TAZ phosphorylation sites using
mass spectrometry. TAZ tryptic peptides were derived from a Coomassie-stained protein
band corresponding to FLAG-TAZ that was isolated from cells treated with proteasome
and phosphatase inhibitors, ensuring a high stoichiometry of phosphorylated FLAG-TAZ
(Figure 3.7A,B).

The tryptic peptides were co-crystallized with a-cyano-4-

hydroxycinnamic acid matrix on a MALDI target plate and subsequently analysed via
MALDI-TOF mass spectrometry in linear mode.
The resultant peptide mass fingerprint, depicted in Figure 3.22, reveals a number
of tryptic peptides matching those of FLAG-TAZ. These peptides are indicated on the
mass spectrum by their experimentally determined m/z ratios.

Among the tryptic

peptides attributed to FLAG-TAZ were a number of putative phosphopeptides.

We

detected five unique phosphorylated peptides, each containing at least one putative
phosphorylation site. Two of the five potential FLAG-TAZ phosphopeptides appear to
be multiply phosphorylated, with the lesser phosphorylated peptides separated from their
higher phosphorylated counterparts by -80 m/z, a mass difference attributed to the
addition of a phosphate group. Within Figure 3.22, the number of symbols used to label
the potential phosphopeptides is representative of the number of phosphorylation sites
presumed to be present.
In order to unambiguously establish the identity and phosphorylation status of
each of the putative FLAG-TAZ phosphopeptides, we performed tandem mass

83

1016.77

669.0

1235.4

2621.94 2776.63
AA
2891.45
2857.77

1801.8
2368.2
Mass (m/z)

2934.6

3501.0

Figure 3.22- Mass Spectrometric Analysis of FLAG-TAZ Reveals a Number of
Putative Phosphopeptides. The tryptic peptides derived from the Coomassie stained band
indicated in Figure 3.7 were analyzed by MALDI-TOF mass spectrometry in linear mode in
an attempt to identify putative TAZ phosphopeptides. The MALDI-TOF peptide mass
fingerprint of FLAG-TAZ is shown above. Tryptic peptide ions matching those predicted
for TAZ by MS-Digest are indicated by their experimentally determined m/z ratios.
Putative phosphopeptides, also predicted by MS-Digest, are denoted by the following
symbols: *, • , A, °, f. The number of symbols in the label indicates the phosphorylation
status of the putative phosphopeptide. This spectra is representative of four separate
experiments.
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spectrometry (MS/MS). Location of the exact site(s) of phosphorylation within the
peptides was attempted through analysis of the resultant fragment ion spectra.

2145.48 m/z, 2225.55 m/z, 2306.02 m/z-

Within Figure 3.22, we detected a

series of tryptic peptides with masses corresponding to the TAZ peptide,
(R)290SITNNSSDPFLNGGPYHSR308(E), containing one (2145.48 m/z), two (2225.55
m/z), and three (2306.02 m/z) phosphate groups. The MS/MS spectrum of the peptide
ion at 2306.02 m/z exhibited four peaks separated by approximately 98 m/z, a difference
attributable to the neutral loss of phosphoric acid (H3PO4) from a phosphoserine or
phosphothreonine, proving that this peptide, which contains five serine/threonine
residues, is indeed triply phosphorylated (Figure 3.23A). Examination of the fragment
ions of the singly phosphorylated tryptic peptide (2145.48 m/z) revealed a number of
carboxy-terminal (y) ions matching those predicted for the TAZ peptide spanning amino
acid residues 290 to 308, (R)290SITNNSSDPFLNGGPYHSR308(E). A number of the
most abundant peaks (y7, yy - 98 m/z, yio, yi 1) detected in the MS/MS spectrum, as well
as numerous less prominent ones, represent phosphopeptide fragments containing only
one phosphorylatable residue, Ser307 (Figure 3.23B). Taken together, this MS/MS data
enabled the unambiguous identification of Ser307 as a novel TAZ phosphorylation site.
Interestingly, two major peptide peaks detected in the MS/MS analysis of 2145.48
m/z do not support our identification of Ser307 as a phosphorylation site. The 773.22
m/z and 1245.29 m/z peptide peaks can be matched to masses predicted for yi and yn
fragment ions, however, only in the absence of a phosphate group on Ser307 (Figure
3.23B). The 773.22 m/z peptide was also detected in the MS/MS spectra of both the
doubly and triply phosphorylated peptides.

Since we are highly confident in our

assignment of Ser307 as a phosphorylation site, we believe that phosphorylation at
Ser307 may oppose phosphorylation at one or more of the amino-terminally located
Ser/Thr residues (Ser290, Thr292, Ser295, Ser296). However, identification of the other
85
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Figure 3.23- Identification of Ser307 as a TAZ Phosphorylation Site. (A) A portion of
the MS/MS spectrum of the peptide at 2306.02 m/z. Three consecutive losses of 98 m/z
from the precursor ion (2303.47 m/z) confirmed the presence of 3 phosphate groups on this
peptide. (B) A segment of the MS/MS spectrum of the singly phosphorylated peptide at
2145.48 m/z. The fragment ions (b and y) with m/z ratios matching those predicted by MSProduct, including y ions with a loss of H 3 P0 4 (98 m/z), are labelled. The detected fragment
ions verified the TAZ peptide to be 290SITNNSSDPFLNGGPYHSR308, as well as enabled
the unambiguous identification of Ser307 as a TAZ phosphorylation site (pS). The boxed
m/z ratios are those which oppose the identification of Ser307 as a phosphorylation site.
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phosphorylation sites within this peptide was not feasible with the MS/MS data obtained,
which is likely explained, at least in part, by the close proximity of the other potential
phosphorylation sites.

2621.94 m/z- Our MS analysis of FLAG-TAZ revealed a tryptic peptide with an
experimental m/z ratio of 2621.94, which corresponds to a TAZ peptide predicted to be
singly phosphorylated (Figure 3.22).

The presence of one phosphate group on this

peptide ion was confirmed via tandem mass spectrometry, as we detected a major peak at
2520.64 m/z, which is approximately 98 m/z less than the precursor ion, 2618.34 m/z
(Figure 3.24). The MS/MS spectrum presented numerous fragment ions characteristic of
the following TAZ peptide, (K)158AMNQPLNHMNLHPAVSSTPVPQR180(S) (Figure
3.25A,C). Interestingly, analysis of the MS/MS spectrum provided compelling evidence
suggesting that Serl73, Serl74, and Thrl75 all undergo phosphorylation (Figure 3.25B).
The ions detected at 777.21 m/z (y6) and 679.15 m/z (y6 - 98 m/z) suggest the
phosphorylation of Thrl75, a proline-directed site, as they represent the mass of the
peptide fragment

l75

TPVPQR180 containing one phosphate group. On the other hand, we

were also able to detect fragment ions at 697.22 m/z, a mass predicted for an
unphosphorylated y6 ion (175TPVPQR180), and at 864.47 m/z and 766.20 m/z, indicating a
phosphorylated y7 ion (174STPVPQR180), which includes Serl74. The detection of these
y ions implies that Serl74 also undergoes phosphorylation. Finally, we were also able to
localize a phosphate group to Serl73, due to the identification of a yj ion at 784.26 m/z,
which represents the peptide 174STPVPQR180 in an unphosphorylated form.
It is important to note that we were unable to detect a doubly or triply
phosphorylated form of this peptide; therefore, it is possible that phosphorylation at any
one of these residues is dependent upon the phosphorylation status of the other two sites.
The extremely close proximity of these three TAZ phosphorylation sites likely favours
our notion of phosphorylation dependency, as the occurrence of multiple negatively
87
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Figure 3.25- Identification of Serl73, Serl74, and Thrl75 as TAZ Phosphorylation
Sites. (A) A portion of the MS/MS spectrum of 2621.94 m/z. The b and y fragment ions
with m/z ratios matching those predicted by MS-Product, including ions with a loss of
H 3 P0 4 (98 m/z), are labelled. The question mark (?) indicates the region of the MS/MS
spectrum that was enlarged in (B). The fragment ions denoted in (B) revealed Serl73,
Serl74, and Thrl75 as TAZ phosphorylation sites (pS, pT). The fragment ions that enabled
the identification of each of the sites are indicated. (C) The fragment ions confirmed the
TAZ peptide under investigation to be 158AMNQPLNHMNLHPAVSSTPVPQR180.
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charged phosphate groups on consecutive residues would likely introduce considerable
electrostatic repulsion in the region of the peptide. Thus, we hypothesize that, at any
given time, only one of the three indicated phosphorylation sites is phosphorylated with
that site undergoing dephosphorylation before the phosphorylation of another site can be
achieved.

2776.63 m/z, 2857.77 m/z, 2937.28 m/z-

Through MALDI-MS analysis of the

FLAG-TAZ tryptic peptides, we detected a series of putative phosphopeptides with
masses corresponding to a TAZ peptide containing one (2776.63 m/z), two (2857.77
m/z), or three (2937.28 m/z) phosphate groups (Figure 3.22).

To ascertain the

phosphorylation status of this peptide, we consulted the MS/MS spectrum of the peptide
ion assumed to be triply phosphorylated (2937.28 m/z), which presents two consecutive
neutral losses of approximately 98 m/z from the precursor ion (2933.08 m/z), indicating
that this peptide is at least doubly phosphorylated (Figure 3.26A). A third loss of 98 m/z
is not evident on the MS/MS spectrum; however, this does not disprove the presence of a
third phosphorylation site on this peptide, as the detection of fragment ions was likely
suppressed by the co-elution of a second putative TAZ peptide (2938.28 m/zav).
MS/MS analysis of the singly phosphorylated TAZ peptide (2776.63 m/z)
revealed a number of fragment ions corresponding to amino acid residues 87 to 114 of
TAZ, (R)87SHSSPASLQLGTGAGAAGSPAQQHAHLRU4(Q) (Figure 3.26B). In our
attempt to identify the phosphorylation site on this peptide, detection of the fragment ion
series, yn to yi6, ruled out Serl05 as a phosphorylation site. Our detection of fragment
ions yig, y2o, and yj\ also disqualified Thr98 as the phosphorylated residue in this peptide.
The presence of b ions with masses matching those predicted for unphosphorylated b*
and bs fragment ions enabled the identification of the phosphorylated residue as Ser93 by
eliminating Ser87, Ser89, and Ser90 as candidate phosphorylation sites. Furthermore, the
detection of y23 and y24 - 98 m/z ions, which correspond to masses of phosphorylated
90
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Figure 3.26- Identification of Ser93 as a TAZ Phosphorylation Site. (A) Part of the
MS/MS spectrum of 2937.28 m/z. The double elimination of H 3 P0 4 , as shown by 2
consecutive losses of 98 m/z from the precursor ion (2933.08 m/z), confirmed the presence
of 2 phosphate groups. The fragment ions did not confirm the existence of a third phosphate
group. (B) A portion of the MS/MS spectrum of the singly phosphorylated peptide at
2776.63 m/z. The b and y fragment ions with m/z ratios matching those predicted by MSProduct are labelled.
The fragment ions confirmed the TAZ peptide to be
87
SHSSPASLQLGTGAGAAGSPAQQHAHLR114. Unambiguous identification of Ser93 as
a TAZ phosphorylation site (pS) was also possible.
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TAZ ions, confirmed our assignment of Ser93 as a TAZ phosphorylation site on this
singly phosphorylated peptide.
Insufficient MS/MS data obtained for the phosphopeptides presumed to contain
two (2857.77 m/z) and three (2937.28 m/z) phosphate groups, respectively, hindered our
attempt to locate the other phosphorylation sites within this peptide. The occurrence of
three of the six phosphorylatable residues within the first four amino acid residues of this
peptide exacerbated our feat of identifying the other two sites. Although, the detected
fragment ions for this peptide did not clearly depict Ser89 as a phosphorylation site,
studies have revealed that TAZ does indeed undergo phosphorylation at Ser89, an event
proven necessary for 14-3-3 recognition [42,43]. Taken together with our identification
of Ser93 as a novel TAZ phosphorylation site, there likely remains at least one more
phosphorylation site to be determined amidst the amino acid residues of this TAZ
peptide.

2891.45 m/z- Examination of the MS spectra portraying the FLAG-TAZ tryptic
peptides revealed a peptide ion with an m/z ratio of 2891.45, which matches that of a
theoretical TAZ tryptic peptide containing one phosphate group (Figure 3.22). MS/MS
analysis of this putative phosphopeptide confirmed the presence of a single phosphate
group, as we detected the neutral loss of phosphoric acid from the precursor ion, 2888.45
m/z (Figure 3.27). Analysis of the fragment ions confirmed that the peptide included
residues 264 to 289 of TAZ, (R)264QLPMEAETLAPVQAAVNPPTMTPDMR289(S)
(Figure 3.28). Within this TAZ peptide, there exists three Thr residues positioned at
amino acid residues 271, 283, and 285. The detection of fragments ions at 601.21 m/z
and 699.20 m/z, which match the theoretical masses of the phosphorylated ys and ys - 98
m/z ions, allowed us to unambiguously discern Thr285 as the site of phosphorylation in
this singly phosphorylated TAZ peptide, as the ys ion contains only one putative
phosphorylatable residue (Figure 3.28A,B).
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Interestingly, Thr285 is immediately
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Figure 3.27- MALDI-MS/MS Analysis of 2891.45 m/z. (A) The MS/MS spectrum of the
tryptic peptide at 2891.45 m/z is shown. The elimination of H 3 P0 4 , evidenced by the loss of
98 m/z from the precursor ion (2888.45 m/z), confirmed the presence of a single
phosphoserine or phosphothreonine on this peptide. (B) The singly phosphorylated tryptic
peptide ion matching 2891.45 m/z.
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Figure 3.28- Identification of Thr285 as a TAZ Phosphorylation Site. (A,B) Different
portions of the MS/MS spectrum of 2891.45 m/z. The b and y fragment ions with m/z ratios
matching those predicted by MS-Product, including ions showing a loss of H 3 P 0 4 (98 m/z),
are labelled. (C) The detected fragment ions enabled the identification of the tryptic peptide
as QLPMEAETLAPVQAAVNPPTMTPDMR, which encompasses TAZ amino acids 264 to
289. It was also possible to unambiguously identify Thr285 as the phosphorylation site (pT)
on this TAZ peptide.
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followed by a proline residue (Pro286), suggesting that this newly identified TAZ
phosphorylation site may be a proline-directed phosphorylation site.

3050.43 m/z-

The peptide mass fingerprint resulting from the MALDI-MS

analysis of the FLAG-TAZ tryptic peptides displayed a peak at 3050.43 m/z, which
corresponds to a TAZ peptide containing one phosphate group (Figure 3.22). MS/MS
analysis of the tryptic peptide ion at 3050.43 m/z confirmed that this peptide is indeed
singly phosphorylated, as a neutral loss of approximately 98 m/z was evident from the
parent ion (3046.69 m/z) (Figure 3.29A). Numerous fragment ions, mainly y ions, were
detected,

which

matched

those

expected

for

the

TAZ

peptide

(R)115QQSYDVTDELPLPPGWEMTFTATGQRI40(Y) (Figure 3.29B). Based upon the
detection of fragment ions at 461.06 m/z and 532.22 m/z, which represent
unphosphorylated y4 and ys ions, respectively, we were able to eliminate Thrl37 as the
site of phosphorylation in this peptide. It was also possible to rule out Thrl35 as the
phosphorylated residue, as we observed fragment ions matching unphosphorylated y6
(632.96 m/z) and yi (780.27 m/z) ions. The detection of numerous y ions ranging from
y8 (881.27 m/z) to yig (2030.94 m/z) further narrowed down the identity of the
phosphorylated amino acid residue by disqualifying Thrl33, as the masses of these
fragment ions match those calculated for the unphosphorylated ions. Examination of the
MS/MS spectrum of this TAZ peptide also revealed masses corresponding to
unphosphorylated yi\ (2346.90 m/z) and y22 (2461.01 m/z) ions, enabling the exclusion
of Thrl21 as the phosphorylation site on this peptide. Thus, through the process of
elimination, it appears that Serl 17 undergoes phosphorylation. Furthermore, we detected
peaks at 425.15 m/z and 587.13 m/z, which match the masses predicted for
phosphorylated b3 and b4 fragment ions, respectively. As there is only one Ser/Thr
residue within these fragment ions, we were able to unambiguously identify Serl 17 as a
novel TAZ phosphorylation site within this peptide.
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Figure 3.29- Identification of Serll7 as a TAZ Phosphorylation Site. (A) MS/MS
spectrum of the TAZ tryptic peptide at 3050.43 m/z. The loss of 98 m/z from the precursor
ion (3046.69 m/z) confirmed the peptide to be singly phosphorylated. (B) Part of the MS/MS
spectrum of 3050.43 m/z. The b and y fragment ions matching those predicted by MSProduct are labelled. The pattern of detected fragment ions verified the TAZ peptide to be
115
QQSYDVTDELPLPPGWEMTFTATGQR140, as well as enabled the unambiguous
identification of Serl 17 as a phosphorylation site (pS) on TAZ.
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In our comprehensive investigation of TAZ phosphorylation, we were able to
detect five unique TAZ phosphopeptides using mass spectrometry. We observed that two
of the five TAZ phosphopeptides were triply phosphorylated, while the remaining three
phosphopeptides were proven to be singly phosphorylated. Most importantly, we were
successful in unambiguously identifying seven TAZ phosphorylation sites. A summary
of the TAZ phosphorylation data and a schematic diagram of TAZ illustrating the
location of the identified phosphorylation sites can be found in Table 3.1 and Figure 3.30,
respectively.

3.9 Phosphorylation ofSer93 Diminishes the Interaction Between TAZ and 14-3-3

Since the cytoplasmic sequestration of TAZ by 14-3-3 has proven to be a very
critical

mechanism

regulating TAZ transcriptional co-activation activities, our

identification of Ser93 as a novel TAZ phosphorylation site was intriguing, as it is
located in close proximity to Ser89, the phosphorylation site responsible for the
phosphorylation-dependent recognition of TAZ by 14-3-3 [42]. Hence, we wondered
whether the occurrence of phosphorylation at Ser93 would in some manner impact the
interaction between TAZ and 14-3-3. In order to investigate the consequence of Ser93
phosphorylation on 14-3-3 binding, we generated two FLAG-TAZ mutant constructs
through substitution of Ser93 with an alanine (FLAG-TAZ S93A) or an aspartate residue
(FLAG-TAZ S93D). Substituting Ser93 with an alanine residue produces a form of
FLAG-TAZ that cannot be phosphorylated at position 93; whereas, substitution with an
aspartate residue serves to mimic constitutive phosphorylation at Ser93. We transiently
transfected these FLAG-TAZ mutant constructs, as well as wild-type TAZ (FLAG-TAZ)
and the 14-3-3 binding mutant of TAZ (FLAG-TAZ S89A) in HEK 293 cells.
Approximately 24 hours post-transfection, the cells were lysed and the cleared cell
lysates were subjected to anti-FLAG immunoprecipitation.
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The resulting anti-FLAG

m/z

#of
Sites

Peptide Sequence
307

2145.48

290

SITNNSSDPFLNGGPYHSR308

2225.55

290

SITNNSSDPFLNGGPYHSR308

2306.02

290

SITNNSSDPFLNGGPYHSR308

1

307

2

307

3

173-175
158

AMNQPLNHMNLHPAVSSTPVPQR180

2621.94

93

2776.63

87

2857.77

87

2937.28

87

2891.45
3050.43

1

SHSSPASLQLGTGAGAAGSPAQQHAHLR114

1

93

SHSSPASLQLGTGAGAAGSPAQQHAHLR114

2

SHSSPASLQLGTGAGAAGSPAQQHAHLR'14

3

264

285

QLPMEAETLAPVQAAVNPPTM1PDMR289

115

1

117

QQSYDVTDELPLPPGWEMTFTATGQR140

1

Table 3.1- Summary of TAZ Phosphopeptides Detected by Mass Spectrometry. The
table lists the m/z ratios and the sequences of the TAZ phosphopeptides identified by mass
spectrometric analysis of FLAG-TAZ. The number of phosphate groups either proven or
presumed to be on the phosphopeptides is also shown. Phosphorylation sites that were
unambiguously identified through our analysis are underlined and their numerical position
within peptide is indicated.
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Figure 3.30- Schematic Model of TAZ. The identified TAZ phosphorylation sites are
shown here (boxed) with reference to key TAZ regions (WW, WW domain; CC, Coiled-coil
domain; PDZ, PDZ-binding motif; S89, 14-3-3 binding site).
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immune complexes were resolved by SDS/PAGE and subsequently immunoblotted with
a pan-14-3-3 antibody, so as to detect any co-immunoprecipitated 14-3-3 (Figure 3.31;
upper panel).
As it has been previously reported, we observed that endogenous 14-3-3 could
indeed co-immunoprecipitate with FLAG-TAZ, but not with FLAG-TAZ S89A, since the
interaction between TAZ and 14-3-3 is reliant upon Ser89 phosphorylation [42].
Interestingly, anti-14-3-3 immunoblot analysis revealed little 14-3-3 in the FLAG-TAZ
S93D immunoprecipitants, indicating that phosphorylation at Ser93 may, to some extent,
disrupt the association between TAZ and 14-3-3. In agreement with this result, FLAGTAZ S93A was shown to have no bearing on 14-3-3 binding, as it was able to bring down
as much 14-3-3 as did wild-type FLAG-TAZ. Thus, these findings suggest that the
phosphorylation of Ser93 influences the interaction between TAZ and 14-3-3, ultimately
governing the ability of TAZ to function as a transcriptional co-activator through
regulation of its cytoplasmic sequestration.

3.10 The Phosphorylation-Defective Mutant, TAZ Sll 7A, Strongly Inhibits Adipocyte
Differentiation

In their assessment of the modular structure of TAZ, Kanai et al. noted that TAZ
contains a centrally located WW domain [42]. It has been well documented that WWdomain-containing transcriptional co-activators utilize their WW domains in the binding
of transcription factors, most favourably binding to those transcription factors possessing
Pro-rich motifs, such as the Leu/Pro-Pro-Xxx-Tyr (L/PPXY) motif optimally bound by
TAZ. Thus, numerous researchers have assessed whether the binding of TAZ to its target
transcription factors is afforded by its WW domain [42,45,48-51].

Within our

comprehensive study of TAZ phosphorylation sites, we unambiguously identified Serll7
as a novel TAZ phosphorylation site, an intriguing finding since Serl 17 maps to a region
100
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Figure 3.31- TAZ S93D Resists 14-3-3 Binding. HEK 293 cells were transiently
transfected with FLAG-TAZ, FLAG-TAZ S89A, FLAG-TAZ S93A, and FLAG-TAZ S93D.
Twenty-four hours post-transfection cells were lysed and subjected to anti-FLAG
immunoprecipitation (IP). The resulting immune complexes were resolved by SDS/PAGE
and immunoblotted (IB) with a pan-14-3-3 antibody (upper panel) and a FLAG antibody
(middle panel). Endogenous 14-3-3 levels were assayed by immunoblot analysis of
SDS/PAGE-resolved lysates with a pan-14-3-3 antibody (lower panel). These results are
representative of 3 separate experiments.
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of TAZ located immediately N-terminal to its WW domain (Figure 3.30). Given the
close proximity of Serl 17 to the WW domain, we questioned whether the presence of a
phosphate group at Serl 17 would influence the manner in which TAZ interacts with the
subset of transcription factors believed to associate with TAZ through its WW domain.
In order to indirectly examine whether phosphorylation on Serl 17 influences the
WW-domain-mediated binding of TAZ to (L/P)PXY motif-containing transcription
factors, we tested the interaction of TAZ with peroxisome proliferator-activated receptor
y (PPARy), a transcription factor critical for the proper differentiation of adipocytes [45].
It was shown by Hong et al. that the binding of TAZ to PPARy, which involves the
recognition of the (IVP)PXY motif of PPARy by the WW domain of TAZ, results in the
repression of the transcriptional activities of PPARy, ultimately, leading to a decrease in
adipocyte differentiation [45]. Since the integrity of the TAZ-PPARy interaction is
inversely related to the capacity of the cells to differentiate into adipocytes, we indirectly
examined the functional consequence of Serl 17 phosphorylation by assessing the degree
of adipogenesis achieved in mouse 3T3-L1 preadipocyte cells.

We generated a

phosphorylation defective mutant (FLAG-TAZ S117A) by substituting Serl 17 with an
alanine residue, creating a TAZ variant that cannot undergo phosphorylation at this
position. A second TAZ phosphorylation mutant was generated by replacing Serl 17 with
an aspartic acid residue (FLAG-TAZ S117D) to mimic a form of TAZ that is
constitutively phosphorylated on Serl 17.
Approximately 30 hours post-transfection, undifferentiated 3T3-L1 cells that had
been transiently transfected with FLAG-TAZ, FLAG-TAZ S117A, or FLAG-TAZ
S117D were induced to differentiate by replacing the culture medium with medium
supplemented with 10% FBS, IX dexamethasone, IX IBMX, and IX insulin. At this
point, a subset of transfected cells were lysed with the resulting cell lysates being
resolved by SDS-PAGE, transferred to PVDF membrane, and immunoblotted. AntiFLAG immunoblot analysis revealed the success of transfection, as well as comparable
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expression levels between the various TAZ constructs (Figure 3.32A). The remaining
preadipocyte cells were then subjected to an eight-day differentiation regimen, as
described previously, following which the differentiated cells were stained with Oil Red
O (ORO) to examine the degree of adipocyte differentiation.
Phase contrast images of the differentiated 3T3-L1 cells were taken immediately
following ORO staining, with cells heavily laden with ORO-stained lipids appearing
darker in contrast than those lacking significant lipid accumulation. It can be seen in
Figure 3.32B, that we were successful in reproducing the result put forth by Hong et ai,
in that FLAG-TAZ over-expression hinders adipogenic differentiation, which can be seen
through a comparison of the degree of adipogenesis observed in the mock (empty vector)
transfected cells [45]. Interestingly, we reproducibly observed that FLAG-TAZ S117A
over-expression reduced adipocyte differentiation to a level markedly lower than that
documented for wild-type TAZ. In accordance with these results, we also found that
cells over-expressing FLAG-TAZ S117D appeared to differentiate to a degree
comparable to, or slightly higher than, wild-type FLAG-TAZ over-expressing cells.
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Figure 3.32- TAZ S117A Greatly Hinders Adipogenesis. Mouse 3T3-L1 preadipocyte
cells were transiently transfected with pFLAG-CMV-2 (empty vector), FLAG-TAZ, FLAGTAZ S117A, FLAG-TAZ S117D. Approximately 24 h post-transfection, transfection
control cells were lysed. The lysates were separated by SDS/PAGE and (A) immunoblotted
with anti-FLAG. To induce adipogenesis, confluent cells were exposed to IBMX,
dexamethasone, insulin, and FBS -24-30 h post-transfection. After 72 h, the cells were
incubated in insulin media for 48 h, following which fresh insulin media was supplied.
Once the desired degree of differentiation was reached, ~48 h after the second change of
insulin media, the cells were fixed and subsequently stained for neutral lipids with Oil Red
O. (B) Phase contrast images of the Oil Red O stained cells were taken at a magnification of
lOOx. These results are representative of two separate experiments.
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Chapter 4
Discussion and Future Work

Within this study, we identified two transcriptional regulators, TAZ and KLF7,
which contain tetra-phosphorylation motifs (TPMs) akin to that first discovered in the
proto-typical TPM protein, P-catenin. Our characterization of the TAZ and KLF7 TPMs
revealed significant similarities, as well as differences, with respect to the regulatory
roles afforded by the P-catenin TPM. We also provide the first direct evidence that TAZ
is a highly phosphorylated protein.

Through mass spectrometric analysis, we

successfully located ten TAZ phosphorylation sites, of which three were mapped to the
TPM.

PART I) Identification and Characterization of TPM-Containing Proteins

4.1 Anti-TPM is a Bona Fide Phosphoantibody

In order to facilitate the identification of putative TPM-containing proteins, we
utilized a novel phosphoantibody raised against a degenerate TPM phosphopeptide
library of the form, pSXXXpSXXXpSXXXpS, in immunoblotting procedures.

The

specificity of this TPM phosphoantibody was evaluated through its reactivity with
differentially phosphorylated synthetic peptides, a p-catenin tetra-phosphorylation mutant
(p-catenin ATPM), and phosphoprotein-enriched cellular lysates (Figures 3.1, 3.2, 3.3).
Dot blot analysis of the differentially phosphorylated peptide libraries revealed that the
TPM antibody reacted most strongly with the tetra-phosphorylated peptides, while

exhibiting no reactivity with the unphosphorylated peptide library (Figure 3.1). These
findings illustrate the phosphospecific nature of the TPM antibody. It was also observed
that the TPM antibody showed relatively low binding specificity with the singly, doubly,
and triply phosphorylated peptide libraries. Although, this reactivity further validates the
phosphospecificity of the antibody, it shows it not to be specifically reactive with proteins
phosphorylated in a TPM. The fact that the intensity of the TPM phosphoantibody
interactions with the various phosphopeptide libraries increases with the number of
phosphate groups on the peptides suggests the antibody to be highly recognizant of
multiply phosphorylated proteins. This lack of specificity for TPM-containing proteins
can be explained by the polyclonal nature of the TPM phosphoantibody, as there likely
exists phosphospecific antibodies with varying epitopes within the antibody preparation.
Thus, the TPM phosphoantibody may be made up of antibodies that react with singly,
doubly, triply, and tetra phosphorylated proteins.
Acidic proteins have long interfered with phosphoprotein enrichment methods
that rely on electrostatic interactions between negatively charged phosphate groups and
immobilized metal cations, as acidic amino acids, such as aspartate and glutamate, mimic
the chemistry of phosphate groups [10]. For the same reason, phosphoantibodies tend to
non-specifically bind to highly acidic proteins. Within our global analysis of TPMcontaining proteins in HEK 293 cells, we observed a number of diffuse, TPM
phosphoantibody-reactive bands that did not show an increase in intensity with
phosphatase and proteasome inhibition, as would be expected for true TPM proteins
(Figure 3.3). We attributed these bands to acidic proteins, as their phosphoantibody
recognition was not diminished upon alkaline phosphatase incubation (data not shown).
Preliminary large-scale purification efforts resulted in the anti-TPM immunoprecipitation
and subsequent mass spectrometric identification of the highly acidic protein,
tropomyosin (data not shown). Interestingly, amino acid sequence analysis of human
tropomyosin revealed four glutamate residues separated from one another by three
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arbitrary residues in a TPM-like fashion. Thus, it is possible that the acidic proteins
reactive with the TPM phosphoantibody, like tropomyosin, feature acidic amino acid
residues in the proper spacing.
In an effort to elucidate the TPM phosphoproteome, we do intend to pursue a
large-scale identification of TPM-containing proteins in a variety of cell types. The
isolation of putative TPM proteins from crude cell lysates will be afforded through the
generation of a chromatographic column containing covalently conjugated TPM
phosphoantibody. The ability of the TPM phosphoantibody to react non-specifically with
phosphoproteins containing less than four phosphate groups, as well as acidic proteins, is
not anticipated to be a major obstacle in the identification of TPM proteins, as mass
spectrometry will be utilized to identify the isolated proteins, filter out any non TPMcontaining proteins, and to unambiguously map the phosphorylation sites that constitute
their respective TPMs.

4.2 TAZ and KLF7 are Novel TPM-Containing Proteins

Small-scale immunoblot analyses focused on detecting the complement of TPMcontaining proteins within HEK 293 cells revealed a number of putative TPM proteins
through their reactivity with the TPM phosphoantibody, as well as by their increased
intensity upon phosphatase and proteasome inhibition (Figure 3.3A).

Correlation of

bioinformatic data compiled through a pattern search of the human SwissProt database
with the TPM sequence, DS/TGXXS/TXXXS/TXXXS/T (Appendix 1), with our
immunological data (Figure 3.3A,B) revealed two proteins, TAZ and KLF7, with
intriguing similarities to P-catenin, as putative TPM-containing proteins.
TAZ, also referred to as WWTR1 (WW domain-containing transcriptional
regulator 1), was initially identified in a screen for 14-3-3 binding proteins [42]. It was
discovered that 14-3-3 binding retained TAZ within the cytoplasm, hindering its nuclear
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localization. The localization of TAZ to the nucleus, as well as to the plasma membrane,
was shown to be mediated by interaction of its C-terminal, PDZ-binding motif with
unknown PDZ domain-containing proteins [42]. The inability of TAZ to enter the
nucleus diminishes its transcriptional co-activation abilities, which have been shown to
mediate the expression of genes linked to the development of bone, fat, muscle, lung,
heart, and limb [41,45,48-50,52-55].
KLF7, or ubiquitous KLF (UKLF), named for its broad expression profile,
belongs to a zinc-finger transcription factor family, primarily characterized by the
presence of a C-terminal, DNA-binding domain, consisting of three zinc fingers of the
Cys2-His2 type, and by the conserved amino acid sequence connecting the zinc fingers,
which was initially observed in the Drosophila segmentation protein, Kriippel [56].
Intensive studies centred on delineating the role of KLF7 in neurogenesis revealed that its
transcriptional regulation is critical for proper differentiation, maturation, and phenotype
maintenance of neurons [57-64]. Transcriptional mediation afforded by KLF7 has also
been implicated in adipogenesis and insulin biosynthesis and secretion [46,47].
Within this study, we have provided evidence confirming the presence of a TPM
within both TAZ and KLF7. Firstly, highly modified forms of over-expressed FLAGTAZ and Myc-KLF7, whose levels were enhanced by phosphatase and proteasome
inhibition, were found to react with the TPM phosphoantibody in immunoblot
experiments (Figures 3.5, 3.6). The recognition of modified TAZ and KLF7 by antiTPM

was

entirely

dependent

upon

phosphatase

inhibition,

suggesting

that

phosphorylation of their respective TPMs is highly regulated by the interplay of yet to be
identified kinases and phosphatases.
Secondly, mutational analyses of the putative TAZ and KLF7 TPM
phosphorylation sites resulted in the generation of potentially lesser phosphorylated
versions of these proteins. Separation by SDS-PAGE revealed that Myc-KLF7 STDM,
which contains alanine substitutions at both Thrl9 and Ser23, migrated at a relatively
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faster rate than did wild-type Myc-KLF7 (Figure 3.13), as well as lacked an upper anti-cMyc reactive band observed within the wild-type protein that can likely be attributed to a
higher modified form of Myc-KLF7 (Figure 3.10). FLAG-TAZ ATPM, which features
an alanine substitution at each of the four putative TAZ TPM phosphorylation sites, also
migrated at a faster rate than did FLAG-TAZ (Figure 3.11). The increased mobility
observed for the TPM mutant forms of KLF7 and TAZ suggested that the mutations
made affected the phosphorylation state of the protein, corroborating our identification of
TAZ and KLF7 as TPM proteins.
Finally, mass spectrometric (MS) analysis of phosphorylated FLAG-TAZ
revealed a tryptic peptide ion with an m/z ratio matching that predicted for a peptide
containing the TAZ TPM with four phosphate groups (2643.18 m/z; Figure 3.8). The
mapping of these TAZ phosphorylation sites by tandem mass spectrometry (MS/MS) was
an important undertaking, as there exists 8 phosphorylatable S/T residues within the
vicinity of the TAZ TPM (57DSGSHSRQSSTDSS70).

MS/MS analysis of this

phosphopeptide verified its tetra-phosphorylation and mapped three of the phosphate
groups to the predicted TAZ TPM sites: Ser58, Ser62, and Ser70 (Figures 3.8, 3.9).
Although we were unable to explicitly locate the site of the fourth phosphate group, the
series of fragment ions detected via MS/MS did enable us to trace it to either Ser65 or
Ser66. Our inability to distinguish between Ser65 and Ser66 as a phosphorylation site on
the TAZ TPM peptide can partly be attributed to the presence of fragment ions from a
number of prominent TAZ peptide ions (2539.71 m/z, 2555.71 m/z, 2572.57 m/z,
2621.05 m/z) within the MS/MS spectrum.

As Ser66 is a predicted TPM

phosphorylation site, with additional attention paid to the separation of the TAZ
phosphopeptides prior to MS/MS by means such as high performance liquid
chromatography (HPLC), we will likely be able to unambiguously identify TAZ as a
TPM protein.
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4.3 Biochemical Characterization of the TAZ andKLF7 TPMs

Amino acid sequence alignments of KLF7 and TAZ orthologues revealed their
TPMs to be entirely conserved in closely related mammals (Figures 4.1, 4.2). This
conservation suggests that the KLF7 and TAZ TPMs may be involved in the regulation of
their activities, comparable to the roles afforded by the P-catenin TPM.

Although

sequence information for TAZ and KLF7 from more distinctly related vertebrate species
is limited, sequence analysis of the available orthologues illustrated that a greater part of
the TPM of both TAZ and KLF7 is conserved, with the exception of the C-terminal-most
phosphorylation sites (Ser70 of human TAZ; Thr31 of human KLF7). The emergence of
the aforementioned C-terminal phosphorylation sites of TAZ and KLF7 in higher
mammals likely evolved as an additional layer of regulation for the processes governed
by the phosphorylation events at the sites conserved across all species. Interestingly, the
consensus P-TrCP binding sequence, DSGXXS, is highly conserved within all of the
TAZ and KLF7 orthologues.

4.3.1 TPM-Dependent Binding ofB-TrCP Likely Facilitates KLF7 Ubiquitination

Within our investigation of the KLF7 TPM, we uncovered a novel interaction
between KLF7 and P-TrCP (Figure 3.10).
majority of its known substrates, including

The interaction between P-TrCP and a
IKBOC,

Snail, Vpu, and P-catenin, has been

shown to be phosphorylation-dependent, requiring the phosphorylation of two serine
residues (DpSGXXpS) [19,65,66]. Our results show that the recognition of KLF7 by PTrCP is likely also reliant on phosphorylation, as the interaction was detected solely upon
phosphatase inhibition, which allows for the accumulation of potentially phosphorylated
KLF7. Furthermore, alanine substitutions at the putative phosphorylation sites (Thrl9
and Ser23) in the proposed P-TrCP consensus sequence,
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Figure 4.1- Amino Acid Sequence Alignment of the N-terminal Region of KLF7
Orthologues. The serine/threonine residues constituting the KLF7 TPM are boxed. The
highly conserved P-TrCP consensus sequence (DTGYFS) is also highlighted. The amino
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binding of KLF7 by (3-TrCP, suggesting that their interaction is mediated by the
phosphorylation of this consensus sequence. It will be interesting to determine whether
sequential phosphorylation of Thr31 and Ser27, the two C-terminal TPM sites, is
necessary for the putative phosphorylation events at Ser23 and Thrl 9, as has been shown
for the phosphorylation of the P-catenin TPM [16]. In order to address the possibility of
hierarchical phosphorylation at the KLF7 TPM, the integrity of the KLF7-P-TrCP
interaction will be assessed using KLF7 phosphorylation mutants of Thr31 and Ser27.
The binding of P-TrCP to phosphorylated P-catenin has been shown to facilitate
the degradation of P-catenin via the ubiquitin-proteasome pathway [18-21]. We provide
evidence here that, like P-catenin, KLF7 also undergoes ubiquitination in a manner
dependent upon its TPM.

Firstly, KLF7 ubiquitination was apparent only in cells

subjected to phosphatase inhibition, which suggested a link between KLF7
phosphorylation and its subsequent ubiquitination (Figure 3.12). Secondly, little to no
ubiquitination was detected on KLF7 STDM, the KLF7 TPM mutant incapable of
binding P-TrCP (Figure 3.13). Thus, it appears that TPM phosphorylation, specifically
the phosphorylation of the sites comprising the inherent P-TrCP consensus sequence
(Ser23 and Thrl 9), is essential for KLF7 ubiquitination.

The dependence of KLF7

ubiquitination on an intact P-TrCP binding site suggests that the binding of KLF7 by PTrCP enables the ubiquitination of KLF7 through its recruitment of the ubiquitination
apparatus. Further studies are required to fully ascertain a causative relationship between
P-TrCP recognition and KLF7 ubiquitination. Such studies may include an analysis of
the ubiquitination state of KLF7 in response to the over-expression of an F-box deletion
mutant of P-TrCP, a dominant negative mutant that cannot bind to the Skpl/Cull
complex, but retains its capacity to bind to its substrates [67]. It will also be important to
verify that the ubiquitin conjugates detected are indeed derived from KLF7 and not from
other proteins capable of co-precipitating with KLF7.

In order to circumvent such

ambiguity in the analysis of ubiquitinated proteins, we will make use of a denaturing step
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proposed by Rotin et al., wherein, cell lysates are boiled in 1 - 2% SDS, prior to
immunoprecipitation, to eliminate all protein-protein interactions that may lead to
erroneous results [68].
Given our findings that KLF7 contains an N-terminally located TPM that is
responsible for both its interaction with P-TrCP and its ubiquitination, it is tempting to
suggest that KLF7 is also degraded in a manner dependent upon its TPM, analogous to
the phosphorylation-dependent degradation of P-catenin [18-21]. Our initial attempts at
determining whether KLF7 stability is mediated by actions at its TPM have been largely
inconclusive. Timed-course analysis of cycloheximide-treated HEK 293 cells revealed
the KLF7 TPM mutant, KLF7 STDM, to be fairly stable over the 12 hour time period;
whereas, it appears that wild-type KLF7 may be destabilized after the 10 hour mark
(Figure 3.16). The levels of wild-type KLF7 and KLF7 STDM present at time intervals
extending beyond 12 hours of cycloheximide incubation must be assessed to confirm the
degradation of KLF7, as well as its reliance upon the KLF7 TPM. The evaluation of
KLF7 turnover will likely benefit from the utilization of a more sensitive method, such as
pulse-chase analysis, which involves the tracing of radioactively labeled proteins over a
defined time period following a short period of in vivo radioactive protein labeling. Since
the analysis of protein stability requires the examination of different cell populations over
time, the generation of cell lines stably expressing KLF7 and KLF7 STDM will likely
limit any differences in their expression due to variations in transfection efficiency
between the cell populations.

4.3.2 TAZ Binds to an SCF*TrCP E3 Ligase Complex to Facilitate the UbiquitinMediated Proteolysis ofPC2

Earlier, we alluded to the presence of a consensus P-TrCP phosphodegron motif
within the TAZ TPM,

DSGSHS , whose existence and conservation in TAZ
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orthologues (Figure 4.2) hinted at the potential for an interaction between P-TrCP and
TAZ.

During the course of our analysis of the TAZ TPM, the results of a study

conducted by Tian et al. were released, which indeed demonstrated an interaction
between TAZ and P-TrCP; however, this interaction did not involve the TPMencompassed P-TrCP consensus sequence, as we had expected, rather it occurred through
the binding of p-TrCP to an atypical P-TrCP phosphodegron within the C-terminal of
mouse TAZ, 306STDSGLG312, which corresponds to 3USTDSGLG317 of human TAZ [41].
Analysis of the novel association between TAZ and P-TrCP introduced a new functional
role for TAZ, that being as an E3 ligase adapter protein. TAZ was found to serve as a
scaffold protein, bringing P-TrCP within the vicinity of a second TAZ binding protein,
polycystin 2 (PC2), a transmembrane protein responsible for the regulation of calcium
entry into and release from the endoplasmic reticulum. The binding of PC2 and P-TrCP
by TAZ enabled the P-TrCP-mediated ubiquitination of PC2, setting the stage for the
subsequent proteolytic degradation of PC2 [41]. Interestingly, the kidneys of surviving
TAZ knockout (TAZ1'") mice exhibited severe cyst formation, accompanied by an
abnormal accumulation of PC2, which were both attributed to a reduction in PC2
degradation.

These findings highlighted the importance of TAZ, not only in the

regulation of ubiquitin-mediated PC2 proteolysis, but also in the development of proper
renal structures [41].
Since P-TrCP substrate recognition has been shown to be highly dependent upon
phosphorylation, the fact that Tian et al. did not uncover a physical association between
P-TrCP and the consensus P-TrCP binding site within the TAZ TPM suggested to us that
the phosphorylation of the TAZ TPM might be sensitive to dephosphorylation by
unknown phosphatases. This notion was supported by our inability to detect the TAZ
TPM in untreated cells through both immunoblotting (Figure 3.5) and mass spectrometry
(data not shown).

Thus, under conditions we had proven favorable to the

phosphorylation of the TAZ TPM, we assessed whether an interaction between P-TrCP
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and the TPM-contained P-TrCP consensus sequence could be unveiled. Our study within
HEK 293 cells, treated with both phosphatase and proteasome inhibitors, once again
demonstrated the binding of {3-TrCP to the uncharacteristic binding site located in the
TAZ C-terminal, while failing to reveal an association between P-TrCP and the TAZ
TPM (Figure 3.11).

4.3.3 TPM Phosphorylation Facilitates TAZ Ubiquitination

Notwithstanding our findings and those published by Tian et al. that illustrate the
functional importance of the C-terminal P-TrCP binding site, we believe that the TAZ
TPM plays a critical functional role in the regulation of TAZ activities. Consistent with
this hypothesis is the conservation of the TAZ TPM from lower invertebrates to more
complex mammals (Figure 4.2). Of particular interest is the highly conserved nature of
the putative P-TrCP binding motif found within the TAZ TPM and its resemblance to the
equivalent consensus sequences in known P-TrCP substrates, such as P-catenin,

IKBCC,

Snail, Vpu, and the newly identified KLF7 [19,65,66]. Such observations strongly imply
that a common mechanism may exist for the regulation of the activities of TAZ and the
aforementioned proteins.

Studies have shown that the binding of P-TrCP to its

substrates, including P-catenin,

IKBCC,

and Vpu, initiates their ubiquitination, ultimately

marking them for degradation by the proteasome [18-21,65,66]. Therefore, despite the
lack of a detectable association between P-TrCP and the TAZ TPM, we questioned
whether TAZ was also subject to ubiquitin-mediated degradation.
Within this study, we demonstrate that TAZ does indeed undergo ubiquitination
in a manner dependent upon phosphorylation of its TPM, which was indicated by the
detection of TAZ ubiquitination chiefly under phosphatase and proteasome inhibition,
treatment conditions shown to favor TPM phosphorylation (Figure 3.14).

Further

evidence for the reliance of TAZ ubiquitination on its TPM was gained from the fact that
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no ubiquitin adducts were found to co-precipitate with the partial TAZ TPM mutant
(TAZ SDM), which contains alanine substitutions at the two serine residues comprising
the putative P-TrCP binding site, Ser58 and Ser62. Although under the conditions tested
the interaction between p-TrCP and TAZ does not require the TAZ TPM, this
phosphomotif is essential for TAZ ubiquitination. Of course, it will be important to
confirm the ubiquitination state of TAZ using the denaturing lysis protocol developed by
Rotin et al, as was proposed earlier for the verification of KLF7 ubiquitination [68].
However, the differential ubiquitination state of wild-type and TPM-compromised TAZ
is highly suggestive of TPM-dependent TAZ ubiquitination. It will also be of interest to
determine whether sequential phosphorylation of Ser70 and Ser66, the more C-terminal
phosphorylation sites of the TAZ TPM, is a prerequisite for the phosphorylation of Ser62
and Ser58, which has been documented for the phosphorylation of the P-catenin TPM
[16]. Future studies will examine the occurrence of hierarchical phosphorylation at the
TAZ TPM through an assessment of the ubiquitination state of TAZ phosphorylation
mutants containing single substitutions at the four TPM phosphorylation sites.
It is of interest to note that sequence analysis permitted the discovery of four
lysine residues in the N-terminus of human TAZ that represent potential sites of
ubiquitination (data not shown). Structural studies focused on delineating the mechanism
underlying the lysine specificity of the E3 ligase, SCFp"TrCP1, revealed the distance
between the P-TrCP binding site and the targeted lysine residue as a principal
determinant of ubiquitination efficiency [20].

Preferential ubiquitination has been

demonstrated for lysine residues spaced 9 - 1 4 amino acids from the aspartate residue of
the P-TrCP consensus sequence in both P-catenin and IicBa [20,21].

Intriguingly,

analysis of the positions of the N-terminal lysine residues of human TAZ revealed that
two of the four residues, Lys45 and Lys46, are located 11 and 12 amino acid residues,
respectively, from the TPM (Figure 4.2). In future studies, it will be interesting to assess
whether mutation of these Lys residues diminishes TAZ ubiquitination.
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Based upon our finding that TAZ undergoes ubiquitination in response to TPM
phosphorylation, we predicted that ubiquitin-conjugated TAZ is destined for degradation
via the proteasome, an outcome that has been well documented for ubiquitinated 0catenin [18-21]. Through a timed-course analysis of cycloheximide-treated HEK 293
cells, we revealed both TAZ and its TPM mutant, TAZ ATPM, to be largely stable over
the 12 hour time period (Figure 3.15). The stability of TAZ ATPM was anticipated, as
we have shown that mutation of the TPM inhibits its ubiquitination, possibly eliminating
the means by which TAZ is marked for degradation. However, the constant protein level
of wild-type TAZ over the time period studied did not support our premise of ubiquitinmediated TAZ degradation, suggesting that TPM-directed ubiquitination has no bearing
on TAZ protein stability. We hesitantly report the results of this timed-course study, as
an assay of the same lysates for endogenous P-catenin failed to illustrate the rapid
degradation of (3-catenin. The employment of more sensitive techniques, namely pulsechase analysis, will likely prove beneficial to our examination of TAZ protein stability.
As was previously discussed for our future investigations into KLF7 protein stability, it is
likely that the analysis of TAZ degradation would also benefit from the development of
stable TAZ and TAZ ATPM cell lines.
In support of the hypothesis that the ubiquitin-proteasome pathway is involved in
the regulation of TAZ, we show that endogenous TAZ is only detected through anti-TAZ
immunoblotting in the presence of phosphatase and proteasome inhibitors, which
suggests that TAZ may be constitutively degraded in vivo (Figure 3.3). Furthermore, in
their study of PC2 degradation, Tian et al. provide evidence that TAZ, like PC2, may be
degraded as a result of its incorporation into the SCF pTlCP E3 ligase complex. Mutation
of Ser306 or Ser309 of mouse TAZ, the critical serine residues that comprise the Cterminal 0-TrCP binding site, was found not only to abolish the binding of TAZ by (5TrCP, but also to stabilize the protein levels of TAZ [41]. Although, commented on only
briefly, this preliminary result is intriguing to us, as it hints at the potential for the
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regulation of TAZ by degradation, as well as links this putative regulatory mechanism to
P-TrCP binding.
Since the most common method of protein degradation involves the proteasome
and Tian et al. demonstrate that TAZ stability appears to be dependent upon P-TrCP
binding, it is likely that the potential turnover of TAZ will involve the ubiquitinproteasome system. In an attempt to mesh our findings with those published by Tian et
al., we have formulated a theory of TAZ degradation, which integrates TPM-dependent
ubiquitination with P-TrCP binding at the C-terminal binding site on TAZ. We speculate
that the putative degradation of TAZ may take place in the context of a feedback loop,
where the degradation of TAZ is initiated, in order to halt the degradation of PC2 or other
target proteins (Figure 4.3). It may be that during periods where PC2 degradation or the
degradation of other target protein is no longer required, a signal is emitted which results
in the liberation of bound P-TrCP from the TAZ C-terminal binding site and its
subsequent binding to the P-TrCP consensus sequence located within the TAZ TPM. It is
also possible that, instead of the same P-TrCP molecule jumping from one site to the
other, a second molecule of p-TrCP may be recruited to the putative N-terminal p-TrCP
binding site.

Lastly, we propose that the binding of P-TrCP to the TPM-located

consensus sequence will facilitate TAZ ubiquitination through its recruitment of the
ubiquitination apparatus, ultimately leading to the degradation of TAZ via the
proteasome. In both scenarios, the presence of P-TrCP at the C-terminal binding site is
believed to be necessary for the putative binding of p-TrCP to the TPM, providing a
potential explanation for the dependency of TAZ degradation on this site presented by
Tianetal. [41].
It is obvious that future investigations will be needed to determine the mechanism
of TAZ degradation. Initially, it will be important to confirm the regulation of TAZ by
degradation and its dependence upon the binding of TAZ by P-TrCP at the C-terminal
binding site, as the study published by Tian et al. provides fairly limited data on these
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Figure 4.3- Model Depicting the Regulation of PC2 Turnover by TPM-Mediated TAZ
Degradation [41 J. Phosphorylation of TAZ at Ser311 and Ser314 of human TAZ facilitates
the binding of P-TrCP, present within an SCF (Skpl/Cull/F-box) complex, to an atypical (3TrCP binding site within the C-terminus (Cl) of TAZ. TAZ functions as an E3 adapter
protein to bring P-TrCP within the vicinity of TAZ-bound PC2, facilitating the polyubiquitination and proteasomal degradation of PC2 [41]. Our theory suggests that during
periods where PC2 stabilization is favored, the phosphorylation of the TAZ TPM is induced,
generating a docking site for P-TrCP within the N-terminus (Nl) of TAZ. This event
initiates the release of PC2 from the destruction complex and results in the ubiquitination
and proteasomal degradation of TAZ. (El, ubiquitin (Ub)-activating enzyme; E2, ubiquitin
(Ub)-conjugating enzyme)
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subjects [41]. Given that we are able to verify these results, likely through pulse-chase
analysis with wild type TAZ and TAZ ClADSG, we next want to reassess the effect of the
TPM on the stability of TAZ using an identical approach with wild type TAZ and TAZ
ATPM, as we proposed earlier.

Finally, we intend to characterize the relationship

between the C-terminal P-TrCP binding site and the TAZ TPM to determine whether the
ubiquitination of TAZ is dependent upon p-TrCP binding at the TAZ C-terminal. This
study will involve a comparison of the ubiquitination states of wild type TAZ and TAZ
ClADSG, the TAZ mutant harboring serine to alanine substitutions at the critical residues
of the C-terminal P-TrCP binding site.
Interestingly, a fairly recent study has revealed that another E3 ligase adapter
protein is itself degraded in the context of the degradation complex that it is responsible
for assembling. Virus protein U (Vpu) is an integral membrane protein of the human
immunodeficiency virus type 1 (HIV-1) that has been implicated in the degradation of
CD4, the cell-surface co-receptor targeted by HIV particles for entrance into the host cell
[1,66]. Vpu mediates the degradation of newly synthesized CD4, present within the
endoplasmic reticulum (ER), by binding both CD4 and human P-TrCP, ultimately
facilitating the association of CD4 with the E3 ligase, SCF pTlCP . As a result of its
interaction with p-TrCP, CD4 is ubiquitinated and degraded by the host cell proteasome
[66]. The ability of Vpu to function as an E3 ligase adapter has long been recognized;
however, only recently was Vpu discovered as a bona fide P-TrCP substrate. It was
found that the binding of p-TrCP to the Vpu phosphorylation motif, 51DpSGNEpS56, also
resulted in the ubiquitination of Vpu and in its subsequent degradation by the proteasome
[66]. Since CD4 degradation is linked to enhanced virion release and is thus, necessary
to ensure viral propagation, it is thought that by halting the down-regulation of CD4
through the degradation of Vpu, the host cell can attempt to combat the progression of the
virus [66]. All in all, the discovery of such a degradation mechanism tied to the
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regulation of an E3 ligase adapter protein supports our proposition that TAZ may also be
regulated in such a manner.

4.3.4 The TAZ TPM Influences the Critical Regulatory Interaction Between TAZ
and 14-3-3

The human 14-3-3 protein family is comprised of seven highly conserved
isoforms, denoted p\ E, y, r\, a, t, and C„ that have been implicated in numerous cellular
signaling pathways, including those that govern cell cycle progression, apoptosis, and
transcription [69].

14-3-3 s are ubiquitously expressed, 30 kDa acidic proteins that

engage in both homo- and heterodimer formation to enable ligand binding. In most
cases, phosphorylation of the target protein is a pre-requisite for 14-3-3 binding, as each
of the 14-3-3 monomers contains a phosphoserine/phosphothreonine-binding pocket [69].
The function of 14-3-3 binding is to regulate the target protein through an alteration of its
behavior, which includes its conformation, protein-protein interactions, and intracellular
localization [69].
As we alluded to earlier, TAZ was identified in an in vitro screening for proteins
capable of interacting with 14-3-3 [42]. This study, conducted by Kanai et al, revealed
that 14-3-3 binding resulted in the retention of TAZ within the cytoplasm and was
dependent upon the phosphorylation of TAZ on Ser89 [42]. Moreover, the 14-3-3mediated cytoplasmic sequestration of TAZ was shown to inhibit the transcriptional coactivity of TAZ, as it effectively reduces the amount of TAZ present in the nucleus [42].
Interestingly, TAZ also contains a consensus PDZ-binding motif within its C-terminal,
whose influence on TAZ localization was found to oppose that of 14-3-3. Mutational
analysis illustrated the PDZ-binding motif to be responsible for localizing TAZ both to
the nucleus, in the form of discrete foci, and to the plasma membrane. This motif was
shown to be necessary for the transcriptional co-activation abilities of TAZ, a finding that
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can likely be explained by the fact that it directs TAZ to the nucleus [42]. Based upon
their results, Kanai et al. depict the regulation of TAZ localization as a competition
between PDZ-mediated

membrane and nuclear targeting and the cytoplasmic

sequestration of TAZ by 14-3-3 proteins [42].

Although, the intricacies of TAZ

regulation remain to be elucidated, it does appear that a major means of directing TAZ
function is through control of its spatial orientation.
In light of the critical role of 14-3-3 in the regulation of TAZ and in an attempt to
establish the function of the TAZ TPM, we questioned whether there existed a connection
between the TPM and the binding of TAZ by 14-3-3. Through co-immunoprecipitation
analysis, we were able to show that serine to alanine substitutions of the critical TPM
residues abolished the interaction between 14-3-3 and TAZ in 3T3-L1 preadipocyte cells
(Figure 3.17). The inability of the TPM mutant of TAZ (TAZ ATPM) to associate with
14-3-3 indicates that events occurring at the TPM, likely phosphorylation, make possible
the binding of TAZ by 14-3-3. One possible scenario explaining the influence of the
TAZ TPM on 14-3-3 binding depicts the phosphorylation of the TAZ TPM as a priming
event for the phosphorylation of Ser89. This theory suggests that TPM phosphorylation
enhances Ser89 phosphorylation in some manner, possibly through a favorable change in
TAZ conformation (Figure 4.4A). Considering our identification of Ser93 as a TAZ
phosphorylation site, a second putative scenario can be contrived. We show that, despite
the presence of Ser89 and an intact TPM, 14-3-3 cannot interact with TAZ S93D, a TAZ
mutant that mimics constitutive phosphorylation on Ser93 (Figure 3.31). This finding
provides evidence that the phosphorylation of TAZ at Ser93 inhibits the binding of 14-33. Thus, it may be that TPM phosphorylation promotes TAZ recognition by 14-3-3
through inhibition of Ser93 phosphorylation or promotion of Ser93 dephosphorylation
(Figure 4.4B).
In order to confirm the dependence of 14-3-3 binding on the TAZ TPM, we
intend to determine whether the subcellular localization of the TAZ TPM mutant (TAZ
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Figure 4.4- Models Illustrating the TPM-Dependence of 14-3-3 Binding of TAZ. 14-33 binding of TAZ is dependent upon the phosphorylation of TAZ on Ser89 (S89). (A) One
scenario suggests that the phosphorylation of TAZ at the TPM induces a conformational
change in TAZ that enhances the phosphorylation of Ser89. (B) Another possibility involves
the negative regulatory phosphorylation site, Ser93 (S93). TAZ phosphorylated on Ser93
resists 14-3-3 binding. Thus, phosphorylation of the TAZ TPM might oppose Ser93
phosphorylation or promote the dephosphorylation of Ser93.
The absence of
phosphorylated Ser93 may make possible the phosphorylation of Ser89 or may unmask a
previously phosphorylated Ser89.

124

ATPM) matches that of TAZ S89A, the TAZ mutant that is known to escape 14-3-3
binding. In future studies, we also want to further prove that the influence of the TPM on
the association of 14-3-3 with TAZ is indeed a result of TPM phosphorylation. Serine to
glutamate/aspartate substitutions of the TPM residues, which will mimic a constitutively
phosphorylated TAZ TPM, will likely make this study possible. As our studies were
conducted with TAZ ATPM, which contains serine to alanine substitutions at each of the
four TPM residues, it will also be important to ascertain whether the binding of 14-3-3 is
dependent upon all four TPM residues or is merely influenced by the residues located in
closest proximity to Ser 89 and/or Ser93. Furthermore, it may be possible to elucidate
the effect of the TAZ TPM on 14-3-3 binding by analyzing the phosphorylation states of
both Ser89 and Ser93 in response to over-expression of a mutant form of TAZ containing
a constitutively phosphorylated TPM. In the instance that our first theory holds true,
Ser89 phosphorylation would be expected to increase as a result of the over-expression of
the aforementioned TAZ mutant. If our second scenario were valid, the level of Ser89
phosphorylation would still be expected to increase; however, it would be accompanied
by a decrease in Ser93 phosphorylation. The monitoring of TAZ phosphorylation at
Ser89 and Ser93 could be conducted using phosphoantibodies or mass spectrometry.
Since we have also shown that the TPM governs the ubiquitination of TAZ, it is
tempting to speculate that the binding of TAZ by 14-3-3 may be linked in some manner
to this ubiquitination. One possibility involves the 14-3-3-mediated export of TAZ from
the nucleus, followed by its ubiquitination and proteasomal degradation in the cytoplasm.
Such a scheme has been implicated in the regulation of the protein levels of the FOXO
proteins, a group of transcription factors implicated in the cellular response to growth
signals and nutrients, oxidative stress, and genomic damage [70]. The activities and fates
of the FOXO proteins are dictated by specific post-translational modifications, which are
induced by various extracellular signals [70]. Most interesting to our study is the
phosphorylation of nuclear FOXO by various kinases in response to growth signaling,
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which favors the inactivation of FOXO-mediated gene expression.

Multisite

phosphorylation has been shown to facilitate the nuclear export of FOXO through the
actions of a series of inhibitory phosphorylations that culminate in the binding of FOXO
by 14-3-3 and the exportin, CRM1 [70]. 14-3-3- and CRMl-bound FOXO is escorted to
the cytoplasm, where it engages with an E3 ligase and is consequently ubiquitinated,
targeting it for proteasomal degradation [70]. Relating our findings that the TAZ TPM is
required for both its ubiquitination and 14-3-3 binding with the regulation of FOXO
degradation described above suggests that TPM phosphorylation of nuclear TAZ sets the
stage for its association with 14-3-3.

The binding of 14-3-3 to nuclear TAZ has

previously been shown to promote the export of TAZ from the nucleus [42]. Once in the
cytoplasm, TAZ may engage with fi-TrCP and as a result be subjected to ubiquitination
in a manner dependent upon the TPM. Finally, ubiquitinated TAZ may then be targeted
to the proteasome for degradation.
The signal-dependent inactivation of the cell cycle phosphatase, Cdc25C,
provides the basis for our second hypothesis concerning the potential interplay of TAZ
ubiquitination and 14-3-3 binding. While our first proposition introduced the possibility
that the binding of TAZ by 14-3-3 and TAZ ubiquitination occur consecutively, this
theory suggests that these two events take place in an isolated fashion.

Through

dephosphorylation and thus, activation, of the cyclin-dependent kinase Cdc2/cyclin Bl
complex, Cdc25C progresses the cell cycle into mitosis [71]. Cdc25C activity is heavily
influenced by phosphorylation, especially phosphorylation of Ser216, which has been
implicated in two distinct mechanisms of Cdc25C inactivation. Cdc25C inactivation is
imperative to the induction of G2 arrest in situations where entry into mitosis would be
unfavorable [71].

Firstly, in response to DNA damage, Ser216 phosphorylation

facilitates the binding of Cdc25C by 14-3-3, which results in the inactivation of Cdc25C
through cytoplasmic sequestration.

The second means of Cdc25C inactivation is

dependent upon the induction of G2 arrest by the tumor suppressor protein, p i 4 ^ ^ In
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this case, the phosphorylation of Cdc25C on Ser216 promotes the ubiquitination and
proteasomal degradation of Cdc25C [71]. In each of these cases, Ser216 phosphorylation
is catalyzed by a different kinase, indicating that the method of Cdc25C inactivation is
mediated by the activation of specific signaling pathways. Most interesting to us, is the
fact that phosphorylation of a single site can elicit two responses depending upon the
upstream kinases. It is thought that the existence of two modes of Cdc25C inactivation
enables the cell to both initiate (cytoplasmic sequestration) and maintain (proteasomal
degradation) G2 arrest [71]. In line with this notion for the dual functionality of Ser216
phosphorylation, it can be hypothesized that the TPM-dependent binding of TAZ by 143-3 may provide a temporary inhibition of TAZ transcriptional co-activation through its
exclusion from the nucleus, while the TPM-mediated ubiquitination of TAZ may serve to
sustain the inhibition of TAZ-related gene expression through TAZ degradation.
Our understanding of the role of the TPM in the regulation of TAZ will likely
benefit from future investigations focused on elucidating whether either of the theories
outlined above are applicable. In order to determine if the ubiquitination of TAZ is
dependent upon its binding by 14-3-3, we intend to analyze the ubiquitination state of the
TAZ mutant that is incapable of interacting with 14-3-3 (TAZ S89A). Given that the
turnover of TAZ is the result of its ubiquitination, it would also be interesting to assess
whether the stability of TAZ is ultimately dictated by its ability to interact with 14-3-3.
Long-term studies dedicated to identifying the kinase, or kinases, responsible for
phosphorylating the TAZ TPM will be important, as such information will allow us to
ascertain whether the implicated signaling pathway(s) favor the binding of TAZ by 14-33 and/or the ubiquitination of TAZ.

This knowledge will ultimately enable us to

determine if these TPM-mediated events are directly related, in a manner resembling the
turnover of the FOXO proteins, or are distinct from one another, as observed in the
regulation of Cdc25C.
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Interestingly, the dependence of 14-3-3 binding on the TAZ TPM appears to be
somewhat cell-type specific. Where the TAZ TPM mutant, TAZ ATPM, completely
escapes 14-3-3 binding within 3T3-L1 preadipocyte cells, we show that, within HEK 293
cells, TAZ ATPM retains its capacity to bind to 14-3-3, albeit to a lesser degree than
wild-type TAZ (Figures 3.17, 3.18). This variation in the dependence of 14-3-3 binding
of TAZ on the TPM suggests that certain signaling pathways targeting TAZ may not be
as prevalent within HEK 293 cells as they are in 3T3-L1 cells. For example, given our
hypothesis that Ser93 phosphorylation interferes with 14-3-3 binding, it is possible that
the kinase responsible for this phosphorylation event may be down-regulated in HEK 293
cells. In this instance, the TPM would have limited bearing upon the 14-3-3 binding of
TAZ, as it would not be required to inhibit the phosphorylation of Ser93, as would be the
case in 3T3-L1 cells.

As TAZ has been implicated in the inhibition of adipocyte

differentiation [45], 3T3-L1 cells are more physiologically relevant, suggesting that the
TPM-mediated 14-3-3 binding of TAZ may be a physiological event. With this in mind,
it will be intriguing to determine whether the interaction between TAZ and 14-3-3 occurs
in a TPM-dependent manner in other TAZ-relevant cell lines, including osteoblasts,
myoblasts, mesenchymal stem cells (MSCs), and lung epithelial cells [45,48,49,52].

4.4 Functional Characterization of the TAZandKLF7 TPMs

TAZ, KLF7, and P-catenin have all been shown to function as transcriptional
mediators in the regulation of adipogenesis, the process by which pluripotent
mesenchymal stem cells (MSCs) differentiate into lipid-storing adipocytes [72]. This
functional parallel between the archetype TPM protein, P-catenin, and the newly
identified TPM proteins, TAZ and KLF7, is intriguing, as it offers the possibility that
common regulatory mechanisms afforded through their respective TPMs govern the
progression of adipogenesis.
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Interestingly, studies have revealed that adipogenesis is sensitive to the protein
levels of P-catenin, highlighting the importance of its TPM in adipocyte differentiation,
as TPM phosphorylation directs the ubiquitin-mediated degradation of p-catenin [18-21].
Firstly, the over-expression of a P-catenin TPM mutant (P-catenin S37A), which is
capable of escaping ubiquitination and degradation because of a compromised p-TrCP
binding site, was found to reduce the degree of adipocyte differentiation in mouse
fibroblast cells [44]. Secondly, treatment with lithium chloride (LiCl), an inhibitor of
GSK3P, inhibited the ability of adipose-derived MSCs (AMSCs) to differentiate into
adipocytes, while stimulating osteogenesis [73].

This inhibition of adipogenic

differentiation potential was attributed to the stabilization of cytoplasmic p-catenin
through the inhibition of GSK3P, one of the kinases responsible for phosphorylating the
P-catenin TPM.

4.4.1 KLF7 Inhibits Adipogenesis in Preadipocyte Cell Lines

Much of the research conducted on KLF7 to date has been focused on its
transcriptional activities during neurogenesis; however, recent years have seen the
introduction of KLF7 as a transcriptional mediator of adipogenesis [46,47,74]. In two
separate studies, KLF7 over-expression was shown to reduce the adipogenic potential of
both human and mouse preadipocyte cells [46,47]. In the present study, we reproduced
the results first published by Maeda et al, which revealed the inhibition of adipogenesis
by the over-expression of KLF7 within mouse 3T3-L1 preadipocyte cells [46]. In an
extension of the previous investigation, we analyzed the effect of the KLF7 TPM mutant
(KLF7 STDM) on preadipocyte differentiation (Figure 3.20). Our results revealed that
by compromising the integrity of its TPM, the inhibitory capacity of KLF7, in the context
of adipogenesis, could be heightened, suggesting a role for the TPM in the regulation of
adipogenesis by KLF7. The possibility that KLF7, like p-catenin, may be regulated by
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TPM-dependent degradation provides a putative explanation for its inhibition of
adipogenic differentiation, whereby the steady state levels of KLF7 control the degree of
adipocyte differentiation. The existence of such a regulatory strategy suggests that the
stabilization of KLF7, possibly through inhibition of the associated kinase(s) or another
member of the degradation machinery, leads to a reduction in adipocyte differentiation;
whereas, under conditions favoring adipocyte formation, KLF7 would be constitutively
degraded in response to phosphorylation of its TPM.

A recent study interested in

elucidating the pro-adipogenic mechanisms of catechins, a form of polyphenol flavenoids
present in green tea, provides support for our hypothesis concerning the relation between
KLF7 protein levels and adipogenic progression. Within their investigation, Cho et al.
demonstrated that a reduction in KLF7 protein levels due to (-)-catechin treatment of
3T3-L1 preadipocyte cells was accompanied by a dramatic increase in adipogenesis [74].
Taken together, these findings largely suggest that KLF7 protein levels govern the
adipogenic differentiation potential of preadipocyte cells, heightening our interest in
determining whether phosphorylation of the KLF7 TPM enables the degradation of
KLF7.

4.4.2 TAZ Governs Mesenchymal Stem Cell Differentiation

In an eloquent study conducted by Hong et al, TAZ was identified as a critical
transcriptional regulator of mesenchymal stem cell (MSC) differentiation.

MSCs are

capable of differentiating into several distinct cell types, including osteoblasts and
adipocytes, whose formation is chiefly driven by the opposing activation of the
transcription factors, Runx2 and peroxisome proliferator-activated receptor y (PPARy),
respectively [45]. By modulating the expression of TAZ, in both model cell lines and in
a more physiological context, TAZ was found to co-activate the transcription of Runx2driven genes, while it repressed the expression of PPARy-dependent genes.
130

In

accordance with its aforementioned functions, TAZ over-expression was found to
promote osteoblast

formation,

while simultaneously

inhibiting the

adipogenic

differentiation program [45]. These findings were further supported through a series of
knock-down experiments where the reductions in TAZ expression coincided with
enhanced adipocyte levels and impaired osteogenic differentiation [45]. Thus, it appears
that MSC

fate determination

transcriptionally active TAZ.

is largely dependent upon the availability of
As we have proposed that phosphorylation-induced

activities at the TAZ TPM may contribute to the degradation of TAZ, we believe that in
this way the TPM may influence the transcriptional abilities of TAZ in MSC
differentiation.
Within the present study, we focused on the TAZ-mediated inhibition of the
adipocyte differentiation program. We confirmed the finding published by Hong et al.,
which revealed that the over-expression of TAZ results in a reduction of the adipogenic
capacity of mouse 3T3-L1 cells (Figure 3.19). More importantly, we provide evidence
that the TPM does indeed impact the TAZ-mediated inhibition of adipogenesis, as overexpression of the TAZ TPM mutant, TAZ SDM, reduced adipocyte differentiation to a
degree far below that observed for wild-type TAZ. By correlating these results with our
hypotheses of TPM-mediated TAZ degradation, we can contrive a possible model to
explain the role of the TAZ TPM in its inhibition of adipogenesis. This proposition
suggests that, in response to adipogenic stimuli, TAZ may be constitutively degraded in a
manner dependent upon phosphorylation of its TPM; whereas TAZ stabilization, like that
of P-catenin, may lead to its translocation into the nucleus, facilitating its repression of
the adipogenic transcriptional program.

In future studies, it will be interesting to

determine whether the putatively more stable TAZ TPM mutant will exhibit predominant
nuclear localization, as is observed for stabilized P-catenin [75]. Such a finding would
further validate our hypothesis of TPM-dependent TAZ degradation and its contribution
to the regulation of TAZ-mediated adipogenic inhibition.
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Of course, we cannot dismiss the possibility that the effect of the TAZ TPM on
adipogenesis may be related to its involvement in the interaction with 14-3-3. The
transcriptional co-activation abilities of TAZ are known to be limited by its interaction
with 14-3-3, as 14-3-3 binding results in the exclusion of TAZ from the nucleus [45].
Thus, our finding that, within 3T3-L1 preadipocyte cells, this interaction is reliant upon
an intact TPM suggests a second possible model explaining the influence of the TAZ
TPM on the inhibition of adipocyte differentiation, whereby the nuclear localization of
TAZ dictates the progression of adipogenesis. Such a regulatory scheme suggests that
reduced nuclear export of TAZ, as a result of a disruption of the TPM-dependent
association between TAZ and 14-3-3, leads to the inhibition of adipogenic differentiation;
whereas, adipocyte formation is favored by the TPM-mediated, 14-3-3-dependent
cytoplasmic sequestration of TAZ. Lastly, it will be interesting to assess whether the
TPM-afforded control of the transcriptional functions of both KLF7 and TAZ, observed
within adipogenesis, will translate into other systems where the transcriptional influence
of these proteins has been implicated.

Such a feat would be possible through the

employment of reporter assays, using the promoter regions of known KLF7 target genes,
as well as those of genes bound by transcription factors that are mediated by TAZ. Such
a study would allow us to determine the prevalence of TPM-mediated regulation in the
control of TAZ and KLF7 transcriptional activities.

4.4.3

TPM-Mediated Inhibition of Adipocyte Differentiation by fl-catenin, TAZ,
andKFL7 Converges on PPARy-Driven Gene Transcription

The transcriptional control of adipogenesis, afforded through the collaborative
efforts of numerous transcriptional regulators, has been extensively studied. In brief,
early adipogenic transcription factors, namely CCAAT/enhancer-binding protein
(C/EBP) P and C/EBP8. are induced, which relay the adipogenic signal through
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activation of a second transcriptional regulator, peroxisome proliferator-activated
receptor y (PPARy).

PPARy functions to induce the expression of yet another

transcription factor, C/EBPa, which in turn serves to stimulate the transcription of
PPARy, initiating a mutual activation loop, where PPARy and C/EBPa positively
regulate the transcription of one another [76]. As we mentioned earlier, p-catenin, TAZ,
and KLF7 have all been shown to inhibit the adipogenic differentiation program.
Intriguingly, although they likely function within distinct signaling pathways, the
contributions of these three TPM-containing transcriptional mediators to the inhibition of
adipocyte differentiation converge on the same transcriptional regulator, PPARy.
Through studies in a human preadipocyte cell line, KLF7 was found to inhibit
adipogenesis at a level downstream of C/EBPp and C/EBP8 by reducing the expression
of both PPARy and C/EBPa [47]. P-catenin has also been shown to inhibit adipogenic
differentiation through its interference of the activities of the master adipogenic
regulators, PPARy and C/EBPa [73]; whereas, through a direct interaction with PPARy,
TAZ was shown to repress PPARy-driven gene transcription [45]. This mutual targeting
of PPARy by three distinct proteins looks to provide a high level of regulation dictating
the progression of adipogenesis, with each leg of this regulatory team acting upon PPARy
in a different manner and in response to a different extracellular signal.

4.4.4

Aberrant Control of TPM-Dependent Inhibition of Adipogenesis May
Contribute to Insulin Resistance

The possibility that P-catenin, TAZ, and KLF7 are all regulated by a similar
mechanism centered upon their TPMs provides a common theme for these otherwise
unrelated transcriptional regulators. The involvement of these three TPM-containing
proteins in adipocyte differentiation has been shown to be influenced by their TPMs,
suggesting a possible role for the TPM in this pathway and potentially implicating this
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regulatory scheme in various obesity-related diseases, namely type 2 diabetes.

The

pathogenesis of type 2 diabetes is primarily characterized by the existence of insulin
resistance in peripheral tissues. Thought to be a secondary effect of insulin resistance, an
impairment of insulin biosynthesis and/or secretion is also often detected in patients with
this metabolic disorder [46]. A definite relationship has been shown to exist between
type 2 diabetes and obesity, revealing adipose tissue as an organ contributing to the onset
and severity of this disease. One key function of mature adipocytes is their storage of
fuel in the form of lipids, which protects non-adipose organs from the deleterious effects
of lipid accumulation [77]. Extensive lipid deposition in non-adipose organs, namely the
heart, liver, and pancreas, can disable and destroy the cells of these organs, eventually
leading to their insulin resistance. Compromising adipogenic storage capacity through a
disruption of adipogenesis increases the deleterious accumulation of lipids in non-adipose
tissues [77].

In this manner, deregulated TPM-mediated inhibition of adipocyte

differentiation may contribute to the development of peripheral tissue insulin resistance,
as the stabilization of P-catenin and the proposed stabilization of TAZ and KLF7 would
lead to a pronounced reduction in adipocyte differentiation, thereby effectively limiting
the adipogenic capacity of adipose tissue.
A second means by which the TPM-mediated regulation of P-catenin, TAZ, and
KLF7 may contribute to the pathogenesis of type 2 diabetes involves a potential
impairment of adipocyte function.

Adipose tissue secretes various hormones and

cytokines that regulate metabolism in other tissues.

Studies revealed that p-catenin

stabilization, as well as KLF7 over-expression, inhibited the expression and secretion of
adiponectin, an adipocyte-specific hormone that enhances insulin sensitivity and
adipocyte differentiation of peripheral tissues [44,47,74]. KLF7 over-expression was
also linked to the augmentation of interleukin-6 (IL-6) expression and excretion, an
adipocytokine known to reduce insulin sensitivity [47]. As a result of its role in the
regulation of adipogenesis, which is largely dependent on its protein levels, the targeting
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of p-catenin signaling has been proposed as a potential therapy for obesity and its related
disorders. Thus, it is possible that with further elucidation of the roles of the TPM in the
regulation of TAZ and KLF7, specifically within the context of adipocyte differentiation,
a better understanding of the biology and pathology of adipose tissue may be achieved,
ultimately enabling the development of anti-obesity and anti-diabetes therapies that target
TAZ and KLF7 through their TPM-dependent regulatory mechanisms.

PART II) A Comprehensive Analysis of TAZ Phosphorylation Sites

During the course of our study, anti-FLAG immunoblot analyses reproducibly
revealed a slower migrating form of exogenous TAZ in response to phosphatase and/or
proteasome inhibition (Figure 3.5, 3.7, 3.14). We show that this change in TAZ mobility
is likely attributable to its phosphorylation, as alkaline phosphatase incubation nearly
abolished the observed mobility shift of treated FLAG-TAZ (Figure 3.21). Since its
discovery, TAZ has been routinely cited as a heavily phosphorylated protein [42,43,78].
However, very little information has actually been published corroborating this claim. To
the best of our knowledge, only three TAZ phosphorylation sites have been identified:
Ser89, Ser311, and Ser 314 of human TAZ [41-43]. Phosphorylation of TAZ at Ser89 is
known to facilitate 14-3-3 binding, while the phosphorylation of both Ser311 and Ser314
mediates the binding of the TAZ C-terminal by the WD40-containing F-box protein, 0TrCP. Both Ser89 and Ser311 have been shown to be phosphorylated by the Lats tumor
suppressor kinase, which functions within the Hippo pathway to govern cell proliferation
and tumorigenesis [43].
Given the possibility that TAZ is a highly phosphorylated protein, it may be that
the key to understanding the molecular details of TAZ regulation, which remain largely
undetermined, lies within the identification and characterization of its multiple
phosphorylation sites. Thus, with this in mind, we conducted a comprehensive analysis
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of in vivo TAZ phosphorylation sites using mass spectrometry. Our efforts lead to the
detection of 5 distinct phosphopeptides (Figure 3.22), on which, we identified 7 TAZ
phosphorylation sites (Figures 3.23-3.29, Table 3.1).

Mapping each of these

phosphorylation sites to their location along TAZ roused our interest in two particular
sites: Ser93 and Serll7 of human TAZ (Figure 3.30). The identification of Ser93 and
Serll7 as TAZ phosphorylation sites intrigued us in light of their proximity to two
critical TAZ regions, the 14-3-3 binding site and the TAZ WW domain, respectively.

4.5 TAZ Phosphorylation on Ser93 Affords a Means of Regulating 14-3-3 Binding

Earlier, we discussed the importance of 14-3-3 binding to the regulation of TAZ.
Briefly, the phosphorylation-dependent binding of TAZ by 14-3-3, which requires the
phosphorylation of TAZ on Ser89, results in the cytoplasmic retention of TAZ.
Consequent to its nuclear exclusion, the ability of TAZ to co-activate transcription is
hindered [42]. Owing to the critical nature of Ser89 phosphorylation to this interaction,
our identification of Ser93 as a TAZ phosphorylation site piqued our interest, as the
location of Ser93, immediately upstream of Ser89, suggested a putative relationship
between these two TAZ phosphorylation sites. Thus, within this study, we initiated a
functional

analysis of Ser93 phosphorylation and provide evidence that this

phosphorylation event does indeed influence the association between TAZ and 14-3-3.
We show that substitution of Ser93 with an aspartic acid residue (TAZ S93D), which
produces a TAZ mutant mimicking constitutive phosphorylation on Ser93, inhibits the
binding of TAZ by 14-3-3; whereas, the alanine mutant of Ser93 (TAZ S93A) has no
bearing on the interaction of TAZ and 14-3-3 (Figure 3.31). These findings illustrate
that, in some manner, the phosphorylation of Ser93 blocks the phosphorylationdependent recognition of TAZ by 14-3-3. This phosphorylation event may be a putative
regulatory strategy, providing the cell with an additional means of governance over the
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binding of TAZ by 14-3-3. Importantly, the amino acid sequence surrounding the 14-3-3
binding site of TAZ, including Ser93, is highly conserved throughout various TAZ
orthologues (Figure 4.5). Moreover, equivalent phosphorylation sites to Ser93 are also
found to be conserved within the human (Serl31), mouse (Serl 16), and chicken (Serl30)
orthologues of the TAZ paralogue, YAP. The highly conserved nature of Ser93 provides
further evidence supporting the importance of this phosphorylation site to, not only the
regulation of TAZ by 14-3-3, but also to the modulation of other 14-3-3 binding partners,
such as YAP.
In the near future, we intend to confirm the Ser93 phosphorylation-dependent
disruption of the association between TAZ and 14-3-3 through immunofluorescence. We
expect the TAZ S93D mutant to exhibit a predominantly nuclear pattern of localization,
akin to that observed for the TAZ S89A mutant, as both TAZ mutants resist 14-3-3
binding [42]. Since a potential means of governing the binding of TAZ by 14-3-3 is
disrupted in the TAZ S93A mutant, we would expect this TAZ mutant to associate to a
higher degree with 14-3-3, thereby promoting its sequestration in the cytoplasm. It will
also be interesting to determine whether there exists a correlation between Ser93
phosphorylation and the ability of TAZ to influence adipocyte differentiation within 3T3Ll cells. We hypothesize that, based upon its ability to escape 14-3-3 binding and
localize to the nucleus, the TAZ S93D mutant would reduce adipocyte differentiation to a
level below that of wild-type TAZ; whereas, the TAZ S93 A mutant may not be able to
inhibit adipogenesis as strongly as wild-type TAZ, as it is likely to be present primarily
within the cytoplasm. Finally, it may also be of interest to assess whether this Ser93depdendent regulation of 14-3-3 binding is functional within other systems in which TAZ
has been implicated.

Such analyses will likely rely on co-immunoprecipitation and

immunofluorescence experiments in physiologically relevant cell lines, as well as the
employment of luciferase reporter assays, wherein the transcriptional co-activity of TAZ
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Figure 4.5- Sequence Alignment of Human TAZ with Orthologues of TAZ and YAP
Illustrates the Conservation of Ser93. Ser93 of human TAZ and its equivalent serine
residues are boxed. The serine residues responsible for the 14-3-3 binding of TAZ and YAP
are highlighted with an asterisk (*). The serine residue located at the -2 position relative to
the 14-3-3 binding site of TAZ is marked with a dot (•). The amino acid positions at which
the alignments were initiated are indicated at left. (hTAZ, human TAZ; mTAZ, mouse
TAZ; rTAZ, rat TAZ; zTAZ, zebrafish TAZ; hYAP, human YAP; mYAP, mouse YAP;
cYAP, chicken YAP)
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will be measured by its ability to promote the expression of luciferase driven by
transcription factors known to interact with TAZ.
It may be possible to explain the inhibitory effect of Ser93 phosphorylation on the
14-3-3 binding of TAZ using a model whereby the phosphorylation of Ser93 antagonizes
the successive phosphorylation of Ser89. Such a scenario has been shown to govern the
activation of the cell cycle phosphatase, Cdc25C [79]. As outlined previously, Cdc25C
functions to enable mitotic entry through activation of the mitosis-promoting kinase,
Cdc2. Throughout interphase and in response to DNA damage, Cdc25C is maintained in
an inactive state through phosphorylation on Ser216. This phosphorylation event affords
the negative regulation of Cdc25C by facilitating its binding by 14-3-3. Within mitotic
cells, however, the inhibitory phosphorylation of Cdc25C on Ser216 is prevented through
its phosphorylation on Ser214. This dual phosphorylation mechanism provides a means
to ensure that Cdc25C remains active during mitosis by eliminating the potential for
Ser216 phosphorylation [79].
Based on the fact that, during our global analysis of TAZ phosphorylation sites,
we detected the TAZ peptide

87

SHSSPASLQLGTGAGAAGSPAQQHAHLR114 in

multiply phosphorylated forms (Figure 3.20, 3.26A), it may be more probable to
hypothesize that both Ser89 and Ser93 can simultaneously exist in a phosphorylated
form. Correlating this theory with our finding that Ser93 phosphorylation inhibits the
binding of TAZ by 14-3-3 suggests that phosphorylated Ser93 conceals the 14-3-3
binding site centered at phosphorylated Ser89. In this instance, the dephosphorylation of
Ser93 is thought to be a prerequisite for the binding of TAZ by 14-3-3, as it could alter
the conformation of TAZ, unveiling the 14-3-3 binding site. Regulation of the activity of
the tumor-suppressing transcription factor, p53, provides an example of the
aforementioned mechanism [80]. Under normal cellular conditions, p53 is retained in a
lowly active state through phosphorylation on both Ser376 and Ser378. In response to
genotoxic stress, p53 is activated, facilitating the induction of cell cycle arrest or
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apoptosis in the affected cells. The activation of p53 is partially driven by its association
with 14-3-3, which serves to heighten the transcriptional activity of p53 by increasing its
binding affinity for DNA. The binding of p53 by 14-3-3 must be preceded by the
dephosphorylation of Ser376, as the removal of this phosphate group unmasks a 14-3-3
consensus binding sequence comprised of phosphorylated Ser376 and its surrounding
residues. The dependence of the interaction between 14-3-3 and p53 on a preceding
dephosphorylation event imparts an additional layer of control to the activation of p53
[80].
In future studies, it will be important to assess the validity of the model depicting
Ser93 dephosphorylation as a prerequisite for the binding of TAZ by 14-3-3. In order to
prove the existence of this regulatory scheme, we must ascertain whether the second
phosphorylation site on the doubly phosphorylated form of the TAZ peptide spanning
amino acids 87 to 114 (2857.77 m/z) can be mapped to Ser89. Interestingly, we also
detected a triply phosphorylated version of this TAZ peptide (2937.28 m/z). Since TAZ,
like both Cdc25C and p53, also features a serine residue at the -2 position (Ser87)
relative to its 14-3-3 binding site (Ser89), we intend to determine whether the third
phosphorylation site of this peptide can be located to Ser87. A successful identification
of Ser87 as a novel TAZ phosphorylation site would suggest the potential for yet another
mechanism of regulating the interaction between TAZ and 14-3-3.

4.6 Serll7 Phosphorylation of TAZ May Influence Its Ability to Bind (L/P)PXYContaining Transcription Factors

The transcriptional co-activation function of TAZ is thought to be, in part,
mediated by a centrally located WW domain [42]. WW domains, named for their typical
inclusion of two signature tryptophan residues, recognize and bind short proline-rich
sequence motifs within their target ligands [81]. Studies have also shown WW domains
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capable of associating with phosphoserine/phosphothreonine residues immediately Nterminal to a proline residue [81]. An oriented peptide library screening revealed the
TAZ WW domain to optimally bind peptides adhering to the sequence, Leu/Pro-ProXxx-Tyr (L/PPXY) [42]. Interestingly, sequences of this form have been identified in the
transcriptional activation domains of a number of TAZ-mediated transcription factors,
most notably within Runx2 and PPARy, the master transcriptional regulators of
osteoblast and adipocyte differentiation, respectively [45,48].

Both the physical

interaction of TAZ with these transcription factors, as well as the co-activation/repressive
influences of TAZ on Runx2- and PPARy-driven gene transcription, respectively, were
shown to be dependent upon the recognition of the (IVP)PXY motifs within Runx2 and
PPARy by the WW domain of TAZ [45].
Our identification of Serl 17 as a novel TAZ phosphorylation site is an intriguing
discovery in light of these findings that illustrate the criticality of the TAZ WW domain
to the transcriptional regulation of both Runx2 and PPARy, as Serl 17 of human TAZ
flanks the N-terminal of the TAZ WW domain (amino acids 124-157) [42]. The highly
conserved nature of Serl 17 was shown through amino acid sequence alignment of
human, mouse, rat, and zebrafish TAZ, suggesting the potential significance of this newly
identified TAZ phosphorylation site (Figure 4.6). Moreover, equivalents of Serl 17 of
human TAZ were also found to be conserved within the human (Serl 64), mouse
(Serl49), and chicken (Serl 62) orthologues of the TAZ paralogue, YAP. Consequent to
its location and conservation, we hypothesized that the phosphorylation of Serl 17 might
influence the WW domain-dependent binding of Runx2 and PPARy, as well as that of
other (IVP)PXY-containing transcription factors, by TAZ. In order to determine whether
Serl 17 phosphorylation did indeed provide a means by which to regulate the interactions
of the WW domain, we examined the functional consequence of this phosphorylation
event on the progression of adipocyte differentiation in 3T3-L1 preadipocytes.
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Figure 4.6- Sequence Alignment of Human TAZ with Orthologues of TAZ and YAP
Demonstrates the Conservation of Serll7. Serll7 of human TAZ and its equivalent
serine residues are boxed. The amino acid positions at which the alignments were initiated
are indicated at left. (hTAZ, human TAZ; mTAZ, mouse TAZ; rTAZ, rat TAZ; zTAZ,
zebrafish TAZ; hYAP, human YAP; mYAP, mouse YAP; cYAP, chicken YAP)
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We provide preliminary evidence suggesting that the phosphorylation of TAZ on
Serll7 may negatively regulate interaction of TAZ and PPARy. We show that overexpression of TAZ S117A, a phosphorylation-defective mutant of TAZ containing an
alanine substitution at Serl 17, reduces the degree of adipocyte differentiation in 3T3-L1
cells to a level below that observed for wild-type TAZ (Figure 3.32). The heightened
inhibitory capacity of TAZ S117A in the context of adipogenesis indicates that the
absence of this putative regulatory phosphorylation site at Serl 17 might enhance the
TAZ-mediated inhibition of PPARy activity. Accordingly, 3T3-L1 cells over-expressing
a mutant of TAZ that is thought to behave as if it is phosphorylated at Serl 17 (TAZ
S117D) appeared to differentiate to a level comparable to, if not slightly higher than,
wild-type TAZ over-expressing 3T3-L1 cells.

This putative increase in adipocyte

differentiation accompanying TAZ S117D over-expression insinuates that Serl 17
phosphorylation of TAZ hinders the ability of TAZ to repress PPARy-driven gene
transcription. Taken together, our findings suggest that the phosphorylation of TAZ on
Serl 17 disrupts the WW domain-mediated binding of TAZ to the PPXY-motif within
PPARy, which provides a potential explanation for our adipogenesis data. Since TAZ
S117A cannot undergo phosphorylation at Serl 17, its over-expression presumably
increases the stoichiometry of TAZ-bound, transcriptionally repressed PPARy; whereas,
over-expression of TAZ S117D, which mimics a mutant of TAZ that is constitutively
phosphorylated on Serl 17, likely results in an increase of unbound, transcriptionally
active PPARy. Hence, it appears that the reversible phosphorylation of TAZ on Serl 17
may afford a means by which the WW domain-mediated binding of TAZ to, not only
PPARy, but also to other (L/P)PXY-containing transcription factors, can be regulated,
ultimately governing the transcriptional co-activation/repression of such transcription
factors by TAZ.
Interestingly, there have been studies citing the significance of regions
surrounding the WW domain, which lends credence to our hypothesis that the
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phosphorylation of TAZ on Serl 17 plays a regulatory role in the WW domain-mediated
binding of (L/P)PXY-transcription factors by TAZ. It is proposed that critical amino acid
residues, lying adjacent to WW domains, may engage in interactions that either stabilize
the fold of the WW domain or enhance the binding affinity of the WW domain for target
ligands [81]. Thus, it is possible that the phosphorylation of such an amino acid residue
(i.e. Serl 17 of TAZ) could disrupt the aforementioned interactions, potentially leading to
an unfavorable change in the conformation of the WW domain or the elimination of
additional binding co-operativity, ultimately hindering the binding of the WW domain to
its target ligand.
In the near future, we intend to directly assess the influence of Serl 17 TAZ
phosphorylation on the WW domain-mediated binding of PPARy by TAZ.

Co-

immunoprecipitation analysis of PPARy with the Serl 17 phosphorylation variants of
TAZ will allow us to determine whether this phosphorylation event does indeed
antagonize the association of the TAZ WW domain and the PPXY motif of PPARy. Our
investigation of the functional consequence of Serl 17 phosphorylation on the
transcriptional repression activity of TAZ on PPARy will likely benefit from the
employment of reporter assays, wherein the ability of the Serl 17 TAZ variants to repress
PPARy can be measured through the expression of a luciferase gene fused to the
promoter region of a PPARy target gene. Moreover, it will be interesting to determine
whether Serl 17 phosphorylation of TAZ will also inhibit the binding of TAZ to Runx2, a
master transcriptional regulator of osteogenesis, as this interaction has also been shown to
be WW domain dependent [45]. Analyzing the effect of Serl 17 phosphorylation of TAZ
on the WW domain-mediated binding of Runx2 and PPARy will allow us to comment on
the prevalence of this phosphorylation event as a putative regulatory strategy governing
the transcriptional co-activation/repression functions of TAZ.
During our comprehensive analysis of TAZ phosphorylation, we were unable to
unambiguously identify all of the phosphorylation sites on the TAZ phosphopeptides that
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were detected.

In future studies dedicated to further elucidating novel TAZ

phosphorylation sites, we intend to employ separation techniques, such as immobilized
metal affinity chromatography (IMAC) and/or high performance liquid chromatography
(HPLC), to facilitate the separation of TAZ phosphopeptides from those that are not
phosphorylated.

If necessary, we can also utilize chemically assisted fragmentation

(CAP) techniques, which enhance the fragmentation of peptide ions during PSD through
the derivatization of tryptic peptides with sulfonic acid. As CAF derivatization promotes
the exclusive detection of y-ions, it can reduce the complexity of the resultant MS/MS
spectra, potentially simplifying both peptide sequencing and the mapping of
phosphorylation sites.
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4.7 Concluding Remarks

The work described in this thesis focuses on a specific phosphomotif that has
been shown to regulate protein degradation. To date, the TPM has solely been implicated
as a regulatory strategy in the maintenance of P-catenin protein levels [16]. However,
based upon the level of sophistication within this mechanism and its fundamentality to
the modulation of p-catenin activity, we hypothesized that this strategy might be a
widespread regulatory scheme. Indeed, within this study, we revealed a number of
putative TPM proteins through their ability to react with a novel phosphorylation-specific
TPM antibody, as well as by their responsiveness to phosphatase and proteasome
inhibition. Specifically, we identified two transcriptional mediators, TAZ and KLF7, as
novel TPM proteins. Using mass spectrometry, we have provided convincing evidence to
support the presence of the TPM within TAZ.
With regard to the biochemical characterization of the KLF7 and TAZ TPMs, our
hypothesis was that TPM phosphorylation would drive their ubiquitin-dependent
proteasomal degradation. This rationale was based upon the role of the P-catenin TPM,
wherein it has been well-established that phosphorylation of the TPM facilitates its
recognition by P-TrCP, which initiates the ubiquitination and subsequent degradation of
P-catenin by the proteasome [16-21]. In accordance with this premise, we uncovered a
novel interaction between KLF7 and P-TrCP and also provide evidence that KLF7 is
subject to ubiquitination. Importantly, both the P-TrCP recognition and ubiquitination of
KLF7 were found to be entirely dependent upon the KLF7 TPM.

Although our

preliminary attempts at linking these TPM-dependent activities to the potential
degradation of KLF7 were inconclusive, the existing parallel between P-catenin and
KLF7, in that each protein contains an N-terminal TPM that mediates its association with
P-TrCP and its ubiquitination, sustains our belief that KLF7, like P-catenin, will be
degraded in a manner dependent upon the TPM.
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Within our investigation of the TAZ TPM, we compiled evidence indicating that
the function of the TAZ TPM is likely much more complex than our original hypothesis
suggested. In line with our hypothesis, we were able to demonstrate that TAZ likely
undergoes ubiquitination in a manner reliant upon TPM phosphorylation.

However,

unlike that of P-catenin and KLF7, this ubiquitination event is not consistent with our
initial hypothesis, as an interaction between P-TrCP and the consensus sequence within
the TAZ TPM could not be detected, both in our study and in a previously published
study [41]. Interestingly, P-TrCP does associate with TAZ through its binding to an
atypical site within the TAZ C-terminal; however, this interaction, which highlights the
role of TAZ as an E3 adapter protein, was shown to facilitate the proteasomal
degradation of a TAZ binding partner (PC2) [41]. Despite its function as an E3 adapter
and our inability to illustrate the turnover of TAZ, there does exist evidence suggesting
that TAZ may also be regulated by degradation. Hence, we proposed that the inclusion
of TAZ in a degradation complex might, in the context of a negative feedback loop, lead
to its demise via the ubiquitin-proteasome pathway in a manner dependent upon both the
TAZ C-terminal and its TPM.
Here, we also revealed the likelihood that the TAZ TPM influences the critical
regulatory interaction between TAZ and 14-3-3, as this association was observed to
depend upon the TAZ TPM. We suggested that this TPM-dependency of 14-3-3 binding
was likely due to phosphorylation of the TPM, which could potentially promote the
phosphorylation of Ser89 or antagonize the phosphorylation of other residues in the
vicinity, such as that of Ser93, that could negatively regulate 14-3-3 binding. Since both
the ubiquitination of TAZ and its association with 14-3-3 were found to be reliant upon
its TPM, we hinted at the possibility that there may exist a direct link between these two
events. Our proposed model portrayed TPM phosphorylation as a nuclear occurrence
required to initiate the 14-3-3-mediated nuclear export of TAZ, which enables the
ubiquitination and subsequent proteasomal degradation of TAZ within the cytoplasm.
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We also discussed the possibility that 14-3-3 binding and ubiquitination of TAZ may be
isolated situations, providing the cell with multiple means by which to regulate TAZ.
Interestingly, the effect of the TPM on the binding of TAZ by 14-3-3 appeared to be celltype specific, for within 3T3-L1 cells, a TAZ TPM mutant could not interact with 14-3-3,
whereas, within HEK 293 cells, the same mutant retained its capacity to bind 14-3-3.
In previous studies, (5-catenin, TAZ, and KLF7 have all been identified as
negative regulators of adipocyte differentiation [44-47,73].

The existence of this

functional parallel incited our functional characterization of the KLF7 and TAZ TPMs, in
terms of their influence on the progression of adipogenesis within 3T3-L1 preadipocyte
cells, as we considered the possibility that the inhibitory capacity of these three TPM
proteins may be afforded by phosphorylation-induced activities at their TPMs. Our
results revealed that serine/threonine to alanine substitutions of the critical TPM residues
within the KLF7 and TAZ TPMs increased the ability of both TAZ and KLF7 to inhibit
adipogenesis. Correlating these findings with our original hypotheses concerning the role
of the TPMs in regulating the stability of TAZ and KLF7, we proposed that the effect of
the TPMs on adipogenesis might be related to their ability to dictate the steady state
levels of TAZ and KLF7, which agrees with studies that presented the role of KLF7 in
adipogenesis, as well as with the working model of TAZ-mediated MSC differentiation
[45-47]. The discovery that the TAZ TPM mutant resists 14-3-3 binding leaves open the
possibility that the enhanced inhibitory influence of this TAZ mutant on adipogenesis
could be a direct result of its ability to escape 14-3-3-mediated cytoplasmic sequestration.
The second part of this thesis describes an analytical project involving the
identification of TAZ phosphorylation sites using mass spectrometry. The results of
previously published studies, as well as those presented within this work, indicated the
likelihood that TAZ is highly phosphorylated [42,43,78]. Since it is likely that the key to
understanding the regulation of TAZ functions is encoded within its multiple
phosphorylation sites, we believed the identification and characterization of these sites to
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be of the utmost importance. In total, our efforts lead to the detection of 6 distinct TAZ
phosphopeptides, including that which contained the TAZ TPM.

Through MS/MS

analysis, we successfully identified 10 TAZ phosphorylation sites, of which 7 were
mapped to regions outside of the TPM. We demonstrated that two of the identified TAZ
phosphorylation sites, Ser93 and Serll7, are located in the vicinity of two critical TAZ
regulatory regions, the 14-3-3 binding site and the WW domain, respectively. In light of
their intriguing locale, we performed preliminary functional analyses of both Ser93 and
Serll7.

We provide evidence highlighting the negative regulatory effect of Ser93

phosphorylation on the binding of TAZ by 14-3-3. Since TAZ S93D could not interact
with 14-3-3, we hypothesized that this phosphorylation event may antagonize the
subsequent phosphorylation of Ser89. We also described the possibility of a second
model, whereby Ser89 and Ser93 are simultaneously phosphorylated and the binding of
TAZ by 14-3-3 must be preceded by the dephosphorylation of Ser93.
Our functional characterization of Serll7 phosphorylation revealed a putative
link between this phosphorylation event and the ability of TAZ to bind to the (IVP)PXY
motif of specific transcription factors through its WW domain. Since the TAZ-induced
transcriptional repression of PPARy-driven gene expression is dependent upon the
binding of the TAZ WW domain to the PPXY motif present within the transcriptional
activation domain of PPARy [45], we hypothesized that the phosphorylation of TAZ at
Serl 17 might disrupt the interaction between TAZ and PPARy. We indirectly illustrated
that this is likely the outcome of phosphorylation at Serl 17, as we showed that the
phosphorylation-defective TAZ mutant, TAZ S117A, exhibited an enhanced capacity to
inhibit adipocyte differentiation within 3T3-L1 cells. Our findings suggest a negative
regulatory role for the phosphorylation of Serl 17 on the WW domain-mediated
interaction of TAZ with not only PPARy, but also with other (IVP)PXY motif-containing
transcription factors.
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Presently, relatively little experimental data has been published regarding the
intricate molecular details of TAZ and KLF7 regulation.

Here, we introduced the

possibility that both TAZ and KLF7 might be regulated in a manner dependent upon a
phosphomotif that was first shown to govern the protein levels of p-catenin. A better
understanding of the course of events occurring at the TAZ and KLF7 TPMs will likely
enhance our understanding of the mechanisms regulating these critical transcriptional
mediators, potentially providing insights into their putative contributions to the
pathogenesis of obesity-related disorders, such as type 2 diabetes. We also reported the
identification of a number of in vivo TAZ phosphorylation sites, whose functional
characterization will likely provide invaluable information concerning the regulation of
TAZ function. Importantly, we provided the first indication of mechanisms governing
the release of TAZ from 14-3-3. In closing, the findings presented within this thesis will
provide a strong foundation for future studies focused on elucidating the mechanisms
responsible for the tight regulation of the activities of the TPM-containing transcriptional
mediators, TAZ and KLF7.

150

Gene
CAD22
BSN
F135B
VGFR2
KIF1C
SYNM
DLL1
CTNB1
ZBT20
YM018
H2B1A
KLF7
MKKS
SI1L3
PLAK
BAZ2B
CASZ1
PRP16
AKP13
FLT3
MLL5
UTP20
S45A3
CEA21
DMKN
WWTR1
AKA11
WNK2
DMRT1
CADH7
CHD1
ZEP1
D0K7

Amino Acid
Position
583-596
682-695
685-698
392-405
675-688
78-91
693-706
32-45
376-389
936-949
53-66
18-31
254-267
1308-1321
23-36
52-65
159-172
219-232
390-403
324-337
1280-1293
1746-1759
417-430
116-129
299-312
57-70
443-456
617-630
331-344
566-579
23-36
672-685
337-350

T P M Sequence
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D

S
T
S
T
S
S
S
S

s
s

T
T
T
S
S
S
S
S
S
T
S
S
T
T
S
S
S
S
S
S
S

s
s

G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G

P
Y
I
N
D
L
C
I
V
N
I
Y
E
I
I
T
P
Y
T
Y
G
G
G
Y
S
S
L
Q
L
S
S
Y
I

P
S
E
Y
D
D
S
H
S
K
S
F
G
D
H
S
S
G
V
Y
E
T
A
Y
E
H
F
G
V
P
A
F
A

T
S
S
T
S
S
T
S
S
T
S
S
T
T
S
S
T
S
S
T
S
S
S
T
S
S
S
S
S
S
S
S
T

L
D
E
V
D
R
S
G
S
D
K
A
V
T
G
D
R
S
D
C
P
A
S
L
S
R
P
T
L
L
G
R
G

S
G
P
I
K
E
K
A
I
K
A
L
V
L
A
T
Q
R
Q
S
C
K
E
Q
W
Q
I
V
S

s
s
s
s

s
I

s

L
R
L
D
T
G
D
M
P
V
Y
N
S
A
R
D
S
V
E
D
V
G
S
R
Y
S
S
G
E
H

T
S
S
T
S
T
T
T
T
T
S
S
S
T
T
S
S

s
s
s
s
s
s
T
S
S
S
S

s

T
S
S
S

G
S
V
N
C
F
K
T
E
P
I
L
Y
S
C
E
G
Q
C
K
C
E
L
Y
S
T
S
D
S
S
G
A
S

T
S
A
P
E
G
Y
A
P
G
M
E
G
S
V
G
E
W
L
H
S
C
M
R
T
D
A
S
P
T
S
D
Y

L
Q
W
I
E
S
Q
P
D
I
N
E
V
P
P
I
A
E
Q
P
P
I
T
N
G
S
F
Q
I
L
S
Q
S

T
S
S
S
S
S
S

s
s

T
S
T
S
S
S
S
S
S
S
S
S
T
S
S
S
S
S
S
S
T
S
T
S

Appendix 1- Compilation of Putative TPM-Containing Proteins. Analysis of the
human SwissProt database with an ambiguous form of the TPM sequence
(DS/TGXXS/TXXXS/TXXXS/T) was conducted using the Pattern Search command of
the My Hits web-based tool (mymts.isb-sib.ch/cgi-bin/pattern_search; Swiss Institute of
Bioinformatics). The genes encoding the TPM-containing proteins identified are listed
and the amino acid positions of their TPMs are indicated. The Ser/Thr residues
constituting the putative TPMs are highlighted, as are the residues comprising the P-TrCP
consensus sequence (DSGXXS). The genes encoding P-catenin (CTNB1), KLF7 (KLF7),
and TAZ (WWTR1) are boxed.
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